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General Introduction 
10 I General Introduction 
1.1 Steroid hormone receptors 
1.1.1 Family members of the androgen receptor 
Nuclear hormone receptors (NHRs) are intermediary factors through which ex-
tracellular signals regulate expression of genes that are involved in homeostasis, 
development, and differentiation (Beato et al. '995, Mangelsdorf and Evans 
1995). These receptors are characterized by a modular structure, with domains 
involved in transcription activation, DNA binding. hormone binding, and dimeri-
zation. The nuclear receptor super-family comprises three subfamilies of recep-
tors, which might have emerged early during evolution (Laudet et af. 1992). 
T 
o 
hsp's 
T DHT 
o • 
r. 
sa· reductase 
o )OOJ 
protein~ 
• RNA 
Figure 1.1 Mechanism of action of androgens. The steroid hormone testosterone (T) enters the cell via 
passive diffusion. In the cytoplasm, testosterone can be converted to the more potent androgen sa· 
dihydrotestosterone (OHT) by the enzyme sa-reductase type II. Both androgens can bind to the AR, 
which is complexed with heat-shock proteins (hsps). Upon androgen binding the receptor dissociates 
from the complex, and the AR binds to DNA as a homodimer, Transcription activation takes place, resul-
ting In a cellular response, TIC: transcription Initiation complex. 
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The first subfamily contains so~called orphan receptors, which either have an 
unknown ligand, or are constitutively active. The second subfamily is fonned by 
receptors for thyroid hormone, vitamin D and retinoids. The third subfamily is 
formed by steroid hormone receptors (SHRs). This subfamily can be further divi-
ded, as the glucocorticoid receptor (GR), progesterone receptor (PR), mineralocor-
ticoid receptor (MR), and androgen receptor (AR) are more closely related to each 
other than to the estrogen receptor (ER) (Evans 1988). Two isoforms of both the 
hPR (PR-A and PR-B) (Krett et al. 1988), and the GR (GR-C( and GR-P) (Bamberger et 
al. 1995) have been identified. These isoforms, which are highly homologous but 
functionally different, are encoded by single genes. Recently, a second estrogen 
receptor (ER-P) encoded by a second gene was cloned (rat ER-P: Kuiper et al. 1996, 
hER-P: Mosselman et al. 1996), which can heterodimerize with the ER-" (Cowley 
et al. 1997, Pettersson et al. 1997), and responds differently to certain ligands 
(Paech et al. 1997). 
In the absence of ligand, the receptors for thyroid hornlOne, vitamin D, and 
all-Irans retinoic acid (TR, VOR, and RAR, respectively) can be involved in silen-
cing of promoter activity through their ligand-binding domain (LBO). In con-
trast, SHRs are bound by a complex of proteins that among others contains the 
heat-shock proteins hSP90, hSP70, and hspS6. The SHR in the complex is directly 
bound to hspgo, which not only keeps the receptor in an inactive state but is also 
essential for proper folding of the receptor protein (reviewed by Pratt and Toft 
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figure 1.2 Human AR gene; structural organization and protein. The AR gene was mapped to the long 
arm of the X chromosome. The hAR protein is encoded by 8 exons. Analogous to other nudear recep' 
tors, the protein consists of several distinct functional domains: the NH,-terminal domain containing 
two polymorphic stretches, the DNA-binding domain, the hinge region, and the ligand-binding 
domain. 
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1997). Upon ligand binding, the SHR dissociates from the complex, forms a 
(homo-)dimer that binds to specific hormone response elements (HREs) to 
modulate chromatin structure, finally resulting in regulation of gene expression 
(Figure 1.1). Apart from gene activation, SHRs are also involved in repression of 
genes. This can be accomplished either by competition for overlapping HREs 
with other SHRs, or by competition for basal transcription factors or coactiva-
tors, or by protein-protein interactions that result in transcriptional interference 
(inhibition of gene expression, regulated by AP-1) (Beato et al. 1995). 
1.1.2 Organization of the androgen receptor gene, promoter structure, 
androgen receptor mRNA, and androgen receptor protein 
The gene encoding the hAR was cloned 10 years ago by several groups (Chang et 
al. 1988a, Lubahn et al. 1988a, Trapman et al. 1988, Tilley et al. 1989) and mapped 
to the qll-q12 region of the X chromosome (Brown et al. 1989). The AR gene, 
which is spanning more than go kilo base {kb} genomic DNA, comprises 8 exons 
(Kuiper et al. 1989, Lubahn et al. 1989) (Figure 1.2). 
Expression of the gene is regulated by a single promoter region that contains 
2 transcription initiation sites (TIS), located in a 13-base pair (bp) region (Tilley et 
al. '990, Faber et al. 1991a). The AR promoter region does not contain a TATA-box 
or a CCAAT-box, but other regulatory sequences like a GC-box (recognition site 
for Sp1), a purine-rich region and a CRE element (AR-CRE, only present in the hAR 
promoter) are present (Baarends et al. '990, Faber et al. '993, Mizokami et al. 
1994). In several androgen-responsive cell lines two mRNA species of different 
length were detected, a 10.6 kb and an 8.5 kb species (Lubahn et al. 1988b, 
Trapman et al. 1988, Tilley et al. 1990). The transcript of 10.6 kb consists of a 1.1 kb 
5' untranslated region (UTR), a 2.7 kb open reading frame (ORF) (Kuiper et al. 1989, 
Lubahn et al. 1989), and a relatively long 3' UTR of 6.8 kb (Faber et al. 1991a). The 
shorter mRNA species that contains the normal ORF results from differential 
splicing in the 3' UTR (Faber et al. 1991a). 
The number of amino acid residues in the AR is variable, due to the presence 
of 2 polymorphic stretches (Faber et al. 1989). Throughout this thesis, numbering 
of amino acid residues is based on an AR consisting of 910 amino acid residues, 
as described by Brinkmann et al. (1989). Analogous to other NHRs, the AR is com-
posed of distinct functional domains. Apart from a ligand-binding domain (LBO) 
and a DNA-binding domain (DBD), a hinge region, and an NH,-terminal domain 
which is involved in transcription activation, can be distinguished (reviewed by 
Beato and Sanchez-Pacheco 1996). The AR protein has an apparent molecular 
" 
mass of 110 kilo Dalton (kDa). Like other SHRs, the AR is post-translationally 
modified by phosphorylation (Kuiper and Brinkmann 1994). Phosphorylation is 
known to be involved in functional control of many proteins, probably by induc-
tion of conformational changes. 
Androgen receptor protein is widely expressed in male reproductive tissues, 
but also in many other tissues in both males and females (Ruizeveld de Winter et 
al. 1991, reviewed by Quigley et al. 1995). Regulation of AR transcript and protein 
expression is complicated, and known to be age- and tissue-dependent (Supakar 
et al. 1993, Wolf et al. 1993). Analogous to other SHRs, autoregulation has been 
implicated (Wolf et al. 1993). Apart from androgens, follicle-stimulating hor-
mone (FSH) is also involved in regulation of AR gene expression (Blok et al. 1989). 
In addition to the full-length AR protein (which has an apparent molecular 
mass of 110 kDa), an NH,-terminally truncated 87-kDa AR isoform was detected 
in human genital skin fibroblasts (Wilson and McPhaul 1994). Previously, two 
functionally different PR isoforms, encoded by a single gene, were identified 
(Krett et al. 1988, Kastner et al. 1990). For both isoforms a different promoter 
specificity was observed (Kastner et ai. 1990) Under certain conditions, the NH2-
terminally truncated isoform (hPR-A) becomes a dominant inhibitor of gene 
activation by the full-length PR (hPR-B), and even inhibition of activation by the 
GR, MR and AR was observed (Tung et al. 1993, Vegeto et al. 1993). These effects 
have to be ascribed to a third autonomous activation function (AF-3) that was 
mapped to the NH,-terminal part of the hPR, being unique to hPR-B (Satorius et 
al. 1994). Analogous to hPR-A, the NH,-terminally truncated AR isoform may 
arise from translation initiation from an alternative translation start site. So far, 
a possible in vivo function of the shortened putative AR isoform is not known. In 
Chapters II and III reinitiation of translation was studied in genital skin fibro-
blasts from androgen insensitive patients, having a mutation in their AR gene 
which leads to a premature stop codon upstream of the first internal methio-
nine residue. 
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1.2 structure and function of steroid hormone receptors, in particular the 
androgen receptor 
1.2.1 The NH2 w terminal domain 
In contrast to the relatively high homology observed for other domains, the NH,-
terminus is not markedly conserved between SHRs (hGR, hER-a, hER-P, hMR, hPR, 
and hAR; Hollenberg ef a1. 1985, Green ef a1. 1986, Mosselman ef a1. 1996, Arriza ef 
a1. 1981, Misrahi et a1. 1981, Faber et a1. 1989, respectively). With the exception of 
ER-a and ER-P, the NH2-terminus constitutes a relatively large part of these 
receptors. 
The NH,-terminal part of the hAR is encoded by one large exon (Faber et a1. 
1989). A highly polymorphic poly-glutamine stretch encoded by (CAG)nCAA, is 
located between amino acid residues 58 and 17 (Sleddens et a1. 1992). Two 
stretches of 6 and 5 glutamine residues, respectively, are located in a more 
COOH-terminal region (Faber et a1. 1989). In addition, a poly-alanine stretch, a 
poly-proline stretch, and a polymorphic poly-glycine stretch, encoded by (GGN)n, 
are present (Faber et a1. '989, Sleddens ef a1. 1993). A polymorphic poly-gluta-
mine repeat, although located in a different region, has also been identified in 
the mouse AR (He ef a1. '990, Charest ef a1. 1991, Faber ef a1. 1991b) and rat AR 
(Chang et a1. 1988b). In these murine species, other homopolymeric stretches 
were absent. NH~wterminal domains of the other members of the SHR family do 
not contain homopolymeric stretches, except for the hMR, which harbors a sigw 
nificant poly-proline stretch (Arriza et a1. 1981). It is believed that acidic, poly-
proline rich, and poly-glutamine sequence motifs confer transcriptional activity 
(Tjian and Maniatis 1994). Apart from the poly-glutamine stretches and a poly-
proline stretch, the AR NH2wterminus contains a relatively high amount of acidic 
amino acid residues (Faber et a1. 1989). There are recent findings, indicating that 
the glutamine stretch is a modifier of AR activity that causes phenotypic variaw 
tion (see Paragraph 1.5.1). 
Transcription activation of target genes depends on subdomains with an 
activation function (AF). Deletion mapping led to the discovery of 2 AFs, located 
in the NH,-terminal domain (AF-1) and the LED (AF-2) of various SHRs (GR, Hol-
lenberg and Evans 1988; PR, Meyer et a1. 1990; ER-o:, Tora ef 01.1989; AR, Simental 
ef a1. 1991, Jenster et a1. 1991). Chamberlain et a1. (1996) identified two smaller 
activation functions in AFwl of the rat AR, which mediate transcription activation 
together. Only recently, a functional AF was identified in the LBD of the hAR 
(Moilanen et a1. 1991). The full-length PR (PR-B) contains an additional NH,-
'5 
terminal AF (AF-3), mapped to the NH,-terminal region, that is unique to this 
receptor (Satorius et al. 1994). Neither the location of AF-I nor the amino acid 
composition is conserved among SHRs, indicating that the NH 2-terminus is 
involved in receptor-specific regulation of target genes. It is generally believed 
that the NH2-terminal domain of SHRs interacts with basal transcription factors 
and specific cofactors (Simental et al. 1991, Adler et al. 1992, Jacq et al. 1994, 
Schwerk et al. 1995, Ford et al. 1997, McEwan and Gustafsson 1997). Upon deletion 
of the LBD, SHRs become constitutively active to a variable degree, depending on 
the type of receptor. This points to a repressive function of the LBD in the 
absence of hormone. In the NH,-terminal part of the AR, besides AF-I (Simental 
et al. 1991, Jenster et al. 1991), a second transcription activation unit (TAU) was 
identified that becomes activated after deletion of the LBD (Jenster et al. 1995). 
D 
o I 0 
G e H • 
Sly 
A 560 G 
A 
G T 
e /P.bOX 
550- C 
T 
- P Q K 
C 570 
• K 
(v,; F F K R 
First Zn Cluster 
K R 
D R 
K - 600 
D_box:r::,O T eX eN: 
~c c 
580 l 
I R 
AAEGKQKY lRK 
Second Zn cfuster 
610 
I 
e y 
NlS 
E A G M 
Figure f.3A The AR DNA-binding domain. The AR-D8D Is defined as a domain, consisting of 65 amino 
acid residues (K548 - E612) (Trapman et al. 1988). In the first zinc cluster the pobox is indicated. Circled 
amino acid residues In the pobox are Involved in ARE half-site recognition (Danielsen et al. 1989). At the 
corresponding position in the ER the amino acid residues EGckA are present (reSidues involved in HRE 
recognition are capitalized). The residues marked with an asterisk might also be involved in contacts 
with the ARE half·site. Residues, marked with boxes are involved in contacts with the phosphate 
backbone of DNA at specific (black boxes) or at non-specific sites (open boxes) (luisi et al. 1991), In the 
second zinc ciuster, the D-box which is Involved in dimerlzatlon, Is indicated (Umesono and Evans 
1989). The second zinc cluster contains also the fjrst part of the nucfear localition signal (NlS). 
16 I General Introduction 
1.2.2 The DNA-binding domain 
Regulation of gene expression by SHRs often involves binding to HREs, which are 
specific sequences located in the promoter region of regulated genes. In this 
way. either transcription activation or repression of genes (occlusion mecha-
nism) can be accomplished. However, interaction of SHRs with other regulatory 
proteins bound.to response elements in promoter regions, might contribute to 
control of gene activation or repression (AR, Kallio et al. '995, Heckert et al. '997; 
ER, Yang et al. 1996; reviewed by Katzenellenbogen et al. 1996). Most genomic 
actions however, involve direct binding of the receptor to DNA, which is accom-
plished by the DBD. 
Structure of the DBD 
The DBD, the region that is most conserved among NHRs, contains 9 conserved 
cysteine residues. Eight of these conserved cysteines are involved in formation 
of 2 zinc clusters. Four cysteine residues in each of the zinc clusters coordinate 
Consensus GRE AGAACA nnn TGTTCT 
• • 
Consensus ERE AGGTCA nnn TGACCT 
Figure 1.3B Mechanism of DNA binding by SHRs. Homodimeric receptor binds to 2 half-sites of the HRE, 
which are organized as an imperfect palindrome, resulting In so-called head-to-head binding. The HRE 
Is located In the major groove of DNA. The consensus HRE for GR-like receptors and for the ER are indi-
cated. The half-sites are spaced by 3 nucleotides (nnn). 
'7 
zinc in a tetrahedral array (Freedman et al. 1988). Nuclear magnetic resonance 
and crystallographic studies, performed for several NHRs (GR: Hard et al. '990, 
Luisi et al. 1991; ER: Schwabe et al. '990, Schwabe et al. '993, RAR: Knegtel et al. 
'993; 9-cis retinoic acid receptor (RXR): Lee et al. 1993), revealed similar structu-
res for the distinct receptors. Between the third and fourth cysteine residues in 
the NH2-terminal and the COOH-terminal zinc clusters, a-helices are present. 
Upon DNA binding, these a-helices are packed perpendicularly to each other 
(see Figure 1.3B) In the COOH-terminal part of the DBD of the RXR an additional 
a-helix that mediates DNA binding of RXR homodimers was detected (Lee et al. 
1993). This helix is not present in the DBDs of SHRs. So far the three-dimensional 
(3-D) structure of the AR-DBD has not been solved. However, as is discussed in 
Chapter V, the AR-DBD is closely related to the GR-DBD (Hollenberg et al. 1985, 
Trapman et al. 1988), and therefore it can be attempted to build a 3-D model of 
the AR-DBD, based on the crystal structure of the GR-DBD. 
The ability to discriminate between response elements resides in 3 amino 
acid residues, two of which are located between the 2 distal cysteines of the NH2 -
terminal zinc cluster, in the so-called proximal box (P-box) (Danielsen et al. 1989, 
Zilliacus et al. 1991) (Figure 1.3A). The a-helix, containing the pobox, is positioned 
in the major groove of DNA, where the three amino acid residues are making 
base-specific contacts with DNA. The pobox of receptors that bind to glucocorti-
coid response element (GRE}-like half-sites contains a glycine, a serine, and a 
valine residue (Danielsen et al. 1989). In the pobox ofthe ER, which binds to estro-
gen response elements (EREs) a glutamic acid, a glycine and an alanine residue 
are present at the corresponding position {Figure I.3A} (Umesono and Evans 
1989). In the COOH-tenninal zinc cluster, a dimerization function was identified 
in the so-called distal box (D-box) (Figure 1.3A) (Umesono and Evans 1989). Upon 
binding to a palindromic HRE, a symmetric dimerization interface is formed 
(Figure 1.3B) (Luisi et al. 1991). Other domains of SHRs might as well be involved 
in dimerization. The LBD of the ER is involved in hormone dependent dimeriza-
tion (Fawell et al. 1990). Both the LBD and the NH,-terminus contribute to dime-
rization of the GR, AR, and PR (Dahlman-Wright et al. 1992, Wong et al. '993, Tetel 
et al. 1997). There are indications that solution dimerization promotes high-
affinity DNA binding, probably by stabilization of the dimer (Kumar and Cham-
bon 1988, Dahlman-Wright et al. 1992, Wong et al. 1993). 
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Hormone response elements 
Nuclear hormone receptors can bind to HREs in several different modes. Apart 
from monomeric binding (for orphan receptors, including NGF1-B and SF-I), 
homodimeric binding and heterodimeric binding can be observed (reviewed by 
Glass 1994, and by Mangelsdorf et al. 1995). Hormone response elements mini-
mally contain a core recognition motif of 6 bp, but most HREs consist of 2 core 
motifs separated by a spacer of variable length. Three different characteristics of 
HREs, which determine response element recognition, can be distinguished. 
First, the sequence of the core motif, which is specific for subgroups of receptors. 
The GR, MR, PR and AR all bind to GRE-like half-sites (TGTTCT), whereas the ER 
and several non~steroid hormone nuclear receptors recognize TGACCT (Figure 
1.3B) (Danielsen et al. 1989, Mader et al. 1989, Forman and Samuels 1990, 
reviewed by Glass 1994). The GRE and ERE differ at positions 3 and 4 in both half-
sites, which are critical for receptor specific recognition (Nordeen et ai. 1990). 
The second characteristic involves the arrangement of the core region, which is 
organized either as a direct repeat, a palindromic, or an inverted repeat. Third, 
the HRE is characterized by the spacing of the two half-sites. 
In general, SHRs bind as homodimers to (imperfect) palindromic HREs with a 
spacing of three nucleotides (Figure 1.3B) (Umesono and Evans 1989, reviewed by 
Zilliacus et al. 1995). These HREs typically contain a high-affinity binding half-
site, and a second half-site of lower affinity. Binding of the first monomer to 
DNA increases affinity of a second receptor molecule, a mechanism that is 
named cooperativity of binding (Dahlman-Wright et al. 1991). The TR, RAR, VDR 
and PPAR are fundamentally different from SHRs with respect to DNA binding. 
These receptors predominantly heterodimerize with the RXR (Kliewer et al. 1992, 
reviewed by Mangelsdorf et al. 1995), and bind to HREs, which are organized as 
direct repeats with a different spacing, or to (inverted) palindromic motifs. 
Ligand binding might control the formation of either homodimers or hetero-
dimers. In the LBD of the RXR, RAR, and TR, a domain involved in formation of 
solution heterodimers, confering high-affinity DNA binding, was identified 
(Perlmann et al. 1996). After formation of heterodimers between these distinc-
tive receptors and the RXR, a second dimerization interface can be formed 
within the DBD, which restricts heterodimer binding to direct repeats (Perlmann 
et al. 1996). The spacing between the direct repeats can vary, and is important 
with respect to specificity, and determines the polarity of binding of the hetero-
dimer as well (Glass 1994). 
'9 
Cell specijicity 
An intriguing question is in what way cell specific effects are exerted when 
more than one SHR is present in a particular cell. Specificity might be introduced 
by tissue specific metabolism of hormones, expression level of the receptor, the 
presence of specific cofadors that modulate DNA binding and/or transcription 
activation, or interaction with another nuclear receptor (Forman and Samuels 
'990, Glass '994, Rundlett et al. 1995). Adler et al. (1992) observed that androgen 
response elements (AREs) in the mouse sex limited protein gene promoter prefer 
activation by androgens. They showed that DNA sequences adjacent to the ARE 
were critical for inhibition of regulation by the GR, suggesting that other 
proteins are involved in AR specific gene activation (Adler et al. 1993). Receptor 
specific response elements might exist as well, as was suggested by Claessens et 
al. (1996). Several groups postulated that high·mobility group protein HMG'1 
enhances DNA binding of steroid hormone receptors. HMG-l causes DNA 
bending, which probably results in a more stable interaction of the receptor with 
DNA (Onate et al. 1994, Verrier et al. 1997). Although it is generally believed that 
SHRs form homodimers on palindromic HREs, Zhou et al. (1997) observed gene 
activation by the AR through an HRE that was organized as a direct repeat (Zhou 
et al. 1997). In addition, several groups presented in vitro and in vivo evidence for 
formation of heterodimers by the GR and MR (Trapp et al. '994, Liu et al. 1995). 
1.2.3 The hinge region 
The DBD and LBD are coupled by a flexible domain, the so·called hinge region. 
Among members of the SHR·family the hinge region is poorly conserved (Evans 
1988). Naturally occurring mutations in the AR that are associated with the 
androgen insensitivity syndrome (ArS) were not identified in the N·terminal 
half of the hinge region. Nevertheless, several functions are ascribed to this 
region. It not only contains a nuclear localization signal (NLS), as was observed 
by several groups for different SHRs (PR, Guiochon·Mantel et al. '989; ER, Ylikomi 
et al. 1992; AR, Simental et al. 1991, Jenster et al. 1993), but the hinge region is also 
involved in interaction with corepressors for NHRs (Chen and Evans 1995, H6r-
lein et al. 1995). In addition,Tetel et al. (1997) observed that solution dimerization 
of the PR involves the hinge region. 
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1.2.4 The ligand·binding domain 
The LBDs of the distinct NHRs are multifunctional; apart from ligand binding, 
the LBD is involved both in hetero- and/or homo-dimerization and in transcrip-
tion activation. In the absence of ligand, some members of the NHR family are 
involved in silencing of promoter activity through their LBO (Horwitz et al. 
1996), whereas SHRs are bound by a complex of heat-shock proteins. Activity of 
SHRs is affected by interaction with hSP90, which is critical for proper folding of 
the receptors (reviewed by Pratt and Toft 1997). Upon deletion of the COOH· 
terminus, SHRs become constitutively active. 
Transcription activation/unction 
While the AFs that were identified in the NH2-terminal domain of SHRs are con-
stitutively active, in the LBD of these receptors a weak autonomous hormone-
dependent AF (AF-z) has been identified (GR, Hollenberg and Evans 1988; ER, Tora 
et al. 1989; PRo Meyer et al. 1990). Activation function-z may be formed by several 
elements, dispersed over the LBD, which are brought together upon ligand bin-
ding, as was found for the ER-o: and TR-P (Webster et al. 1988, Baniahmad et al. 
1995). A highly conserved region located near the COOH-terminal end of NHRs 
was found to be essential for hormone-dependent activation in the GR and ER-a 
(Danielian et al. 1992), and for both hormone-dependent transcription activation 
and relief of silencing by the TR-P (Baniahmad et al. 1995). Interestingly, this par-
ticular region is lacking in v-erbA, a constitutive silencer (Baniahmad et at. 1995), 
and in some orphan receptors that lack AF-z activity (Danielian et al. 199Z). 
Squelching experiments indicated that AF-2 is likely to be involved in interaction 
with specific coactivators (Baniahmad et al. 1995), a supposition, which was con-
solidated after the cloning of transcriptional coactivators (Horwitz et al. 1996). 
Although the conserved AF-2 region is also present in the AR-LBD, it was pre-
viously thought that AF-z was not active in the AR (Jenster et al. 1995). However, 
TIF2 and GRIPI (the mouse homologue of TIPz), two transcriptional mediators of 
ligand· dependent activation of NHRs, were able to induce AR activity (Hong et 
al. 1996, Voegel et alI996). In addition, Moilanen et al. (1997) recently established 
a ligand-dependent activation function in the AR-LBD, which was weak in mam-
malian cells, and relatively active when the AR was expressed in yeast. AR AF-2 
activity was impaired by presence of the neighbouring hinge region, suggesting 
that repressor proteins that bind to the hinge region modulate AF-2 activity. 
The proteins involved, possibly well conserved from yeast to mammals, might be 
present in relatively high amounts in mammalian cells. 
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Figure 1.4 Schematic view of the ligand binding domain structure, as predicted for the AR. An anti-
parallel 3-iayered «-helical structure, In which helices 4. 5. 6, 8, and 9 are sandwiched between Hl and 
H3 on one side and helices 7, la, and 11 on the other side, is predicted. The 12 ((-helices are represented 
by cylinders and the 2 p-strands by arrows. NH2- and eaOH-terminal amino acid residues of the a-heli-
ces and p-strands, as predicted for the AR, are: Ht:Y6S8-V675 ; H2:? ; H3:A68g-K711 ; H4:V721-Yno ; 
HS:S731-W742; !3t:M752-P757 j jll:P7S8-N762; H6:E763-K768; H7:C775-W787; H8:P792-l803; Hg:Q81S-
K836 ; HlO:R846-E863 ; Hll:L864-K874 ; HI2:E884-S8g1 (Wurtz et al. 1996). Upon ligand binding helix 12 
folds back to the ligand-binding pocket. 
Structure of the LBD 
The structure of the AR-LBD and that of LBDs from other SHRs was probed by 
limited proteolytic digestion analysis (Allen et al. 1992, Beekman et al. 1993, 
Kallio et al. 1994, Kuil et al. 1994, Lazannec et al. 1997). Ligand binding resulted in 
increased stability towards proteases, indicative of a more compact structure. 
Hormone-induced conformational changes were also observed in gel-retar-
dation assays. Receptor-HRE complexes showed a faster migration pattern in the 
presence of an agonist. From both assays it could be concluded that anti-
hormones induce different conformations (Allen et al. 1992, Kallio et al. 1994, 
Kuil et al. 1994). 
In 1995, the crystal structure of the unliganded hRXR-o: LBD (apo-LBD) and 
the structures of the hRAR-yand rat TR-o: LBDs, liganded with agonists (holo-
LBDs), were resolved (Bourguet et 01.1995, Renaud et 01.1995, Wagner et 01.1995). 
The LBDs of these receptors contain 12 a-helices and 2 J3-strands, which are fol-
ded in an a-helical structure of 3 anti-parallel layers, composed of a core region 
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that is sandwiched between two additional layers (Figure 1.4) (Eourguet et af. 
'995, Renaud et af. 1995). Comparison of the structures established for the holo-
LEDs of hRAR-y and rTR-a, and the apo-LED of hRXR-a, revealed one major 
difference; the holo-LBDs displayed a more compact structure, as was previously 
observed in limited proteolytic digestion assays. Ligand binding induces confor-
mational changes mainly affecting helix 12. The AF-2 core region, located in helix 
12, folds back to the ligand-binding pocket and comes in close contact with the 
ligand and helices 3 and 4, thereby forming the 'lid' of the ligand-binding cavity 
(Wurtz et af. 1996). Due to this conformational change, an AF-2 is generated that 
can interact with coactivators (Renaud et af. '995, Wagner et af. 1995). Subse-
quently, Hentlu et af. (1997) showed that substitution of lysine residue 366 in the 
ER - an amino acid residue that is conserved in most NHRs and located in helix 3 -
by an alanine residue, resulted in disturbed ligand-induced transcription activa-
tion. Interaction with coactivator SRC -1 was disturbed, indicating involvement of 
helix 3 in formation of the interacting surface (Hentlu et af. 1997). Although the 
RXR and the RAR belong to different subfamilies (Laudet et af. 1992), their LEDs 
are folded quite similar. Moreover, the AF-2 core region in helix 12 is conserved in 
many NHRs involved in ligand-dependent activation. Wurtz et af. (1996) there-
fore proposed that LEDs of other NHR members might display a common struc-
ture. Recently, the structure of the ER-a, bound to 17P-estradiol and the tissue 
specific antagonist raloxifene was solved {Brzozowski et al. 1997}. The overall 
structure was indeed similar to that observed for the other holo-LBDs. The 
binding cavity for 17P-estradiol is formed by parts of H3, H6, H8 with its 
preceding loop, Hl1 and H12, and the hairpin that is formed by the p-strands. The 
selective antagonist raloxifene induced a different position of helix 12, which 
prevents activation of the AF-2 region. The liganded ER-LED formed homo-
dimers, mainly through contacts between Hll helices, resulting in a 'head-to-
head' arrangement (Brzozowski et af. 1997). 
Interaction between the NH]-terminus and the COOH-tenninus of the 
androgen receptor 
The COOH-terminal domain of SHRs is involved in dimerization (Kumar and 
Chambon 1988, Fawell et af. 1990, Dahlman-Wright et af. 1992, Tetel et af. 1997). In 
addition, upon binding of an agonist, a stable interaction with the NH2-terminal 
domain can be established (Kraus et af. '995, Langley et af. '995, Doesburg et af. 
1997). Indications for such an interaction came initially from several studies. 
Wong et af. (1993) observed that AR dimerization and DNA binding were inhibi-
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ted by the NH,-terminal part of the AR in the absence of hormone. From these 
findings it was concluded that molecular interactions between the NH1- and 
COOH-terminal parts of the receptor might be involved in DNA binding. In an-
other study, it was observed that the NH,-terminus of the AR lowers the dissocia-
tion rate of androgens (Zhou et al. 1995). Moreover, the NH,-terminus of the AR 
contains two TAUs; I.e. TAU-1 and TAU-5 (lenster et al. 1995). TAU-5 becomes acti-
vated upon deletion of the AR LBD (lenster et al. 1995), again indicating an inter-
action between the NH1- and eDOH-terminal domain. From deletion mapping 
studies on the NH1-terminal domain of the AR it was concluded that amino acid 
residues 141~337 were not involved in the interaction, whereas the regions com-
prising amino acid residues 14-149 and 338-490, respectively, were indispensable 
(Langley et al. 1995). Apparently, the TAU-1 region (amino acid residues 100-370) 
is not involved in the NH.- eDOH-terminal interaction, whereas TAU-5 (amino 
acid residues 360-485) is essential (Langley et al. '995, Doesburg et al. 1997). 
Synergism of AF-1 and AF-2 was observed in the ER (Tora et al. 1989). Interaction 
between the NH,-terminal and the COOH-terminal domains might be involved 
in integration of both AFs. Mcinerney et al. (1997) studied the role of coactivator 
SRC-l in the interaction between the NH1-terminus and eaOH-terminus of the 
ER, and concluded that enhancement of ER transcription activation by SRC-1 
requires an NH2-terminus that contains an intact AF-l. Interestingly, 
a functional interaction between the respective domains was established also in 
the presence of an anti-estrogen, using an expression plasmid encoding the 
COOH-terminus of the ER fused to the VP16-activation unit (McInerney et al. 
1997). In addition, coactivators that bind to the AF-2 core region in the COOH-ter-
minus of the AR might be involved in establishment of the interaction. So far, it 
is not known whether this functional interaction is intra- or inter-molecular, 
and whether it concerns a direct or indirect interaction. The fact that Doesburg 
et al. (1997) were not able to detect in vitro interactions suggests that adapter 
proteins might be involved. 
1.2.5 Transcription activation 
Transcription initiation complex 
Sequence specific transcription factors, such as SHRs, interact with general 
transcription factors (GTFs) in the control of gene activation. The GTFs interact 
with the core promotor elements to induce basal transcription (Beato and San-
chez-Pacheco 1996). 
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RNA polymerase JI (RNA Pol~JI) interacts with promoters that contain a TATA~ 
box. To start basal transcription, the GTFs (TFJID, TFJIA, TFIIE, TFJIH, TFJIB) and 
RNA Pol~JI assemble in a transcription initiation complex (TIC). TFJID, composed 
of TATA~binding protein (TBP) and TBP~associated factors (TAF,s), binds to the 
TATA~box. Subsequently, TFJIB, RNA Pol~JI, and TFJIF are recruited. Although 
these factors can form a minimal TIC, the complex is completed upon binding of 
TFJIA, TFJIE and TFIIH (Beato and Sanchez~Pacheco 1996). Evidence has been 
obtained, indicative of the presence of a preformed conlplex that contains RNA 
Pol~JI and GTFs in cells (OSSipow et al. 1995). 
Steroid hormone receptors enhance basal transcription activation, either by 
directly interacting with GTFs or with TAF,s. McEwan et al. (1997) recently 
showed that transadivation by the AR involves recruitment of the transcription 
machinery via TFIIF. In vitro and in vivo interaction of the NH2- terminus of the 
AR with TFJIF was observed. Ford et al. (1997) observed interaction between TAU~ 
1 (n) of the GR and the TBP~subunit of TFJID. In vitro interaction between the PR 
and TAF,lO, involving the PR~DBD, was reported (Schwerk et al. 1995), and TAF,30 
interacts with the AF~2 region in the ER (Jacq et al. 1994). Apart from these direct 
interactions between SHRs and TIC, indirect interactions, mediated by transcrip-
tion intermediary factors or coactivators, aTe likely to be involved (discussed 
below). 
Interaction of SHRs with other sequence specific transcription factors has 
been described. Hormone response elements were shown to synergize with 
response elements for other factors (Schule et al. 1988). Interaction of SHRs 
themselves with other transcription factors has also been observed; protein-
protein interactions between the GR and AP-l result in mutual modulation of 
their gene regulatory activities (Beato et al. 1995). 
Chromatin structure 
In eucaryotic cells DNA is wrapped around histones, forming a nucleosome. 
In this way a nucleosomal structure is obtained, called chromatin. The structure 
of chromatin is an important detenninant of gene regulation (reviewed by 
Beato and Sanchez~Pacheco 1997, and by Wolffe 1997). Nucleosomes can be 
destabilized by histone acetylation, causing relaxation of the DNA structure, 
which facilitates entry of core transcription factors to recognition elements 
(reviewed by Wolffe 1997). On the other hand, access of these transcription 
factors can be restricted by histone deacetylation, causing a 'closed' DNA struc-
ture (reviewed by Pazin and Kadonaga 1997, and Wolffe 1997). Recently, evidence 
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was obtained for a role of coactivators and corepressors for NHRs in remodeling 
of the chromatin structure via recruitment of histon acetylase and his ton deace-
tylase activities, respectively. 
Coactivators 
Apart from SHRs and basal transcription factors, other factors, called coacti-
vators, are involved in gene activation by steroid hormones. Evidence for the 
existence of these factors came from squelching experiments {squelching is the 
phenomenon that a very high expression level of a receptor in transfected cells 
results in inhibition of the transcription activation function of that receptor or 
other receptors}, indicating that coactivators are present in limiting amounts. 
Coactivators were defined as factors which, upon ligand binding, interact 
directly with nuclear receptors. They possess an autonomic activation function, 
are able to relieve autosquelching of NHRs, and enhance NHR-activity upon 
overexpression (Horwitz et al. 1996, Voegel et al. 1996). Potential NHR coactiva-
tors have been cloned, and it appeared that several of these have a high level of 
amino acid sequence identity. Some coactivators, interacting with NHRs, were 
found to have intrinsic histone acetyl transferase (HAT) activity, whereas others 
might recruit proteins with HAT-activity. Different (groups of) coactivators, 
interacting with SHRs, will be discussed below. 
A factor which might function as bridging factor, is TRIPI (TR interacting pro-
tein), a homologue of SUgl, a component of the RNA Pol-II holoenzyme (Lee et al. 
1995). Interestingly, SUgl was shown to interact with TBP (Swaffield et al. 1995) 
and TAF,,30 (Vom Baur et al. 1996). Mouse SUgl binds to the AF2-domain of the 
liganded ER (Vom Baur et al. 1996). 
Several coactivators are, either directly or indirectly, involved in chromatin 
remodeling. TIFI (transcriptional intermediary factor 1) interacts with the ligand 
activated AF-2 of the ER and PR (Le Douarin et al. '995, Vom Baur et al. 1996), and 
might interact with proteins that influence chromatin structure (Le Douarin et 
al. 1996). SRC-l (steroid receptor coactivator-l) (Onate et al. 1995) and ERAP160 
(ER-associated protein) (Halachmi et al. 1994) interact with the ER, GR, and PR in 
the presence of their respective ligands, and enhance transcription activation. 
SRC-l was also found to interact with P300/CBP (CREB binding protein) (Kamei et 
al. 1996) and pCAF (P30o/CBP-associated factor) (Yang et al. 1996), which are pro-
teins that possess intrinsic HAT activity. Recently, SRC-l was found to have 
intrinsic HAT activity as well (Spencer et al. 1997). TIF2 (transcriptional interme-
diary factor 2) and GRIP1 (GR-interacting protein 1); (mouse homologue of TIF2) 
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(Voegel et of. 1996, Hong et af. 1996) are partially homologous with SRC-1, sugge-
sting the existence of a gene family of nuclear receptor transcriptional media-
tors (Voegel et af. 1996). TIF2 and GRIP1 interact with the AF-2 region in the LBD 
of the ER, GR, PR, and AR, and contain an activation domain. Another factor rela-
ted to SRC-1 and TIF2 is RAC3 (receptor-associated coactivator 3) (Li et af. 1997) 
that was shown to interact in a ligand-dependent way with the AF-2 region of 
non-steroidal NHRs, resulting in enhanced transcription activation. 
The protein P300/CBP interacts directly with the LBD of the GR (Kamei et a/. 
1996, Yao et a/. 1996), and with the coactivators SRC-1 and ERAP160 (Hanstein et 
af. '996, Yao et a/. 1996, Spencer et af. 1997). It was observed by Smith et a/. (1996) 
that SRC-l and CBP synergize in their stimulation ofER- and PR-dependent trans-
cription. Interestingly, P300/CBP appears to bind to many other transcription 
factors, such as CREB, c-Fos, v-Jun, c-Jun, and the viral oncoprotein Ela. In addi-
tion, interaction with the GTFs TBP and TFIIB was observed (reviewed by Shi-
kama et af. 1997). The protein P300/CBP may function as an integrator, which 
enables regulatory molecules to be recruited and assembled at sites of transcrip-
tional activity (Shikama et 0/. 1997)). Mutations in the CBP gene were associated 
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Figure 1.5 Mechanisms of chromatin remodeling. Upper part: corepressors [for example nuclear recep-
tor corepressor, (N-CoR)) interact with factors such as mSin3, causing histone deacetylation. As a result, 
basal transcription is repressed. Upon ligand binding (+H), the NHR-corepressor complex dissociates, 
and coactivators are allowed to bind. lower part: both non-steroidal N HRs and SHRs tether coactiva-
tors to DNA, which possess intrinsic HAT activity (SRC-l, P300/CBPj, or interact with other factors, 
found to have HAT activity (P300/CBP, pCAF) (Based on a model proposed by Heinzel et of. 1997). 
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with Rubinstein-Taybi syndrome, an autosomal-dominant disease, characteri-
zed by mental retardation, physical abnormalities, and increased incidence of 
neoplasia (Petry et af. 1995). A general dysregulation of gene expression may 
underly this syndrome. 
As summarized in Figure 1.5, SHRs can recruit HAT activity via interaction 
with coactivators, which can even possess HAT activity by themselves. Although 
acetylation of histones is an important step with respect to gene activation, it is 
not sufficient. According to Jenster et af. (1997) gene activation by SHRs involves 
a two-step model. Apart from relaxing the DNA structure, the function of recep-
tors and coactivators is the recruitment of basal transcription factors. 
The target protein(s) of several other candidate coactivators is at present 
unknown. One of them is R1P140 (receptor-interacting protein 140), which 
enhances transcription activation upon binding to the AF-2 region of the 
liganded ER (Cavailles et af. 1994, Cavailles et al. 1995). Another example is ARA70 
(AR-associated protein), cloned as an androgen-binding protein. Ligand depen-
dent interaction of ARA70 with the LBD of the AR results in lO-fold increased 
transcription activation (Yeh and Chang 1996). Activation of the PR, GR and ER is 
only weakly increased. 
Corepressors 
Some non-steroidal NHRs bind to DNA in the absence of hormone and repress 
basal promoter activity. The mechanism underlying this way of gene expression 
was not understood until 1995, when two corepressor proteins were isolated; i.e. 
N-CoR (nuclear receptor corepressor) (H6r1ein et al. 1995, Kurokawa et al. 1995) 
and SMRT (silencing mediator for retinoids and thyroid hormone) (Chen and 
Evans 1995). Corepressor proteins, which are present in the cell in limiting 
amounts, are tethered to DNA by interaction with non-steroidal NHRs. Upon 
ligand binding, the corepressor is released, allowing interaction of the receptor 
with coactivator proteins (reviewed by Horwitz et al. 1996). N-CoR was shown to 
interact with a region in the hinge region of TR, RAR, and TR-RXR, and RAR-RXR 
heterodimers (H6rlein et af. 1995, Kurokawa et al. 1995). Interestingly, the type of 
response element determines the affinity of N-CoR binding (Kurokawa et al. 
1995). The second corepressor that has been identified is SMRT, a factor inter-
acting with TR, RAR, and RXR (Chen and Evans 1995). Repression results from 
tethering of histone deacetylases to the DNA at sites close to the responsive 
element. Both N-CoR and SMRT interact with mSin3A (a homologue of the yeast 
global transcriptional repressor), which in turn interacts with HDACI (histone 
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deacetylase 1) (Heinzel et al. '997, Nagy et al. 1997). Thus, a three-step mechanism 
can be proposed with respect to transcription regulation by these non~steroidal 
NHRs, Step one involves the establishment of a repressive chromatin structure, 
and step two the release of corepressors upon ligand binding, subsequently lea-
ding to recruitment of acetyl transferases which disrupt the chromatin tem~ 
plate. Finally, step three, the interaction of the AFs of both the receptors and the 
recruited coactivatoIs with basal transcription factors results in gene activation 
(Wolffe 1997). Steroid hormone receptors are probably not involved in tethering 
of histon deacetylase activity to DNA, as they are bound by a hsp complex in the 
absence of ligand. However, SHRs are inhibitory when they are occupied by 
antagonists, and Horwitz et al. (1996) suggested that corepressors might playa 
role in this repression. Recently, dominant negative mutations in the TR~P gene 
were associated with persistent SMRT binding in the presence of ligand, while 
ligand binding was hardly affected (Yah et al. 1997). 
A factor that bound to the LBD of the TR, named TRUP (TR-uncoupling protein) 
inhibited transcription activation by TR and RAR in the presence of ligand, TRUP 
was shown to inhibit binding of TR-RXR and RAR-RXR heterodimers to DNA 
(Burris et al. 1995). 
In Paragraph 1.1, a simple model explaining the mechanism of action of SHRs 
was shown. The picture, however, is getting more and more complicated, which 
is reflected in the statement by Beato and Sanchez-Pacheco (1996): "SHRs might 
act as signal integrator; sensing a variety of other signaling systems and at the 
same time influencing the function of these other pathways". 
1,3 Sex differentiation 
1.3.1 Mammalian sex differentiation 
Chromosomal sex is established at the time of fertilization, when the ovum, con-
taining 22 autosomes and 1 sex chromosome (X) in the female pronucleus, is 
complemented with 22 autosomes and 1 sex chromosome (X or Y) in the male 
pronucleus, which is derived from the sperm nucleus. Upon DNA replication and 
fusion of the female and male pronuclei, a 46,XX or 46,XY zygote is formed. In 
the presence of a Y chromosome, male gonadal sex is established around day 43-
50 of gestation in the human. Analyses of sex chromosomes of 46,XY females 
and 46,XX males led to the discovery of the SRY gene, which could be mapped to 
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the testis-determining region of the Y chromosome (Sinclair et al. '990, Berta et 
al. 1990). This SRY gene triggers the development of the indifferent gonad into a 
testis (Figure 1.6), and mutations in the DNA-binding domain of SRY protein are 
associated with gonadal dysgenesis in 46,XY males (Berta et al. '990, Jager et al. 
1990). On the other hand, overexpression of the mouse homologue of SRY (Sry) in 
transgenic mice with an XX constitution caused also sex reversal (Koopman et 
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Figure 1.6 Sex differentiation cascade 
DAX-l : DSS-AHC-critical region on the X gene; SRY : Sex determining region Y ; SOX 9 : SRY-like HMG 
box 9; lHR: Luteinizing hormone receptor; AMHR : Anti-mOllerian hormone receptor; StAR: Steroido-
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al. 1991). The SRY gene encodes a DNA-binding protein containing an HMG-box, 
which is also present in several other transcription factors. On DNA-binding, 
downstream genes which are involved in sex differentiation are activated. One 
of the candidate downstream genes is steroidogenic factor 1 (SF-l), encoding an 
orphan nUclear-receptor protein. The SF-l gene product is, among other tissues, 
expressed in the urogenital ridge prior to differentiation of the gonad (Ikeda et 
al. '994, Luo et al. 1994). Inactivation of the gene encoding the mouse homologue 
of SF-l (Ftz-Fl) resulted in mice in which adrenals and gonads were lacking (Luo 
et al. 1994). Apart from being involved in formation of steroidogenic organs, SF-1 
also plays a more direct role in steroidogenesis (Luo et al. 1994). Expression of 
P450 steroidogenic enzymes is regulated by SF-1 (Clemens et al. '994, Bakke and 
Lund 1995). 
Mutations in several other genes cause various syndromes, with gonadal 
dysgenesis, indicating that these genes may playa role in development of the 
gonads. One of them is SOX9, an SRY-related gene. Mutations in the SOX9 gene 
are associated with an autosomal dominant syndrome characterized by skeletal 
abnormalities (campomelic dysplasia) and gonadal dysgenesis, causing sex 
reversal in 46,XY individuals (Wagner et al. 1994). Mutations in the gene enco-
ding DAX-1, a member of the NHR family, result in congenital adrenal hypoplasia 
and hypogonadotropic hypogonadism (Foster et al. '994, Muscatelli et al. 1994). 
In mice, the gene is expressed at early stages of development of adrenals and 
gonads. In fetal testes a downregulation is observed, whereas expression 
continues in developing ovaries (Swain et al. 1996). Recently, Swain et al. (1997) 
suggested that DAX-1 functions as an anti-testis gene. 
The fetal testis produces two hormones, indispensable for establishment of 
phenotypic male sex characteristics (Figure 1.6). Sertoli cells produce anti-mulle-
rian hormone (AMH), a member of the TGF-p family of peptide growth/differen-
tiation factors, which is responsible for miillerian duct regression in the male 
embryo (Josso et al. 1977). Expression of AMH is possibly regulated also by SF-1 
(Shen et al. 1994). In the female embryo, where the ovaries lack production of 
AMH, mullerian ducts are allowed to develop into female internal genitalia (fal-
lopian tubes, uterus, and the upper part of the vagina) (Conte and Grumbach 
1997). AMH overexpression in female transgenic mice caused inhibition of miil-
lerian duct differentiation (Behringer et al. 1990). AMH exerts its effects through 
the AMH type II receptor (Baarends et al. '994, di Clemente et al. 1994). Muta-
tions in the gene encoding AMH or the gene encoding the AMH-receptor are 
associated with persistent miillerian duct syndrome, characterized by the pre-
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sence of miillerian derivatives in normal virilized males (Josso et al. 1993, 
Grootegoed et al. 1994, Imbeaud et al. 1996). Sertoli cells are not only involved in 
production of AMH, but also stimulate differentiation of Leydig cells from testi-
cular interstitial cells. These Leydig cells, which appear around day 60 of human 
gestation, start to secrete testosterone. First autonomously, and later under 
influence of maternal hCG (human chorionic gonadotropin). In the male embryo, 
the internal genital system (epididymis, vas deferens, seminal vesicles, and eja-
culatory ducts) subsequently develops from the wolffian ducts in the presence of 
testosterone. The male and female internal genital systems are formed from dif-
ferent primordia. In contrast, external genitalia, and prostate and vagina, respec-
tively, develop from the same primordia. In the human, male masculinization of 
the external genitalia is observed, starting around days 65-77 of gestation. Con-
version of testosterone to the more potent androgen DHT by the enzyme 50:-
reductase type II in the target tissues is essential (Andersson et al. 1991). In the 
female embryo, the clitoris, labia minora and labia majora (female external geni-
talia) develop from the genital tubercle, folds and swellings, respectively, and the 
urogenital sinus becomes the vagina. In the male embryo the presence of DHT 
results in formation of glans penis, shaft penis and scrotum from genital tuber-
cle, folds and swellings, respectively. The prostate develops from the urogenital 
sinus under influence of DHT. 
The development of secondary sex characteristics is regulated by increased 
production of sex hormones during puberty. At that time, the pituitary gland is 
stimulated by gonadotropin-releasing hormone, secreted by the hypothalamus. 
The pituitary starts in turn to secrete the gonadotropins LH (luteinizing hor-
mone) and FSH, resulting in increased production of sex hormones. In boys, 
secondary sex characteristics start to develop between 9,5 years and 13,5 years 
(Marshall and Tanner 1970). Deepening of the voice, appearance of body and 
pubic hair and spermatogenesis are induced by elevated concentrations of 
androgens. Usually, the maximum rate of growth is reached when the genitalia 
are already well-developed (Marshall and Tanner 1970). In girls, puberty starts 
around the age of 11 years. Breast development, growth of pubic hair (under 
influence of adrenal androgens), and a growth spurt are observed. The first 
menarche represents one of the physical changes observed in pubertal girls 
(Marshall and Tanner 1969). During adult life, gonadotropins and sex hormones 
are responsible for maintenance and functioning of sex organs in males and 
females. 
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1.3.2 Abnormal male sex differentiation 
As discussed in the previous section, sex differentiation results from a cascade of 
events, involving many proteins that are encoded by autosomal- and sex-chro-
mosomal genes. Mutation of these genes can result in aberrant sex differen-
tiation. In general, disorders of sex differentiation can be divided in three 
categories: true hermaphroditism, female pseudohermaphroditism, and male 
pseudohermaphroditism. These categories are related to abnormalities in gona-
dal development and/or gonadal dysgenesis. 
Many different forms of gonadal dysgenesis can be observed. Mutations in 
the SRY gene are associated with gonadal dysplasia in both 46,XX and 46,XY 
individuals. SOX9 gene mutations can cause, apart from campomelic dysplasia, 
gonadal dysplasia (reviewed by Conte and Grumbach 1997). True hermaphrodi-
tism is seen in individuals presenting with both ovarian and testicular tissue in 
one or both gonads. The differentiation of the internal genital system and 
external genitalia is highly variable and depends on the condition and composi-
tion of the gonads. 
Female pseudohermaphroditism: individuals with a 46,XX constitution pre-
senting with masculinization of internal genital system and external genitalia, 
although ovaries are present. Congenital adrenal hyperplasia, due to mutations 
in genes involved in cortisol synthesis [2Ia-hydroxylase gene (P450C21), 
lIf3-hydroxylase gene (P450ClI)], is frequently observed. A high ACTH (adreno-
corticotropic hormone) level results in increased adrenal androgen production 
(Morel and Miller 1991). The degree of masculinization depends on the androgen 
level and the period of gestation during which the fetus was first exposed to the 
increased androgen level. 
Mutation of the P450 aromatase gene, encoding an enzyme involved in conver-
sion of C19 steroids to estrogens, is another cause of female pseudohermaphrodi-
tism. An excessive amount of testosterone, resulting from inactive placental 
P4S0 aromatase, can cause masculinization of the external fetal genitalia. At the 
time of puberty, a high testosterone level may cause mild virilization (hirsutism 
and acne). In addition, absence of breast development, polycystic ovaries, abnor-
mal menstruation, tall stature, and osteoporosis can be observed, because pro-
duction of estrogens is blocked (Conte et al. 1994, Simpson et al. 1994). 
Male pseudohermaphroditism, 46,XY individuals with testes, showing 
incomplete masculinization of internal and external genitalia. Several causes, 
such as Leydig cell hypoplasia, defects in enzymes involved in testosterone 
synthesis, sa.-reductase type II deficiency, and androgen resistance due to muta-
tion of the AR gene, are discussed below. 
l3 
Male pseudohermaphroditism 
46,XY individuals with the persistent rnullerian duct syndrome have a rare form 
of male pseudohermaphroditism. Persistent mullerian duct syndrome is caused 
either by mutation of the AMH gene, or by a defect in the gene encoding the 
AMH type II receptor, both indispensable for miillerian duct regression (Josso et 
al. '993, Grootegoed et al. '994, Imbeaud et al. 1996). Characteristic for this syn-
drome, is the presence of a uterus and of fallopian tubes in otherwise normally 
virilized males. 
Leydig cell hypoplasia results in a low rate of production or even absence of 
testosterone. During the critical period of sex differentiation, testosterone secre-
tion by the Leydig cells is initially autonomous, and thereafter controlled by 
maternal hCG. After establishment of the pituitary-gonadal axis, this task is 
accomplished by LH. In some individuals with Leydig cell hypoplasia, mutations 
were detected in the gene which encodes the LH receptor, through which both 
hCG and LH are signaling (reviewed by Themmen et al. 1997). An inactivating LH 
receptor mutation can result in different phenotypes, ranging from 46,XY indivi-
duals with completely female external genitalia, to individuals who are mildly 
affected (hypergonadotropic hypogonadism and micropenis). Evidence for auto-
nomously produced testosterone by the fetal Leydig cells came from the obser-
vation that androgen dependent structures, epididymides and vasa deferentia, 
are present in individuals carrying an LH receptor mutation that completely 
abolished receptor function (Kremer et al. 1995, Thernmen and Brunner 1996). A 
different type of mutation of the LH receptor gene is associated with male-limi-
ted precocious puberty. A mutation of the LH receptor gene resulting in constitu-
tive activation of the encoded receptor protein of these indiViduals, results in 
continuous stimulation of Leydig cells in the absence of LH (Themmen and Brun-
nef1996). 
Defects in enzymes involved in testosterone biosynthesis are another cause 
of genital ambiguity in males (Figure 1.6). The recently cloned steroidogenic 
acute regulatory (StAR) protein facilitates transport of cholesterol from the outer 
to the inner membrane of mitochondria, a rate limiting step in steroidogenesis 
(Lin et al. 1995). Both LH and SF-1 (Clark et al. 1994), regulate StAR expression. 
Mutation of the gene encoding the StAR protein, or one of the genes encoding 
the downstream enzymes 3P-hydroxysteroid dehydrogenase type II (3P-HSD) 
and 17f'-hydroxylase (P450c17), affect both testosterone and cortisol synthesis 
(Lin et al. '995, Simard et al. '995, Yanase et al. 1991, respectively). As a result, 
either male or fernale pseudohennaphroditism, and adrenal insufficiency, are 
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observed. The enzyme 17P-hydroxysteroid dehydrogenase (17P-HSD) type III is 
exclusively expressed in the testis (Geissler et ol. 1994). Mutation of the gene 
encoding this isotype was identified in 46,XY individuals with unambiguous 
female external genitalia at the time of birth. During puberty, virilization of the 
external genitalia is observed. This phenotype closely resembles an incomplete 
androgen insensitivity phenotype. 
The enzyme sa-reductase is essential for conversion of testosterone to DHT. 
Both testosterone and DHT activate transcription through the AR. However, DHT 
binds the AR with greater affinity than testosterone, and is a more potent acti-
vator of androgen-responsive genes in vivo (Wilbert et al. 1983, Deslypere et al. 
1992). Conversion to DHT and thus amplification of the androgenic response 
may be essential in peripheral tissues, where testosterone concentrations are 
lower (Wilbert et ol. 1983). Alternatively, testosterone and DHT may be involved 
in regulation of specific genes (Randall 1994a). Two sa-reductase isoforms have 
been identified, each showing a tissue specific expression pattern. sa-Reductase 
type II, the isoform involved in development of male external genitalia, is 
expressed in many androgen target tissues (Andersson et al. 1991, Wilson et al. 
1993). Male individuals with sa-reductase deficiency, caused by mutation of the 
type II gene, have normal absence of miillerian duct development and normal 
virilized wolffian duct structures. However, differentiation of the urogenital 
sinus and genital tubercle is not observed, resulting in absence of the prostate 
and ambiguous or female external genitalia at birth. Affected individuals are 
therefore often raised as girls (Imperato-McGinley et al. 1974). At puberty, addi-
tional virilization results in deepening of the voice, an increased muscle mass, 
growth of the penis, scrotal development, testicular descend, and affected indivi-
duals may even ejaculate. A typical female pubic hair pattern develops (Impe-
rato-McGinley et al. 1974). The additional virilization may result from the action 
of testosterone, because testosterone is available at a high level during puberty. 
In addition, some testosterone may be converted to DHT by residual sa-reduc-
tase activity and/or by other sa-reductase isotypes (Randall 1994a). 
Inactivating mutation of the AR gene resulting in partially or non-responsive 
androgen target tissues, is the main cause of AIS. The clinical phenotypes and 
the underlying molecular basis of AIS will be discussed in Paragraphs 1.4.1 and 
1-4.2• 
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1.4 Androgen insensitivity syndrome 
1.4.1 Clinical characteristics 
In '947, Reifenstein reported about families presenting with hypospadias, infer-
tility, and gynecomastia, a syndrome that showed an X-linked pattern of inheri-
tance. A few years later, Morris (1953) described 82 individuals with a female 
appearance and with testes, a syndrome that he named 'testicular feminization'. 
Wilson finally proposed that both testicular feminization and Reifenstein syn-
drome result from end-organ resistance to androgens (Wilson et al. 1974). Once 
the AR gene was cloned by several groups, it turned out that mutation of the AR 
gene formed the molecular basis of these forms of male pseudohermaphrodi-
tism, called androgen insensitivity syndrome (AIS). AIS is an X-linked disorder 
(the AR was mapped to Xql1-12), and only 46,XY individuals seem to be affected 
(Brown et al. 1989). Female carriers are unaffected although some delay in 
puberty has been observed (Quigley et al. 1995). Women carrying two affected 
alleles have never been described, and, as affected males are infertile, this would 
involve a rare genetic event. The large spectrum of clinical phenotypes observed 
in AIS will be discussed below. 
In individuals with complete androgen insensitivity syndrome (CAIS) due to 
fuB inactivation of the AR, testes are present and wolffian ducts are absent. In 
general, the external genitalia show a female phenotype, and miillerian ducts 
are usually absent as AMH action in the fetus is normal. However, histopatho-
logical studies revealed that in some CAIS patients miillerian duct structures are 
present (Rutgers and Scully 1991). This may be explained by a high estrogen level 
in the AIS fetus, which may interfere with AMH action (Ulloa-Aguirre et al. 
1990). Alternatively, complete AMH action may require androgen action (Quig-
ley et al. 1995). At puberty, androgen resistance results in a high LH level and 
subsequently in an increased testosterone level. Testosterone is in turn aroma-
tized to estradiol, which is responsible for the breast development and the typi-
cal female body contour seen in CAIS. Pubic and axillary hair is absent or sparse. 
In a 46,XY individual with a complete AR gene deletion, sparse pubic hair was 
observed (Quigley et al. 1992b); possibly, such sparse hair growth can also occur 
in the absence of androgens. Individuals with CATS usually come under medical 
attention for an inguinal hernia containing a testis, in infancy, or at puberty 
because of primary amenorrhea. 
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Partial androgen insensitivity syndrome (PAIS) includes several phenotypes 
ranging from individuals with a predominantly female appearance (cases with 
external female genitalia and pubic hair at puberty, or with mild cliteromegaly, 
and some fusion of the labia), to cases with ambiguous genitalia, or individuals 
with a predominantly male phenotype (also called Reifenstein syndrome). 
Patients from this latter group present with a micropenis, perineal hypospadias, 
and cryptorchidism (non-descended testes). Wolffian duct derived structures 
may be fully developed or rudimentary in PAIS, dependent on residual androgen 
activity. At puberty, elevated LH, testosterone and estradiol levels are observed, 
but in general, the degree of feminization is less as compared to individuals with 
CAIS. In some publications, it is suggested that the spectrum of phenotypes in 
AIS should be broadened to include individuals with mild symptoms of undervi-
rilization [mild androgen insensitivity syndrome (MAIS1]. 
Although severe forms of hypospadias have been described as a feature of 
AIS (Batch et al. 1993b, Ris-Stalpers et al. 1994b, Kaspar et al. 1993), AR mutations 
do not seem to be a frequent cause of isolated hypospadias (Hiort et al. '994a, 
Allera et al. '995, Sutherland et al. 1996). 
In several AIS patients having the same AR mutation, genotype· phenotype 
variation has been observed (Batch et al. '993a, Imasaki et al. '994, Evans et al. 
1997; see also Table I.1). There are indications that receptor activity is influenced 
by length of the polymorphic poly-glutamine stretch (Mhatre et al. '993, Cham-
berlain et al. '994, Jenster et al. '994, Kazemi-Esfarjani et al. 1995). In addition, 
receptor functioning is modulated by additional factors (e.g. androgen level, or 
the expression level of co activators). It is evident that genotype-phenotype 
variation is one of the complicating factors with respect to genetic counseling 
(Morel et al. 1994). 
1.4.2 Clinical diagnosis, mutation detection, and functional studies 
Since the cloning of the AR, molecular biology has greatly improved the diagnos-
tics of AIS. However, as these techniques are very time consuming, clinical endo-
crinological tests are still indispensable, to exclude beforehand mutation of the 
LH receptor gene, of the genes encoding enzymes involved in testosterone 
synthesis (P450c17 gene, 17f3-HSD gene), or of the 5a-reductase type II gene. These 
defeds may underlie a phenotype resembling AIS, especially in young children. 
In some individuals with AIS, an elevated testosteroneJDHT ratio is measured, 
although the ratio is still lower than in cases with 5c<-reductase type II defi-
ciency. This phenomenon is ascribed to decreased peripheral sa-reductase 
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Table 1.1 Mutations observed at least 3 or more times in unrelated individuals with AIS. 
Mutation Number oftimes reported epG-site 
CAIS PAIS 
Arg 598 Gin 3 yes 
Arg 606 His 4 yes 
Asn 696 Ser 3 no 
Asp 723 Tyr 3 no 
PheJSSleu 3 no 
Ala 7S6 Thr 4 yes 
Arg 76S Cys 6 yes 
Arg 76S His 4 yes 
Arg 770 Trp 3 yes 
Met 771 lie 2 3 no 
Gin 789 Glu 3 no 
Arg 822 Stop 3 yes 
Arg 831 Cys 3 yes 
Arg 831 His 10 yes 
Arg 846 Cys 9 yes 
Arg 846 His 3 6 yes 
Val 8S7 leu 4 no 
Val8S7 Met 3 2 yes 
According to the AR gene mutation database of Gottlieb et al. 1997 (release september 1997). 
Numbering of the amino acid residues Is based on an AR with a poly-glutamine stretch of 
20 glutamines, and a polymorphic glycine stretch of 16 residues (Brinkmann et al. 1989). 
activity, secondary to AIS (Imperato-McGinley el al. 1982, Wilson el al. 1993). 
An important clinical test, which can easily be performed and discriminates 
between CAIS and PAIS, is Ihe SHBG (sex hormone-binding globulin) suppres-
sion test (Sinnecker el al. 1997). Testosterone in blood is bound (98%) by SHBG 
(60%) and albumin (38%). Sex hormone-binding globulin is produced in the 
liver, and in normal males the production is down regulated by androgens. 
Measuring the SHBG level before and after administration of the anabolic 
steroid stanozolol, which does not have virilizing potency, provides an indication 
of AR functioning in vivo (Sinnecker el al. 1997). This test may be very useful with 
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respect to sex assignment in children with partial AIS. Holterhus et al. 1997 (see 
also Chapter III) reported an exceptional case presenting with PAIS, in whom the 
outcome of the SHBG-test and the phenotype did not match, due to somatic 
mosaicism. 
Molecular analysis of the androgen receptor 
Most of the mutations that have been found for the AR, are caused by point 
mutations or small deletions and insertions. Although some mutations were 
found several times in unrelated individuals (Table 1.1) no major hotspots for 
mutations, as for example is observed in cystic fibrosis (Macek et al. 1997), exist 
in the AR gene. This implies that exon- and intron-flanking sequences have to be 
determined to find mutations (Gottlieb et al. 1997). Screening methods like poly-
merase chain reaction (PCR)-denaturing gradient gel electrophoresis (Sheffield 
et al. 1989, De Bellis et al. 1994). and PCR single-strand conformation polymor-
phism (SSCP) analysis (Orita et al. 1989, Brilggenwirth et af. 1996; see also Chapter 
II) followed by sequencing, are frequently used for mutation detection in the AR. 
Both methods allow fast screening, and only small amounts of genomic DNA are 
needed. Once a mutation has been established, expression plasmids containing 
eDNA of a mutated receptor can be created, and subsequently functional studies 
can be performed. DNA binding can be studied in vitro by the use of a gel-shift 
assay, or ex vivo, in a promoter-interference assay (Kuil et al. 1996), Cotrans-
fectian of an AR expression plasmid and a reporter plasmid to Chinese hamster 
ovary (CHO) cells, or monkey kidney cells (COS-I) provides information about 
transcription activation capacities of a specific AR. Reporter plasmids carry a 
gene of which expression can easily be measured, such as the chloramphenicol 
acetyl transferase (CAT) gene, the luciferase (iuc) gene, or the growth hormone 
gene. Expression of these genes is regulated by simple or complex androgen-
responsive promoter sequences that are cloned in front of the reporter gene. 
Recently, McPhaul et al. (1993a) described an adenovirus-mediated transcription 
activation assay. Genital skin fibroblasts derived from AIS patients and controls 
were infected with reporter plasmids, allowing measurement of transcription 
activation capacities of the endogenous AR in a patient-specific cellular back-
ground (McPhaul et al. 1993a, McPhaul et al. 1997). Although genital skin fibro-
blasts are no androgen target cells, this assay may be more sensitive than 
cotransfection studies performed in mammalian cells. 
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Biochemical studies 
Before the cloning of the AR gene, only hormone-binding studies were available 
to establish the diagnosis AIS. Nowadays binding studies are still performed to 
study receptor abnormalities. Cultured genital skin fibroblasts, a suitable model, 
are often used. These cells can be obtained relatively easy, and do not contain 
PRs and ERs (Brown and Migeon 1981). For AR-binding assays, genital skin fibro-
blasts are cultured in monolayers and incubated with an increasing amount of 
tritiated hormone. The data obtained can be transformed (Scatchard analysis) to 
calculate the maximal number of specific binding sites (Bmax) and the equili-
brium dissociation constant (Kd). In addition, the hormone-dissociation rate (k) 
and AR- thermolability can be measured. Based on the results of Scatchard ana-
lysis, patients can be classified as being receptor positive or receptor negative. In 
this latter situation, hormone binding cannot be detected, whereas in receptor-
positive AIS either normal, or qualitatively (aberrant Kd) and lor quantitatively 
(low Bmax) abnormal binding can be observed. 
Western blotting followed by immunostaining, is performed to study AR 
protein expression in transfected cells and in genital skin fibroblasts. The wild 
type AR appears normally as a 110-112 kDa doublet, although the calculated 
molecular mass is 98.4 kDa. It is known that the glutamine stretch in the NH2-
terminal part of the receptor retards migration of the AR during SDS-poly-
acrylamide-gel electrophoresis (PAGE); i.e. AR protein is more retarded when it 
contains a longer glutamine stretch. In addition, lengthening of the glutamine 
stretch causes an increased spacing between the isoforms, indicating that the 
observed retardation not only results from an increased molecular mass (Jenster 
et a1. 1994). The 112-kDa isoform represents a hormone-independently-
phosphorylated isoform. Serine 80 and Serine 93, which are in two Ser-Pro direc-
ted kinase consensus sites, are essential for the appearance of the 112-kDa 
isoform, as was shown by amino acid substitution studies (Jenster et al. 1994, 
Zhou et a1. 1995). Upon incubation of transiently transfected cells or genital skin 
fibroblasts with androgen (RI881), a third isoform of 114 kDa of which the 
appearance is correlated with DNA binding, is induced (Jenster et a1. 1994). This 
phenomenon was also observed for the PR and ER (Takimoto et a1. 1992, Lahooti 
et a1. 1994). In genital skin fibroblasts of a patient with PAlS, an aberrant hormone-
induced upshift was observed (Briiggenwirth et a1. '997; see also Chapter VI). 
Subcellular localization studies can be performed by immunohistochemistry 
(Simental et a1. 1991, Quigley et a1. '9923, lenster et a1. 1993). Although immuno-
histochernistry works fine on genital skin sections, it is difficult to perform on 
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cultured genital skin fibroblasts. Bruggenwirth et al. (1997) (see also Chapter VI) 
therefore studied subcellular localization of the AR by preparing cytosols and 
tight nuclear-bound fractions which were analyzed by Western-immunoblot-
ting. Recently, Georget et al. (1997) studied AR trafficking in living cells using 
green fluorescent protein derived from the jellyfish Aequoria victoria and fused 
to the AR protein. 
Genetic counseling 
AIS is not a life-treathening disease, however, because PAIS may lead to severe 
physical abnormalities that are often causing psychological problems, genetic 
counseling is offered to AIS families. Once the causative mutation has been 
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Figure 1.7 Restriction site analysis in a family with (AIS. Genomic DNA was amplified by the use of exon 
2 primers. peR products were completely digested with 89111. Gel-electrophoresis was performed on a 
1% agarose gel. In case of a wild type AR gene, a 312 bp peR fragment is visible, whereas In the presence 
of a mutation the peR product is digested, and yields 2 PCR fragments of204 and 108 bp. Details about 
the patient are described In Chapter V. lane 1: 46,XX grandmother of the index patient who is a carrier 
of the mutated gene: lane 2: 46,XX aunt of the index patient; lane 3: 46.XX mother, who is a carrier of 
the mutated allele; lane 4: 46,XY index patient; lane 5: 46,XY father of the index patient. The index 
patient is indicated with an arrow. 
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traced, pedigree analysis can be performed. Some mutations create or destroy a 
recognition site for a restriction enzyme, allowing rapid screening (for an 
example, see Figure 1.7). Alternatively, intragenic polymorphisms like the highly 
polymorphic (CAG)nCAA-repeat encoding a glutamine stretch (Sleddens et a/. 
1992), the polymorphic (GGC}n-repeat encoding a glycine stretch (Sleddens et a/. 
1993), and the HindIII polymorphism (Brown et a/. 1989) or Stu I polymorphism 
(Lu and Danielsen 1996), can be used (in combination) as an X-chromosomal 
marker (Ris-Stalpers et a/. '994a, Davies et a/. 1995). The HindIll polymorphism 
was even applied for prenatal diagnosis in a family with PAIS while the causa-
tive mutation had not been identified (Lobaccaro et a/. 1994). This is not without 
risk in PAIS families, as ambiguous genitalia can result from mutations in other 
genes as well (Hughes et a/. 1994). Therefore, Lobaccaro et a/. (1994) confirmed 
the diagnosis by sonography and androgen-binding studies, performed on 
trophoblastic cells. Boehmer et a/. (1997) recently described a family, in which 
the length of the (CAG)nCAA-repeat could not be consistently associated with 
the disease phenotype, as germ-line mosaicism appeared in the mother. In addi-
tion, in X-linked diseases like AIS, a relatively large number of de novo mutations 
are found. This is a complicating factor for pedigree analysis based on polymorp-
hisms, in families with only one affected member (Davies et a/. 1995). 
1.4.3 Mutations found in individuals with androgen insensitivity 
syndrome 
After the cloning of the AR gene, many different AR gene mutations were detec-
ted, especially when compared to other NHRs. There are several explanations for 
this observation. First, other nuclear hormone receptors are encoded by genes 
located on autosomes, so the effect of a mutated allele may be compensated by 
the other allele. However, some mutations, which confer a dominant negative 
phenotype, may form an exception, as was shown by generating mutations in 
the ER and PR (Ince et a/. '993, Gong et a/. 1997). Besides, in the majority of indivi-
duals with thyroid hormone resistance due to a mutation in one of the alleles 
encoding the TR-P, an autosomal pattern of inheritance is observed, while sub-
jects with a deletion of one allele do not show clinical abnormalities 
(Refetoff et a/. 1993). Dominant-negative receptors may form inactive hetero-
dimers with a wild type receptor. Moreover, mutant homodimers and hetero-
dimers block DNA binding of wild type homodimers. Secondly, mutations in 
both alleles of many of the other SHRs, causing complete hormone resistance, 
may be incompatible with life. However, ER gene disruption is not lethal, as was 
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shown by the construction of ER knockout mice which survived to adulthood, 
and by the fact that a male patient with estrogen insensitivity was found 
(Lubahn et al. '993, Smith et al. 1994). The recently cloned ER-~ may compensate 
for the mutated ER-a, and thereby mask a developmental defect caused by lack 
of ER-a activity (Kuiper et al. 1996, Mosselman et al. 1996). 
Complete gene deletions or large deletions are a rare cause of AISj only three 
individuals with a complete gene deletion have been described, and in two of 
these cases AIS was accompanied by mental retardation (Trifiro et al. 1991a, 
Quigley et al. 1992b, Davies et al. 1997a). Amino acid substitutions are most fre-
quently found, and, in general, conservative mutations were less deleterious 
than nonconservative mutations. The majority of mutations were found in the 
exons encoding the DNA-binding zinc clusters, and in the 3' half of exon 4 and 
the exons 5-8 encoding the LBD. This should in part be ascribed to bias caused by 
the fact that originally mainly patients with abnormal androgen binding were 
selected and investigated, 
CpG dinucleotides 
Some mutations were frequently observed in unrelated individuals (for over-
view see Table 1.1). According to Quigley et al. (1995) this is not due to a founder 
effect, as many of the AIS families concerned are of different genetic back-
ground. CpG dinucleotides, subject to high mutation rate, have been recognized 
as a cause of hot spot mutations in hemophilia A (Youssoufian et al. 1986). In AIS, 
a strong association between CpG~dinucleotides and recurrent mutations was 
also observed (Gottlieb et al. 1997). 
1,5 Other pathologies related to the androgen receptor 
1.5.1 Spinal and bulbar muscular atrophy 
Molecular basis of spinal and bulbar muscular atrophy (SBMA) 
Several polymorphic repeats are located in exon 1, which encodes the NH2-
terminal part of the hAR (Faber et al. 1989). A polymorphic poly-glutamine 
stretch, encoded by (CAG)nCAA, is located between amino acid residues 58 and 
77 (numbering of residues is based on an AR consisting of 910 amino acid resi-
dues; Brinkmann et al. 1989, Sleddens et al. 1992). An expanded poly-glutamine 
stretch is the molecular basis of spinal and bulbar muscular atrophy (SBMA) (or 
Kennedy's disease) (La Spada et al. 1991). In normal individuals the (CAG)nCAA-
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repeat contains 9-33 CAGs, whereas 38-75 CAGs are associated with SBMA 
(Nance 1997). Disease severity is inversely correlated with length of the 
(CAG)nCAA-repeat (Doyu et al. 1993, Igarashi et al. 1992, La Spada et al. 1992). 
Clinical characteristics 
Spinal and bul bar muscular atrophy is characterized by progressive muscle 
weakness and atrophy, and these symptoms are often preceded by cramps. Clini-
cal symptoms usually manifest in the third to fifth decade (reviewed by Nance 
1997), and result from severe depletion of lower motornuclei in spinal cord and 
brainstem, and distal axonopathy of the dorsal root ganglion cells can be obser-
ved (reviewed by Robitaille et al. 1997). In addition, SBMA patients frequently 
exhibit endocrinological abnormalities including testicular atrophy, reduced or 
absent fertility, gynecomastia, and elevated LH, FSH and estradiol levels; these 
symptoms are also observed in MAIS. Sex differentiation proceeds normally and 
characteristics of mild androgen insensitivity appear later in life. This may be 
related to a reduced AR expression level and a lower testosterone level observed 
in elderly men (Ono et al. 1988, Swerdloff and Wang 1993 and references therein). 
Spinal and bulbar muscular atrophy is an X-linked disease, and only men are 
affected. In heterozygous women mild symptoms can be observed (Sobue et al. 
1993, Ferlini et al. 1995), indicating that female carriers are protected by (non-) 
random X-inactivation. Women might as well be protected by a lower androgen 
leveL At present it is not known whether liganded or unliganded receptors are 
involved in the development of SBMA. However, in two brothers with SBMA, 
who underwent testosterone therapy for more than 18 months, neither positive 
nor negative effects of testosterone were observed (Goldenberg and Bradley 
1996). 
Molecular mechanism underlying the disease 
Bingham et al. (1995) developed transgenic mouse lines with normal and expan-
ded (CAG)nCAA-repeats in the AR gene, as a model to study SBMA. No diseased 
phenotype was observed, which was ascribed to a low expression level of the 
mutant protein. From the clinical signs, observed in SBMA, one can conclude 
that SBMA is likely to result from a combination of a gain-of-function mecha-
nism in motorneurons and a loss-of-function mechanism, causing partial loss of 
receptor function in androgen target tissues. The fact that neurological 
symptoms of SBMA are not observed in cases with AIS, which is caused by inac-
tivating mutation of the AR gene, points to a gain-of-function mechanism. 
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However, endocrine abnormalities were also observed in SBMA, indicative of 
impaired receptor functioning. 
Gain-oIJunction mechanism (1) 
Apart from SBMA, six other progressive neurodegenerative diseases are caused 
by an expanded CAG-repeat that is located in the coding region of the respective 
gene; i.e. Huntington's disease (HD), dentatorubral-pallidoluysian atrophy 
(DRPLA), the spinocerebellar ataxias (SCA) type " SeA type 2, SCA type 3 
(Machado-Joseph disease), and SCA type 6 (reviewed by Nance 1997). Although 
the proteins encoded by the mutated genes [AR, huntingtin (protein product 
involved in HD), ataxin-3 (protein product involved in SCA type 3), and probably 
also the other proteins J are widely expressed throughout the body, neuronal tis-
sue is specifically affected (Doyu et al. '994, Schilling et al. '995, Paulson et al. 
1997). This might be related to the fact that neuronal cells are differentiated and 
post-mitotic cells, which can not regenerate. Analogous to inactivating mutation 
of the AR gene, targeted disruption of the HD gene in the mouse caused a pheno-
type that was different from a HD phenotype (Duyao et al. '995, Nasir et al. 1995). 
In addition, an individual heterozygous for a deletion in the HD gene did not 
develop a typical HD phenotype (Ambrose et al. 1994). Thus, HD is also likely to 
result from a gain-of-function mechanism. 
Theoretically, intragenic expanded CAG-repeats could be pathogenic at DNA, 
RNA, or protein level. Mclaughlin et al. (1996) observed increased binding of 
RNA-binding proteins to RNAs containing expanded CAG-repeats. They pro-
posed that these RNAs might disrupt normal transport in the cell, or titrate away 
cytoplasmatic proteins that bind to CAGs. Absence of a disease phenotype was 
observed in transgenic mice that expressed a high 'level of HD transcript, but no 
huntingtin protein, because protein expression was prevented by a frameshift 
mutation (Goldberg et al. 1996). This proves that DNAs and RNAs containing 
expanded CAG-repeats are not directly involved in pathogenic interactions. 
Additional evidence came from Onodera et al. (1996), who studied toxicity of 
fusion proteins in E.-coli and observed that only expanded poly-glutamine 
stretches and not expanded alanine stretches (encoded by GCA, frameshifted 
CAG) were toxic. Recently, transgenic mice were created that expressed exon 1 of 
a human HD gene, containing an expanded GAG-repeat under control of the 
huntingtin promoter (Mangiarini et al. 1996). Strikingly, this was sufficient to 
cause a HD-like phenotype. Thus, it is very likely that the underlying mechanism 
involved an expanded poly-glutamine stretch (Figure l.8). 
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Figure 1.8 location of the poly-glutamine stretch within the NH,-terminal part of the AR. In normal 
individuals the stretch is a modulator of receptor activity. Receptor activity is inversely correlated with 
length of the stretch. An expanded repeat, encoding a longer stretch triggers toxic protein-protein 
interactions, resulting in SBMA. Mild symptoms of AIS can also be observed in SBMA patients. 
Green et al. (1993) proposed that proteins with an expanded poly-glutamine 
stretch could be a better substrate for trans glutaminase, an ubiquitously expres-
sed enzyme that catalyses coupling of glutamine and lysine residues. Kahlem et 
al. (1996) showed that peptides that contained longer glutamine stretches 
indeed are better substrates (in vitro). Accumulation of protein aggregates might 
be toxic for cells. According to Perutz et al. (1994) peptides, containing poly-glu-
tamine stretches might function as polar zippers. Amyloid-like protein aggrega-
tes formed in vitro, after proteolytic cleavage of GST-huntingtin fusion proteins 
that contained poly-glutamine stretches of a critical length (Scherzinger et al. 
1997). Formation of p-sheets by polar zippers may be involved in aggregate for-
mation. Interestingly, the nuclear aggregates were also detectable in neuronal 
cells of the transgenic mice, which expressed the NH2-terminal part of hunting-
tin that contained the poly-glutamine stretch (Scherzinger et al. 1997). In these 
transgenic mice, neuronal intranuclear inclusions, containing huntingtin and 
ubiquitin, were detected (Davies et al. 1997b). Intranuclear inclusions and 
dystrophic neurites, containing huntingtin aggregates, were also present in 
affected brain regions of patients with HD (DiFiglia et al. 1997). The finding that 
those neuronal intranuclear inclusions were present in symptomatic patients, 
and absent in presymptomatic patients, indicates that this phenomenon is clo-
sely linked to the onset of disease. The presence of ubiquitin, a small protein that 
tags proteins for destruction (Varshavsky 1997), in these aggregates suggests 
that they are targets for ubiquitin-mediated proteolysis. ProteolYSis seems to be 
incomplete, and thus the aggregates might interfere with normal neuronal 
functioning, finally causing HD. It would be interesting to know whether such 
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aggregates can be found in the affected brain regions of SBMA patients as well. 
Because many similarities were observed between neurodegenerative diseases, 
associated with CAG-repeat expansion, a common mechanism might be invol-
ved. This disease model does however not explain the different phenotypes. 
Loss-oflunction mechanism (2) 
Endocrine abnormalities observed in SBMA patients were indicative of reduced 
receptor functioning. Because many transcription factors contain polymorphic 
glutamine stretches, the question was raised whether the poly-glutamine 
stretch might be a modulator of transcription activation (Courey et al. 1989, Ger-
ber et al. 1994). Cotransfection studies demonstrated that the polymorphic poly-
glutamine stretch influences transcription activation capacities, although 
promoter dependent differences were observed (Mhatre et al. '993, Chamberlain 
et al. 1994, Jenster et al. '994, Kazemi-Esfarjani et al. 1995). Length of the 
(CAG)nCAA-repeat was inversely related to transcription activation capacities. 
Ligand binding (Kd) was not affected (Mhatre et al. '993, Chamberlain et al. '994, 
Kazemi-Esfarjani et al. 1995). From these studies, it was concluded that length of 
the (CAG)nCAA-repeat might influence intrinsic properties of the receptor. In 
contrast to these in vitro findings, androgen-binding abnormalities were detec-
ted in cells derived from SBMA patients. MacLean et al. (1995) established abnor-
mal binding affinity in 5 out of 6 cases that were studied. Zhou et al. (1995) 
postulated that the AR NH2-terminal domain might be involved in receptor sta-
bilization by lowering the dissociation rate of bound hormone and AR degrada-
tion. In this wayan expanded poly-glutamine stretch might affect the Kd or 
Bmax. Recently, a functional interaction between the NH2-terminal and COOH-
terminal domains of the AR was established (Langley et al. '995, Doesburg et al. 
1997). However, Langley et al. (1995) showed that expansion of the poly-gluta-
mine stretch from 21 to 66 residues did not interfere with the NH2-/COOH-inter-
action. Other groups observed a reduced Bmax in genital skin fibroblasts derived 
from SBMA patients (Warner et al. 1992, Danek et al. '994, Lumbroso et al. 1997). 
AR mRNA expression in the spinal cord of an SBMA patient was decreased as 
well, in contrast to spinal cord of controls (respectively three subjects with lung 
cancer and three subjects with amyotrophic lateral sclerosis) (Nakamura et al. 
1994). These results are difficult to interpret; as quite variable AR expression 
levels are observed in normal individuals. Transient transfection studies in COS 
cells and motor-neuron hybrid cells revealed that ARs containing expanded 
poly-glutamine stretches were expressed at lower levels (Choong et al. 1996a, 
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Brooks et of. 1997). However, Tut et af. (1997) did not observe these different 
expression levels. Lower protein expression levels were accompanied by lower 
mRNA levels (Choong et al. 1996a). Therefore it was proposed that the 
(CAG)nCAA-repeat might interfere with transcription of the AR gene, indicating 
that the mutation also plays a role at the DNA level. On the other hand, expan-
ded poly-glutamine stretches (59-81) caused toxicity in bacteria and COS-cells 
(Onodera et af. 1996), so that a lowered AR expression level probably has to be 
attributed to increased cell death. 
Interestingly, Nasir et af. (1995) observed behavioral and morphological chan-
ges in heterozygous huntingtin knockout mice. Some of these characteristics 
were also observed in HD patients, suggesting that a partialloss-of-function 
mechanism may also be involved in HD. 
1.5.2 Prostate cancer 
Prostate cancer is the second most frequently observed malignancy in men 
(Brinkmann and Trapman 1995). Androgens, predominantly DHT, are involved in 
growth and development of the normal prostate, and also playa role in the ini-
tiation of prostate cancer (Coetzee and Ross 1994). Because prostate cancer is 
often diagnosed at an advanced stage, radical surgery is no longer possible. 
However, the tumor is initially androgen dependent, and therefore endocrine 
deprivation therapy can be given. About 80% of the patients initially respond to 
endocrine deprivation therapy, but ultimately the majority of them show tumor 
recurrence. Failure of endocrine therapy can be explained by several molecular 
mechanisms, which are either androgen dependent or independent. 
The first androgen independent mechanism involves somatic mutation of 
the AR gene, leading to activation of the receptor by other steroids and anti-
androgens. The first mutation was detected in the human prostate carcinoma 
cell line LNCaP that only expresses the AR but surprisingly showed increased 
growth rate after culture with estrogens or progestagens (Veldscholte et af. 
1990). This phenomenon was explained following identification of a mutation in 
the AR gene causing substitution of the threonine residue at position 868 by an 
alanine residue, resulting in increased binding affinity for estradiol and for 
progestagens (Veldscholte et af. '990, Ris-Stalpers et af. 1993). Even antiandro-
gens (cyproterone acetate and hydroxyflutamide) were able to induce transcrip-
tion activation (Veldscholte et af. 1992). The discovery of this LNCaP mutation 
initiated screening of the AR gene in tumor specimens. Mutations were rarely 
observed in primary tumors {Newmark et al. 1992, Ruizeveld de Winter et al. 
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'994, Elo et 01. '995, Evans et 01. 1996), with the exception of the study reported 
by Tilley et 01. (1996). The majority of mutations were identified in hormone 
refractory tumor samples (Culig et 01. 1993b, Castagnaro et 01. '993, Gaddipati et 
01. '994, Suzuki et 01. 1996) and metastatic lesions (Taplin et 01. '995, Suzuki et 01. 
1996). Most mutations mapped to the LBD, which may be related to the fact that 
in most studies only the DBD and LBD were screened. Tilley et 01. (1996) reported 
that 25% of the mutations they identified were located in the NH2-terminal 
domain. Only a small part of the mutations were functionally investigated 
(see Table 1.2). Interestingly, some defects were repeatedly identified in unrela-
ted individuals: i.e. Val-706-Met (reported twice) (Culig et 01. 1993b, database 
Gottlieb et 01. 1997), His-865-Tyr (reported twice) (Taplin et 01. '995, database 
Table 1.2 AR Mutations identified in prostate cancer which were functionally charaderized 
Exon Mutation Remarks Reference 
4 Gly 674 Ala Normal transcription activation Koivisto et al. 1997 
4 Val 706 Met Broadened steroid-binding specificity Culig et 01. 1993a 
Gottlieb et 01.1997 
5 Arg 717 leu Broadened steroid-binding specificity Elo et 01. 1995 
5 Val 721 Met Broadened steroid-binding specificity Newmark et al. 1992 
Peterziel et al. 1995 
5 Val 748 Ala Normal binding of R1881, but no trans- Gottlieb et 01. 1997 
scription activation 
6 Gin 789 Glu Inactivating mutation EVans et al. 1996 
(also associated with PAIS) 
8 His 865 Tyr Broadened steroid-binding specificity Taplin et 01.1995 
Gottlieb et al. 1997 
8 Thr 868 Ala Broadened steroid-binding specificity Veldscholte et al.1990 
Gaddipati et 01. 1994 
Suzuki et 01.1996 
Gottlieb et al. 1997 
8 Thr 868 Ser Broadened steroid-binding specificity Taplin et 01.1995 
Numbering of the amino acid residues is based on an AR with a poly-glutamine stretch of 
20 glutamines, and a polymorphic glycine stretch of 16 residues (Brinkmann et 01. 1989). 
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Gottlieb el al. 1997). Thr-868-Ala (reported 12 times) (Veldscholte el af. '990, 
Gaddipati el af. '994, Suzuki el al. 1996, database Gottlieb el af. 1997), and 
strikingly all of them caused a broadened steroid-binding spectrum (Veldscholte 
el af. '990, Culig el af. '993a, Taplin el af. 1995), indicating that these mutations 
may playa role in the cancer process (Table 1.2) (reviewed by Brinkmann and 
Trapman 1995). AR mutations in prostate cancer might also reflect genetic insta-
bility. Recently, two germ-line mutations were identified in the 5' UTR of the AR 
gene in two individuals with prostate carcinoma (Crocitto et al. 1997). One of the 
point mutations was identified in AR-TIS I [AR-transcription-initiation site I 
(Faber el of. 1993)J and the other mutation in the GC-rich region. The patient with 
the AR· TIS I mutation had a father and brother with prostate cancer. The authors 
proposed that these mutations could cause a higher AR expression level. Al-
though a large number of tumors were investigated, AR mutations were rarely 
observed, indicating that they do not play an important role in development of 
prostate cancer. 
The recent discovery of AR gene amplification offers a second, androgen 
dependent mechanism (Visakorpi el af. 1995). Amplification was observed in a 
substantial part of hormone recurrent tumors but not in primary tumors 
(Koivisto el af. 1997). Androgen receplor gene amplification resulted in a higher 
AR mRNA level, a finding that corresponds with the observation that the 
majority of androgen independent tumors express a high level of AR protein 
(van der Kwast et al. 1991, Ruizeveld de Winter et al. 1994). Increased expression 
of AR may result in increased sensitivity to low androgen concentrations during 
therapy, finally causing tumor recurrence (Visakorpi et al. 1995, Koivisto et al. 
1997). Amplification of a gene encoding AlB 1, a SHR coactivator, was observed in 
breast and ovarian cancer (Anzick et al. 1997). Higher expression levels of the 
usually limiting protein may affect expression of genes, regulated by SHRs, 
finally resulting in a growth advantage. Amplification of steroid-receptor speci-
fic coactivators might be involved in development of prostate cancer as well. 
Steroid hormone receptor target genes can be activated through the receptor 
in the absence of ligand, by cross-talk between SHR pathways and other signal 
transduction pathways (reviewed by Weigel 1996). Ligand-independent activa-
tion was also observed for the AR (Culig el af. '994, Nazareth and Weigel 1996). 
In contrast, Ikonen el af. (1994) and de Ruiter el af. (1995) observed potentiation 
of androgen-dependent activity. Pietras el af. (1995) proposed that acquired 
defects in these signal transduction pathways might contribute to development 
of hormone independent tumors. Phosphorylation might induce conformational 
50 I General Introduction 
changes in the LBD of the SHRs, which are also induced upon ligand binding, and 
activate the receptor through AF-, (White et aZ. 1997). Ignar-Trowbridge et aZ. 
(1993) proposed that the estrogen-like effects of epidermal growth factor, obser-
ved in the mouse uterus in the absence of estrogens, are due to activation of the 
AF-l in the ER NH,-terminus. It might also be possible that factors, interacting 
with receptors, are activated by phosphorylation (de Ruiter et aZ. '995, Bai et 01. 
1997)· 
Lell9tll of tile (CAG)IICAA-repeat, a risk factor for prostate callcer 
In one prostate tumor, somatic variation of the polymorphic (CAG)nCAA-repeat 
in exon 1 of the AR gene was observed (CAG,,"',,) (Schoenberg et 01.1994). It is not 
known whether this mutation was involved in a growth advantage. Recently, 
evidence was obtained that the (CAG)nCAA-repeat might be a modulator of 
several androgenic endpoints, even when its length falls within the normal 
range (9-33 CAGs). Obviously, expanded poly-glutamine stretches in the AR are 
associated with a partial loss of receptor function in patients with SBMA. Irvine 
et oZ. (1995) suggested that (CAG)nCAA-repeat length could be a determinant of 
prostate cancer. In addition, in a small case-control study, a possible positive 
correlation was found between (CAG)nCAA-repeat length and the age at diagno-
sis of prostate cancer (Hardy et al. 1996). Two large case-control studies were 
published recently; Giovannucci et al. (1997) observed an inverse correlation 
between (CAG)nCAA-repeat length and a more aggressive form of prostate 
cancer (587 cases versus 588 controls, mainly Caucasians). A study involving 301 
prostate cancer cases and 277 controls (Caucasians) consolidated that length of 
the (CAG)nCAA-repeat is one of the risk factors associated with development of 
prostate cancer (Stanford et aZ. 1997). 
1.5.3 Breast cancer in males 
Breast cancer in males is very uncommon. Clinical conditions involving hypogo-
nadism, which in turn can cause gynecomastia, form an increased risk (Thomas 
et al. 1992), There is evidence supporting a protective role of androgens in breast 
cancer cells. Androgens inhibit proliferation of the human breast cancer cell line 
MFM-223, and this effect could be antagonized with antiandrogens, thus indica-
ting that the protective action is through the AR (Hackenberg et al. 1991). 
By increasing the oxidative activity of 17P-HSD in ZR-75-1 human breast cancer 
cells, androgens induce degradation of estradiol (potent estrogen) to its pre-
cursor estrone, which may in part explain the anti-proliferative effects of andro-
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gens in these cells. The effect of androgens on 17P-HSD was almost completely 
reversed by the antiandrogen hydroxyflutamide, indicating that the AR is in-
volved (Couture et al. 1993). It is also known that ER levels are downregulated by 
androgens in ZR-75-1 cells (Poulin et al. 1989). Mutations in the AR gene, im-
pairing androgen action, might therefore be involved in breast cancer. Indeed, 
the arginine residue at position 598 (DBD) was found to be substituted by a glu-
tamine residue (Arg-598-Gln) in two brothers with PAIS and carcinoma of the 
breast (Wooster etal. 1992). Lobaccaro et al. (1993) screened the AR-DBD of13 men 
with breast cancer for germ-line mutations. Surprisingly, the arginine residue at 
position 599 (adjacent to arginine 598) was substituted by a lysine residue (Arg-
599-Lys) in a case with PAIS and carcinoma of the lett breast. Both mutations 
were also found in cases presenting only with partial androgen resistance. The 
Arg-599-Lys mutation was reported to cause PAIS in a man who had undergone 
bilateral mastectomy at the age of 13 because of gynecomastia (Saunders et al. 
1992). This might have protected him from developing breast cancer. The Arg-
598-Gln mutation was recently detected in a case with PAIS who has a predomi-
nantly female phenotype and is probably at increased risk of developing breast 
cancer (Hiort et al. 1996a). Although both mutations associated with breast car-
cinoma were germ-line, Hiort et ai. (1996a) reasoned that somatic mutations in 
males without AIS might as well be involved in development of male breast can-
cer. However, after screening tumor material from 11 individuals, no mutations 
were found. 
Arginine 598 is conserved in SHRs and arginine 599 in all members of the 
NHR-family, indicating that these residues are important for proper receptor 
functioning. Functional studies revealed that ARs harboring either the Arg-598-
GIn or the Arg-599-Lys mutation displayed normal ligand-binding characteris-
tics. Decreased binding to a consensus GRE was observed in a gel-retardation 
assay, and consequently transcription activation capacities on androgen respon-
sive genes were reduced (Poujol et al. 1997). Functional studies were completed 
with molecular nlOdeling studies, which revealed that the interaction between 
monomers was disturbed [Poujol et al. 1997, for details about modeling, see also 
Briiggenwirlh et al. 1998 (Chapter VJl. Large structural alterations of the AR-DBD 
were not observed. The receptor mutant did not bind to an ERE, which is not 
surprising because response element specificity is detennined by the P-box, 
located in the first zinc cluster (Green and Chambon 1987, and Freedman et al. 
1988). Molecular modeling revealed that both affected arginine residues are 
surface exposed, indicating that they may be involved in protein-protein inter-
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actions. Poujol et al. (1997) therefore hypothesized that the mutations might 
confer a gain of function, probably by disturbing interactions with accessory 
factors. Loss of the protective effect of androgens might also playa role (Lobac-
cara et al. 1993). However, although a large number of mutations were found in 
patients with AIS, only two AR mutations were associated with male breast 
cancer. This implies that mutation of the AR does not playa main role with 
respect to male breast cancer. On the other hand, patients with a male pheno-
type who develop gynecomastia will undergo mastectomy, which might protect 
them. 
1.5.4 Other clinical abnormalities related to the androgen receptor 
Hirsutism 
The condition characterized by excessive hair growth in women in areas other 
than public and axillary hair is called hirsutism (Rittmaster 1997). Androgens are 
important with respect to hair growth. This is clearly illustrated by the absence 
of pubic and axillary hair and absence of beard growth in individuals with CAIS. 
In addition AIS patients do not develop male type baldness (Randall 1994b). It is 
known that testosterone is only active in hair follicles after conversion to DHT 
(Mauvais-Jarvis 1986). In general, hirsutism points to an underlying excessive 
androgen production, such as can occur in congenital adrenal hyperplasia, Cus~ 
hing's syndrome, or androgen secreting neoplasms. However, also androgen~ 
independent forms of hirsutism exist. In most cases of hirsutism, a combination 
of a mildly increased androgen production and increased skin sensitivity to 
androgens is responsible for the phenotype (idiopathic hirsutism) (Rittmaster 
1997). The majority of hirsute women can thus be treated with anti androgens 
and/or with 5o:~reductase inhibitors. 
Increased skin sensitivity might result from increased 5o:~reductase activity 
or from an increased AR expression level (Mauvais~Jarvis 1986, Randall et al. 
1994b). Mutations that confer a gain of function to the AR might be involved in 
hirsutism as well. It could be postulated that increased gene activation results 
from a mutation that renders the AR more sensitive to other steroid hormones, 
or a mutation that improves the interaction with a coactivator. In this latter case 
tissue-specific factors might be involved. 
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Male infertility 
A reduced AR level was found in genital skin fibroblasts derived from azoosper-
mic and oligospermic, but otherwise normally virilized males (Aiman and 
Griffin 1982, Morrow et al. 1987). However, in these studies the molecular basis 
underlying AR impairment was not sufficiently established. A deletion of exon 4 
of the AR gene was detected in an infertile man (Akin et al. 1991). Detailed 
molecular studies were not performed with this mutant receptor. This finding, 
however, is very controversial, because two deletions of each 3 nucleotides in 
exon 4, encoding either an aspartic acid residue at position 681 or an asparagine 
residue at position 683, respectively, caused PAIS and CAIS. In another study, the 
coding parts of the AR gene of 16 idiopathic oligospernlic or azoospermic men 
were analyzed. No gross deletions and insertions were detected; point mutations 
were probably missed, as no sequencing analysis or SSCP analysis was per-
formed (Puscheck et al. 1994). Interestingly, a mutation was found in exon 5 of 
the AR gene, from a man with severe oligospermia (Yong et al. 1994). The aspa-
ragine residue at position 718 was changed into a lysine residue. Treatment for 4 
months with the androgen analogue Mesterolone resulted in a rise in sperm 
density, indicating that this ligand could rescue the effect of the mutation. 
Recently, a relatively long (CAG)nCAA-repeat in the AR gene was associated with 
impaired spermatogenesis (Tut et al. 1997). 
Osteoporosis in men 
Osteoporosis, characterized by low bone mass and microarchitectural deteriora-
tion of bone tissue (Consensus Development Conference on Osteoporosis 1993) 
has a strong genetic component (Christian et al. 1989, Pocock et al. 1987). 
Polymorphisms in genes, which encode proteins that might be involved in bone 
metabolism, were analyzed and related to bone mineral density (BMD). The AR is 
expressed in os teo blasts (Colvard et al. 1989) and in the presence of androgens 
AR mRNA was upregulated through the AR (Wiren et al. 1997). In view of a 
possible role of the AR in bone metabolism, Bruggenwirth et al. (unpublished 
data) studied the relationship between bone mineral density and length of the 
polymorphic (CAG)nCAA-repeat in a population of men at the age of 55 years 
and higher from the Rotterdam study (Hofman et al. 1991) (see also Chapter IV). 
Effects were not observed in the overall population. After stratification to body 
mass index (BMI) (median) a positive association between (CAG)nCAA-repeat 
length and bone mineral density was observed in the low BMI group 
(Bruggenwirth et al. unpublished results). 
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1,6 Aim of the study and scope of the thesis 
The AR is a ligand-dependent transcription factor that regulates expression of 
genes involved in sex differentiation of the male fetus. Postnatal development of 
male secondary sex characteristics and functioning of the male sex organs 
depends on androgen action. In the female, androgen action is apparent from 
axillary and public hair growth, and the AR may also have a role in other proces-
ses. Mutation of the gene encoding the AR, is the cause of androgen insensitivity. 
In addition, expansion of the polymorphic poly-glutamine stretch, encoded by a 
(CAG)nCAA-repeat located in exon 1, is associated with spinal bulbar muscular 
atrophy, a progressive neuromuscular disease. These defects in AR action are not 
life-treathening, and subjects with androgen insensitivity Of with other patho-
logies related to the AR provide an opportunity to study the role of the AR in 
several processes related to sex differentiation and development. Experiments 
described in this thesis were performed to study structure-function relationship 
of the AR. Because of the large homology between members of the steroid 
hormone receptor family, the study of different mutations in the AR gene might 
provide new information relevant for other members as well. Moreover, 
mutation detection followed by functional analysis is important with respect to 
counseling and treatment of families with AIS. The present study was focussed 
on mutations found in the NH,-terminal part and the DBD of the AR. In the past, 
these domains were not always extensively investigated. On the one hand 
because, initially, mainly AR genes from individuals with androgen-binding 
abnormalities were screened. On the other hand, exon 1 is relatively large and 
GC-rich, which has hampered large-scale screening. Mutations in the NH 2-
terminal part and DBD may provide information about transcription activation 
and/or DNA binding, processes known to be important with respect to normal 
receptor function. In addition, many potential phosphorylation-sites, which 
might influence receptor functioning, are located in exon 1. 
In Chapters II and III mutations associated with AIS that were identified in 
the NH2-terminal domain of the AR are described. Only a small number of muta-
tions was found in this particular domain (Chapter II). All of these mutations 
resulted in the introduction of a premature stop codon and were the cause of 
CAIS. Single amino acid substitutions are probably not sufficient to cause a phe-
notype and can thus be tolerated. In Chapter III a subject in whom genotype and 
phenotype did not match is described. It turned out that this individual was a 
somatic mosaic for a mutation in the AR. There are some indications that the 
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polymorphic poly-glutamine stretch in the NH2-terminal part of the hAR is a 
modifier of AR activity. In addition, lines of evidence exist, indicating that the AR 
might be directly involved in bone metabolism. Therefore, length of the poly-
glutamine stretch (functional polymorphism) was analyzed in relation to bone 
mineral density in a sample of elderly men (from the Rotterdam Elderly Study) 
with either low or high bone mineral density (chapter IV). 
In Chapters V and VI, two different mutations, causing CAIS and PAIS, respec-
tively, which both affect DNA binding, are presented. The mutation that caused 
CAIS was studied by functional assays and 3-D modeling, as reported in Chapter 
V. The results obtained with both methods were compared. In Chapter VI a very 
unusual splice acceptor site mutation is discussed. Two receptor variants that 
were functionally inactive due to disturbed DNA binding were detected. One of 
them was associated with aberrant androgen~dependent receptor phosphoryla-
tion. 
In the General Discussion (Chapter vll), the different AR gene mutations 
described in this thesis are discussed, and compared with mutations reported by 
other groups. The possibility of post-receptor defects, causing an androgen 
insensitivity-like phenotype, is considered. Finally, the possible influence of the 
length of the poly-glutamine stretch in the NH,-terminus of the AR on andro-
genic end points is discussed. 
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Summary 
Mutations in the androgen receptor gene in 46,XY individuals can be associated 
with the androgen insensitivity syndrome of which the phenotype can vary 
from a female phenotype to an undervirilized or infertile male phenotype. We 
have studied the androgen receptor gene of androgen insenSitivity patients to 
get information about amino acid residues or regions involved in deoxyribonu-
cleic acid binding and transcription activation. Genomic DNA was analyzed by 
PCR-single strand conformation polymorphism analysis under two different 
conditions. Three new mutations were found in exon 1 of three patients with a 
female phenotype. A cytosine insertion at codon 42 resulted in a frameshift and 
consequently in the introduction of a premature stop at codon 171. Deletion of an 
adenine at codon 263 gave rise to a premature stop at codon 292. In both these 
cases, receptor protein was not detectable and hormone binding was not measu-
rable. In a third patient, a guanine to adenine transition at codon 493 converted 
a tryptophan codon into a stop codon. Genital skin fibroblasts from this patient 
Were not available. In exon 2 of the androgen receptor gene of a patient with 
receptor positive androgen insensitivity, a cytosine to adenine transition, 
converting alanine 564 into an aspartic acid residue, resulted in defective DNA 
binding and transactivation. In three other receptor-positive androgen insensi-
tivity patients no mutations were found with PCR-single strand conformation 
polymorphism analysis. 
Introduction 
Androgens playa major role in male sexual differentiation and development. 
The actions of androgens are exerted through the AR, which modulates trans-
cription of androgen responsive genes. The AR belongs to a superfamily of recep-
tors for steroid hormones, thyroid hormones and retinoids. Characteristic for the 
members of this family are the distinct functional domains; the NH2-terminal 
domain involved in transcription regulation, a DBD, composed of two zincclus-
ters, a hinge region and the C·terminal LBO (Evans ]988). Mutations in the AR 
gene in 46,XY individuals are associated with AIS, a disorder with a wide spec-
trum of phenotypes. Subjects with CAIS exhibit a female phenotype, whereas 
other AIS subjects show a phenotype with ambiguous genitalia, called PAIS. The 
majority of the mutations reported so far are point mutations, located in the LBD 
(Brinkmann et al. ]992, Sultan et al. ]993). AIS subjects with an AR of normal 
molecular mass and no abnormalities in ligand binding are an interesting 
group, because they may provide information about essential amino acid resi-
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dues or regions, directly involved in transcription activation. Deletion mapping 
revealed that almost the entire NH2-terminal domain is necessary for full AR 
transactivating activity (Jenster ef al. 1995). Therefore, AR mutations interfering 
with correct receptor functioning may be expected in this domain. However, 
except for the expanded glutamine stretch, associated with Kennedy's disease, 
only 6 mutations in exon 1 of the AR have been reported (La Spada ef al. 1991, 
McPhaul ef al. '99,a, McPhaul ef al. 1991b, Batch ef al. 1992, Zoppi ef al. 1992, Hiort 
ef al. 1994b). Five of them resulted either directly or indirectly in the introduction 
of a premature stop codon. 
In this study we describe three new exon 1 mutations, all resulting in the 
introduction of premature stop codons. Zoppi ef al. (1992) reported a patient in 
which a single nucleotide substitution introduced a premature stop at codon 60. 
Synthesis of AR protein was found to be initiated downstream of the termina-
tion codon. Therefore, we have investigated whether truncated AR forms were 
present in genital skin fibroblasts from the patients with an exon 1 mutation. 
A new mutation was also detected in the first zinc duster of the DBD of a patient 
with receptor-positive AIS. Exon 1 mutations, resulting in receptor-positive AIS, 
were not found. In three other patients with receptor-positive AIS, no mutation 
was detected by PCR-SSCP analysis. 
Subjects and methods 
Clinical subjects 
- Subject A: 46,XY index patient with CAIS was admitted at the age of 1 yr. because 
of a bilaterally inguinal hernia. She has a younger 46,XY sister with the same 
phenotype. 
- Subject B: 46,XY patient, diagnosed as having CAIS. The sister of the patient's 
mother was known with primary amenorrhea. 
- Subject C: 46,XY patient, with a complete female phenotype and from a family 
with more affected members. 
- Subject D: 46,XY patient who was diagnosed as having CAIS at birth in the 
absence of a positive family history. She came to medical attention because of 
suspected dysmorphology. After further clinical examination the diagnosis AIS 
was made. 
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Table 11.1 Summary of phenotypes and AR gene mutations of Index subjects 
Subject Phenotype, Mutation: Position change: 
A cAIS C insertion codon 42 
B cAIS A deletion codon 263 
C cAIS TGG -TGA Trp493StoP 
D cAIS GCT - GAT Alas64Asp 
E pAIS no Illutation· 
F cAIS no mutation· 
G cAIS no mutation· 
The animo acid numbering is based on 910 reSidues, corresponding with a glutamine stretch of 
20 residues and a glycine stretch of 16 residues.' Only screened by PCR~SSCP. 
- Subjects without a mutation, all patients displayed a 46,XY chromosome 
pattern, had no miillerian duct remnants and male hormonal levels were 
present in the serum. Two of them had the typical phenotype of CAIS and one 
case has a phenotype with ambiguous genitalia. The phenotype and the AR gene 
mutation of each subject are summarized in Table 11.1. 
Mutation detection 
Genomic DNA, isolated from blood lymphocytes, was screened by PCR-SSCP. 
Seventeen primer sets for overlapping fragments were used to amplify the 
coding region and the exon flanking intronic regions of the human AR (hAR). A 
15 ~tl PCR reaction mixture was used, containing 100 ng genomic DNA, 70 ng of 
each oligonucleotide, 40 flM of each dNTP, 10 mM Tris HCI (pH 9.0), 1.5 mM 
MgCI2, S mM KCI, 10% DMSO (in case of amplifying exon 1), 1.0 flCi [a"P] dATP 
(Amersham, Little Chalfont. UK) and 0.1 unit Supertaq DNA polymerase (HT Bio-
technology LTD). For PCR fragments covering the glycine stretch, 50% deaza 
dGTP was used with 50% dGTP. Reactions were denatured at 95°C and subjected 
to 30 cycles of denaturation at 95 °c for 1 minute, annealing for 2 minutes at dif-
ferent temperatures (Table II.2) and elongation at 72°C for 1 minute. In Table II.2, 
oligonucleotides used for PCR amplification of the human AR gene and for direct 
sequencing are indicated. Samples consisting of 1 fll of PCR product and 9 ftl 
sample buffer (95% formamide, 5% glycerol, 20 mM EDTA, 0.02% bromophenol 
blue and 0.02% xylene cyanol FF) were denatured before loading on a gel, 
Table 11.2 Sequence of oligonucleotides used for PCR-SSCP screening of the human AR gene 
Oligo location PCR Fragment Annealing Sequence 
Temperature °c 
-70A 5'-UTR, exom Exon 1 A* 55 GCCTGTTGAACTCTTCTGAGC 
95 B Exon 1 CTTGGGGAGAACCATCCTCA 
35A Exon 1 Exon 1 B 58 TcCGCGAAGTGATCCAGAAC 
95 B Exon 1 CTTGGGGAGAACCATCCTCA 
80A Exon 1 Exon 1 C 64 AGCAAGAGACTAGCCCCAGGCAGC 
172B Exon 1 CGGAGCAGCTGCTTAAGCCGGGG 
160A Exon 1 Exon 1 D 62 GCTGCCCCATCCACGTTGTCCCTGCT 
250B Exon 1 ACTCAGATGCTCCAACGCCTCCAC 
240A Exon 1 Exon 1 E 62 TGTGTAAGGCAGTGTCGGTGTCCAT 
320B Exon 1 CGCCTTCTAGaCCTTTGGTGTAAC 
305A Exon 1 Exon 1 F 64 CAGGCAAGAGCACTGAAGATACTGC 
385B Exon 1 GGTTCTCCAGCTTGATGCGAGCGTG 
361A Exon 1 Exon 1 G 58 CGCGACTACTACAACTTTCCACTGG 
445 B Exon 1 CACACGGTCCATACAACTG 
1A Exon 1 Exon 1 H 55 TCCTGGCACACTCTCTTCAC 
490B Exon 1 GCCAGGGTACCACACATCAGGT 
470A Exon 1 Exon 1 I 57 GTAGCCCCCTACGGCTACA 
1B Intron 1 CAGAACACAGAGTGACTCTGC 
2A Intron 1 Exon 2 55 GTCA TTTATG CCTG CAGGTT 
2B Intron 2 TCTCTCTCTGGAAGGTAAAG 
3A Intron 2 Exon 3 55 TCAGGTCTATCAACTCTTG 
3B lntron 3 GGAGAGAGGAAGGAGGAGGA 
4A Intron 3 Exon 4 A 55 ATTCAAGTCTCTCTTCCTTC 
14NB Exon 4 TGCAAAGGAGTtGGGCTGGTTG 
4AA Exon 4 Exon 4 B 55 CAGAAGCTtACAGTGTCACACA 
4B Intron 4 GCGTTCACTAAATATGATCC 
5A Intron 4 Exon 5 55 GACTCAGACTTAGCTCAACC 
5B Intron 5 ATCACCACCAACCAGGTCTG 
6A Intron 5 Exon 6 55 CAATCAGAGACATTCCTCTGG 
6B IntTon 6 AGTGGTCCTCTCTGAATCTC 
7A Intron 6 Exon 7 55 TGCTCCTTCGTGGGCATGCT 
7B Intron 7 TGGCTCTATCAGGCTGTTCTC 
8lA Intron 7 Exon 8 55 AGGCCACCTCCTTGTCAAC 
8B 3' UTR, exon 8 AAGGCACTGCAGAGGAGTA 
'This PCR product is relatively large and was therefore digested with the restriction enzyme PstI, 
prior to PCR-55CP analysis. The CAG(n)CAA-repeat length was studied with primer pair 35A and 95B. 
Mismatches are indicated with a small letter. 
6, II Molecular Basis of Androgen Insensivity 
containing 7% acrylamide, 1 x TBE buffer (Tris-borate, pH 8.2, 2.5 mM EDTA) and 
5% or 10 % glycerol. Gels were run for 16 hours at 6 Watt either with 0.5 x TBE 
buffer (5% glycerol gels) or 1 x TBE (10% glycerol gels) at room temperature. Direct 
sequencing was performed in case an aberrant SSCP pattern was detected. 
Amplification took place in 100 ~Il reaction mixtures containing 100 ng genomic 
DNA, 400 ng of each primer, 200 [1M of each dNTP, 10 mM Tris HCI, 1.5 mM 
MgCI2, 5 mM KCI, 10% DMSO (in case of amplifying exon 1) and 2.5 units Ampli-
taq DNA polymerase (Perkin Elmer, Roche Molecular Systems Inc. Branchburg, 
NY, USA). PCR products were purified from Seakem agarase with Spin-X columns 
(Costar, Badhoevedorp, The Netherlands) and about 100 ng PCR-product was 
used as template in the cycle sequencing reaction (Sequitherm kit, Epicenter, 
Biozyme, Landgraaf, the Netherlands). Primers, developed for PCR-SSCP, were 
end-labeled with T4 polynucleotide kinase in the presence of [y_BP] dATP (Amer-
sham, Little Chalfont, UK) and used in the cycle sequencing reaction. 
Cell culture conditions 
Genital skin fibroblasts were cultured in Modified Eagle's medium (MEM, 
containing 10% fetal calf serum, minimal essential amino acids (GibeD, Life Tech-
nologies, Breda, The Netherlands) and antibiotics at 37"C and 5% CO,. Fibroblasts 
were grown to confluence, washed two times with PBS-buffer and cytosols or 
whole celllysates were prepared. 
Preparation of wllole celllysates 
Genital skin fibroblasts were grown to confluence and scraped in 1 mllysis-
buffer [40 mM Tris, 1 mM EDTA pH 7.4, 10 % glycerol, 10 mM dithiothreilol (DTT), 
1% (vol/vol) Triton, 0.08% SDS, 0.5% sodium-deoxycholate, 600 [1M phenyl-
methylsulfonylfluoride (PMSF), 500 [1M bacitracin]. After 5 minutes the cell 
extract was centrifuged for 10 minutes at 4000 RPM at 5 0c. The supernatant was 
stored at - 80 "C. 
Preparation of cytosols 
Cells were scraped in 1 ml cytosol-buffer (40 mM Tris, 1 mM BDTA pH 7.4, 10 % gly-
cerol, 10 mM DTT, 10 mM molybdate, and freshly added, 600 [1M PMSF, 500 [1M 
bacitracin and 500 mM leupeptin), and hornogenized with a Teflon potter. 
The derived cell homogenates were centrifuged for 10 minutes at 100,00oxg, and 
the supernatants stored at -80 O( until use. 
Exon 1 
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Figure 11.1 PCR·SSCP analysis of AR gene mutations. SSCP analysis of dIfferent parts of exon 1 and of 
exon 2. lane I, wild type AR pattern of fragment A [nucleotides (-70)-(+286)}; lanes 2 and 3, patterns of 
fragment A of index patient A (2) and her 46,XY sister (3); lane 4, wild type pattern of fragment D 
(nucleotides 7°7'958); lane 5, pattern of fragment D of patIent B; lane 6, wild type pattern of fragment 
G, starting at nucleotide 1402 and ending In Intron 1; lane 7, 55CP pattern of fragment G of patient C; 
lane 8, wild type pattern of exon 2 fragment starts In rntron 1 and ends in intran 2; lane 9. exon 2 pat-
tern of patient D. Numbers are based upon an open reading frame of 2730 nudeotides (BrInkmann et 
af.lg8g). 
Characterization of the AR protein by SDS-PAGE and immunostaining 
The AR protein was immunoprecipitated from genital skin fibroblast lysates, 
with monoclonal antibody F39-4.I. as described before (Ris-Stalpers et al. 1991). 
After electrophoresis on a 7% SDS-PAGE gel, the proteins were transferred 
to nitrocellulose and immunostained with polyclonal antibody Sp061. After 
washing, the membrane was incubated with a second, peroxidase·coupled anti-
body. to visualize the protein. 
Scatchard analysis 
For studying the binding characteristics two different assays were used: either a 
binding assay in which genital skin fibroblast cytosols were used, or a whole cell 
assay. Cytosols were incubated overnight at 4 "c with increasing concentrations 
(0 - 0.1 - 0.25 - 0.5 - 1.0 - 2.5 - 5.0 - 10.0 nM) of 17P-hydroxY-17a-['H)-methyl-4.9.n-
estratrien-3-one (['H]R1881) (NEN-DuPont de Nemours. 's Hertogenbosch. 
The Netherlands), in the absence or presence of a 100 fold molar excess of non-
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labeled R1881 to determine non-specific binding. After protamine precipitation 
to remove the free steroid, specifically bound ['HR1881] was measured. The total 
amount of protein was assayed according to the method of Bradford (Bradford 
1976). 
Genital skin fibroblasts were incubated with increasing concentrations of 
['H]R1881 (0.02, 0.05, 0.3, 1.0, 3-0 nM) to obtain a saturation state. The non-specific 
binding was determined after incubation with a 100 fold molar excess of non-
radioactive steroid. After a one-hour incubation period at 37°C, cells were was-
hed four times with ice-cold 20 nM Tris, 0.15 mM NaCl, pH 7-4. The cells were 
scraped in 1 mllysis-buffer (TEG pH 7.4: 20 mM Tris, 15 mM EDTA, 10 % (vol/vol) 
glycerol, 600 [1M PMSF and 500 [1M bacitracin). After 10 minutes centrifugation 
at 800xg the pellet was lysed by adding 1 011 0.5 N NaOH and a 30 minutes incu-
bation at 56 °C. Scintillation cocktail (5 ml) Clumin (Packard) was added to 500 [11 
of each sample and lH-activity was measured in a scintillation counter. 
The amount of protein was quantified by the method of Bradford. Scatchard 
analysis was carried out to determine the Kd and the Bmax. 
Results 
The coding part of the hAR gene was screened by amplification of genomic DNA 
with a set of '7 primer pairs, followed by SSCP analysis, performed under two dif-
ferent conditions. In case of an aberrant PCR-SSCP profile, direct sequencing was 
performed. Three new exon 1 mutations, all resulting in the introduction of a 
premature stop codon were detected in the hAR of 3 CAIS patients (Figure ILt). 
In one receptor-positive patient a mutation was found in exon 2 (Figure II.1). 
In three other patients, diagnosed as having a receptor -positive form of AIS, no 
aberrant PCR-SSCP pattern was detected. 
Sequence analysis indicated a cytOSine insertion at codon 42 of the AR gene 
of patient A resulting in a frame shift and consequently in a premature stop at 
codon 171 (Figure 1l.2). In a second CAIS subject (B) a deletion of an adenine at 
codon 263 of the AR gene gave rise to a stop codon at position 292 (Figure 1l.2). 
A guanine to adenine transition at codon 493 changed a tryptophan codon (TGG) 
into a stop codon (TGA) in the AR gene of patient C (Figure 1l.2). The Kplli restric-
tion site, a unique site in AR cDNA was destroyed by the mutation and is infor-
maUve with respect to carrier detection. Western immunoblotting was 
performed to investigate if a truncated AR form was expressed in genital skin 
fibroblasts of subjects A and B. Truncated forms might result from internal reini-
tiation of translation, proceeding from internal AUG co dons (Figure II.2). In case 
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Figure 11.2 localization of mutations and internal AUGs In exon 1 of the AR gene. The mutations found 
in exon 1 of the AR gene are shown; + C: insertion of a cytosine at codon 42, resulting In a premature 
stop at codon 171; -A: deletion of an adenine at codon 263, resulting In a premature stop at codon 292. 
At codon 493 a transition of a guanine to an adenine was found, directly resulting In a premature stop 
codon. Translatfon start sites and the molecular mass of proteins, resulting from translation initiation, 
governed by these AUGs, are depicted. 
of patient A an AR protein of 87 kDa could not be detected (Figure 1l.3, lane 2). 
This corresponds with the observation that ligand binding was not measurable 
in cytosols, prepared from genital skin fibroblasts of patient A. The stop codon, 
introduced in the AR of patient B is also located upstream of an internal in frame 
AUG. However, a shortened AR protein could not be detected on a Western blot, 
because the epitope is missing (Figure 1l.3, lane 3). Furthermore ligand-binding 
studies were negative. Genital skin fibroblasts from patient C were not available. 
A new mutation was found in exon 2, which encodes the first zinc cluster of the 
DBD of the AR. A transition of cytosine to adenine converts an alanine residue at 
position 564 into an aspartic acid residue. This mutation resulted in defective 
DNA binding and trans activation, and will be described in more detail else-
where (see Chapter V). 
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Figure 11.3 Western blot analysis of AR expression. AR protein was immunopreclpltated with mono-
clonal antibody f39.4.1 from genital skin fibroblast Iysates, and separated on a 7% 5DS-PAGE gel. After 
electrophoresis the proteins were transferred to nitrocellulose and immunostalned with the polydonal 
antibody SP061. The AR protein was visualized with a peroxidase-coupled goat anti·rabblt antibody. 
lane 1, Wild type (Wt) AR from control genital skin fibroblasts; lane 2, AR with insertion of cytosine 
(+lC) from genital skin fibroblasts of subject A; Jane 3. AR with deletion of adenine (-lA) from genital 
skin fIbroblasts of subject B. Position of molecular mass markers are indicated on the left. 
In two of the patients, diagnosed as having CAIS and in 1 patient with PAIS no 
mutation was found after screening all the exons and their flanking intronic 
sequences with PCR-SSCP. All 3 patients were clinically well diagnosed. AR pro-
tein was isolated from genital skin fibroblasts, obtained from these subjects, and 
molecular mass was established after SDS-PAGE and Western blotting. In all 
cases the AR protein migrated as a normal 110-112 kDa doublet. Receptor charac-
teristics were further studied by Scatchard analysis, from which it became clear 
that the AR of these three patients displayed normal Kd and Bmax values. 
Discussion 
Genomic DNA from patients with either CAIS or PAIS was screened by PCR-SSCP 
analysis for mutations in the AR gene. Studying new mutations in receptor-posi-
tive AIS patients may reveal new information on amino acid residues in func-
tional domains, involved in DNA binding and transcription regulation. Besides 
mutations in exons 2 and 3, encoding the DBD of the AR, exon 1 mutations may 
be expected, because the NH2-terminal region plays a role in transcription acti-
vation (Jenster el al. 1995). In exon 1 of the AR gene of three CAIS patients we 
have found mutations resulting either directly or indirectly in the introduction 
of premature stop codons. Translation reinitiation is known to occur in mamma-
lian cell mRNAs. Mammalian ribosomes can reinitiate translation at an AUG 
codon, atter termination at an upstream site (Liu el 01. 1984, Peabody and Berg 
1986). According to Peabody and Berg (1986) it may be possible that the 40 S ribo-
somal subunit remains associated with the mRNA, and regains the capacity to 
scan along the mRNA, until it encounters an initiation codon. At this point, the 
loose ribosomal subunit becomes associated and synthesis of the polypeptide 
chain starts again. In the Tfm (testicular feminization) mouse a single nucleotide 
in a hexacytidine stretch (nucleotides 1107-1112) is deleted in the AR gene, resul-
ting in a frame shift and the introduction of a premature stop at codon 412. 
Downstream of this premature stop codon three AUGs are located, in frame with 
the premature termination codon. A low level of high affinity binding to andro-
gens and also to DNA could still be measured, which is indicative of reinitiation 
of translation (Charest el 01. 1991, Gaspar el al. 1991, He el 01. 1994). The low pro-
tein level resulted from instability of the mRNA (Charest el 01.1991, Gaspar el al. 
1991). Zoppi el 01. (1992) described an AIS patient in which a cytosine to thymine 
transition, converting a glutamine (CAG) residue at position 60 in the polymor-
phic glutamine stretch, into a premature stop (TAG). In addition, in vilro experi-
ments suggested that internal initiation occurs from the first in frame AUG 
codon at position 188, resulting in an 87-kDa protein. In genital skin fibroblasts a 
low, but detectable level of specific androgen binding with an accelerated disso-
ciation rate was measured. In patient A, the premature stop codon was present 
at codon 171. A shortened protein of approximately 87 kDa, however, could not be 
detected in genital skin fibroblasts. These results correspond with the observa-
tion that specific androgen binding was not measurable in cytosol from the 
patient's genital skin fibroblasts. In the other two mutant AR genes we descri-
bed, the stop codon occurred after the first internal AUG. No truncated receptor 
proteins could be detected in genital skin fibroblasts derived from patient B. It is 
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unclear which factors dictate the efficiency with which such translation reini-
tiation occurs. To some extent the efficiency of reinitiation may be governed by 
the position of the termination codon, relative to the subsequent downstream 
AUG codons (Liu et al1984, Peabody and Berg 1986, Kozak 1987). In patient A, the 
new start is located 10 co dons downstream of the premature stop codon, 
whereas in the patient described by Zoppi et al. (1992) and in the Tfm mouse, this 
distance was 128 and 132-134 codons, respectively. This might be the reason why 
in genital skin fibroblasts from this patient A, no 87 kDa AR and ligand binding 
were detected. 
Two isoforms of the PR have been described, a protein of normal structure 
(PR-B) and a shortened form (PR-A),lacking 164 amino acids at the NH,-terminus 
(Kastner et al. 1990). Depending on cell type and promoter context, functional 
differences between the two forms have been found. PR-A can act as an activator 
of transcription and as a repressor of transcription by PR-B and even as an inhi-
bitor of transcription, mediated by the glucocorticoid receptor, the mineralocor-
ticoid receptor and the AR (Tung et al. '993, Vegeto et al. 1993). Wilson and 
McPhaul (1994) reported that two forms of human AR, comparable to the PR iso-
forms, are present in human genital skin fibroblasts. An 87-kDa isoform was pos-
tulated, which constitutes 7-15% of the total AR, arising from alternative 
initiation of translation. We were, however, unable to detect such a 87-kDa pro-
tein in genital skin fibroblasts of a control subject. 
So far, amino acid substitutions in exon 1, resulting in a receptor-positive form of 
AIS have not been found. However, recently a proline to leucine substitution at 
position 339 was found, in DNA isolated from a prostate tumor (Castagnaro et 01. 
1993). No functional studies have been performed as yet to study the signi-
ficance of this mutation. 
The cytosine to adenine transition at codon 564. converting an alanine 
residue into an aspartic acid residue in the first zinc cluster of the DBD of the AR, 
resulted in a CAIS phenotype. The phenotype was caused by the defective DNA 
binding and transactivation capacities of the mutant receptor. Although the 
correct 3-D structure of this mutant AR is not available, the effect of the muta-
tion can be deduced from the 3-D structure of the glucocorticoid-receptor DBD 
(Luisi et al. 1991). Cysteine 560, histidine 561, and tyrosine 562 are involved either 
in specific or non-specific contacts with the phosphate backbone of the DNA 
(Figure 1.3A). The amino acid substitution in the mutant receptor might interfere 
with these contacts, resulting in defective DNA binding. 
In the AR gene of 3 subjects with an AIS-like phenotype, no mutations were 
found with PCR-SSCP. Although receptor characteristics appear to be normal, the 
presence of a mutation, not influencing ligand binding, cannot be excluded. 
There is still a possibility that some mutations are being missed by the screening 
procedure we used, However, in our laboratory so far all mutations, that were 
previously found by direct sequencing, could be confirmed by PCR-SSCP after-
wards. AR proteins appeared as normal 110-112 kDa doublets in genital skin 
fibroblasts and furthermore normal Kd and Bmax values were measured. This 
does not rule out abnormal protein expression in other target tissues. Another 
explanation for the androgen resistance syndrome might be the presence of a 
mutation in a gene, encoding a factor specifically involved in regulation of trans-
cription of AR target genes. 
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Summary 
Premature stop codons of the human androgen receptor gene are usually asso-
ciated with a complete androgen insensitivity syndrome. We, however, identi-
fied an adult patient with a 46,XY karyotype, carrying a premature stop codon in 
exon 1 of the androgen receptor gene presenting with signs of partial virilization: 
pubic hair Tanner stage 4 and clitoral enlargement. No other family members 
were affected. A point mutation at codon position 171 of the androgen receptor 
gene was detected that replaced the original TTA (Leu) with a premature stop 
codon TGA (opal). After careful examination ofthe sequencing gel. however, also 
a wild type allele was identified, indicating a mosaicisln. In addition, elimina-
tion of the unique AfIII recognition site induced by the mutation was incom-
plete, thus confirming the coexistence of mutant and wild type androgen 
receptor alleles in the patient. Normal RI88I binding and a normalno-112 kDa 
androgen receptor doublet in Western immunoblots consolidated the molecular 
genetic data by demonstrating the expression of the wild type receptor in the 
patient's genital skin fibroblasts. Transfection analysis revealed that only a rela-
tively high concentration of plasm ids carrying the mutated androgen receptor 
complementary DNA lead to expression of a shortened androgen receptor due to 
downstream reinitiation at methionine 188. Thus, reinitiation does not playa 
role in the presentation of the phenotype; rather the partial virilization is caused 
by the expression of the wild type androgen receptor due to a somatic mosaic. 
We conclude that somatic mosaicism of the androgen receptor gene can repre-
sent a substantial factor for the individual phenotype by shifting it to a higher 
degree of virilization than expected from the genotype of the mutant allele 
alone. 
Introduction 
The androgen insensitivity syndrome probably represents the most common 
cause of male pseudohermaphroditism (Quigley ef al. 1995). Mutations of the AR 
gene are responsible for a variable degree of impaired androgen action. The AIS 
phenotypes extend over a broad clinical spectrum ranging from external female 
genitalia through a large group of subjects with incomplete masculinization 
and ambiguous genitalia to minimal forms with only slightly diminished virili-
zation and/or infertility (McPhaul ef al. 1993b, Hiort ef al. 1996b). However, relia-
ble genotype-phenotype correlations do not exist, and the phenotype can vary 
even in different patients carrying the same mutation McPhaul ef al. 1993b, 
Rodien ef al. 1996, Sinneker ef al. 1997). 
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Single base mutations resulting in amino acid substitutions (missense muta-
tions) represent the most common structural defects of the AR gene in either 
PAIS or CAIS (Sultan et 01.1993, Brinkmann et 01.1995, Quigley et 01.1995, Hiort et 
al. 1996b). More extensive structural alterations at the protein level can be due to 
nonsense mutations inducing the formation of a premature translation termi-
nation (stop) codon. This may be the result of either the direct conversion of 
amino acid co dons into stop codons through point mutations (Trifiro et al. 1991b, 
Zoppi et al. 1992, Hiort et al. 1994b) or the indirect formation after disarrange-
ments of the translational reading frame by frame shift mutations (He et al. 
1991, Batch et al. 1992, Hiort et al. 1994b, Brinkmann et 01.1995). Based on events 
on the molecular level [truncation of the AR, reduced AR mRNA level (Marcelli et 
01. 1990, Charest et al. 1991), and physiologically insufficient downstream initia-
tion (Zoppi et al. 1992)] androgen action is seemingly completely abolished in 
vivo. As expected, in the current literature premature stop codon mutations have 
exclusively been associated with the CAIS phenotype (Trifiro et al. 1991b, Batch et 
al. 1992, Zoppi et al. 1992, Hiort et al. 1994b, for a review see QUigley et al. 1995 
and references therein). 
To characterize causes for incongruent genotype-phenotype correlations in 
patients with androgen insensitivity, we investigated an AIS patient with 
partial virilization of the external genitalia despite the presence of a premature 
stop codon within the AR gene. Functional studies were performed on the DNA 
level and on the protein level, leading to the elucidation of the underlying mole-
cular mechanism, We discuss the clinical significance of an almost unrecognized 
and probably underestimated phenomenon for the clinical treatment and the 
genetic counseling of patients with androgen resistance. 
Subjects and methods 
Patient 
A 23-yr.-old woman of Polish origin contacted her physician because of primary 
amenorrhea, Her external genitalia were predominantly female. However, 
clitoral enlargement to 2,0 em and pubic hair Tanner stage 4 indicated partial 
virilization (Figure IIL1). Orificium urethrae externum and introitus vaginae 
were separated. No fusion of the posterior labial folds was present. In addition, 
bilateral axillary hair was observed, and the voice was normal female. Breast 
development corresponded to Tanner stage 5. Two different karyotype analyses, 
on blood lymphocytes and on genital skin fibroblasts, displayed a 46,XY karyo-
type. Serum testosterone (31.2 nmolll) was in the upper male range, LH (11.0 UIl) 
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Figure 111.1 External genitalia of the patient, showing pubic 
hait Tanner stage 4 and clitoral enlargement 
and the LH x testosterone product (343) were elevated (normal LH x testosterone 
product, < 170). As an estimation of in vivo function of the AR, serum SHBG was 
measured before and after 3 days of oral administration of 0.2 mg/kg body 
weight/day of the anabolic steroid stanozolol according to a standardized test 
protocol (Sinnecker et al. 1997). Basal SHBG was low but still normal for age (27.8 
nmolll). No decrease in SHBG, but, rather an increase was observed in response 
to stanozolo!. The lowest value corresponded to 112.7% (31.3 nmol/l) of the initial 
concentration (normal response: 51.4% ± 2.1% (±SE)i range, 35.6-62.1%] (Sinnecker 
et al. 1997). On laparoscopy, bilateral ivory-colored testis-like structures each 
measuring 2-3 em in length, were demonstrated. No mullerian remnants were 
detected. To prevent the patient from further virilization, the gonads were remo-
ved. Histological examination revealed testis-specific tissue differentiation with 
atrophic germinal epithelium and Leydig-cell hyperplasia. After gonadectomy, 
hormone substitution therapy was started with estradiol valerate. 
Cultering conditions of cells 
All cells were cultured at 37°C and 5% CO,. Genital skin fibroblasts of the patient, 
obtained during gonadectomy, and male control fibroblasts, derived fronl fore-
skin specimens, were maintained in MEM (Life Technologies, Grand Island, NY), 
supplemented with 10% (vol/vol) FCS, 1% (vol/vol) MEM non essential amino 
acids (Life Technologies) and penicillin (200IE/ml)/streptomycin (0.2 mg/ml). 
7S 
COS-l and CHO cells were cultured in DMEM with the nutrient mix F12 (Life Tech-
nologies), 5% (vol/vol) FeS, and antibiotics. For transcription activation studies, 
CHO cells were plated in medium containing 5% dextran-charcoal-treated Fes. 
Androgen binding studies 
Androgen binding studies were performed as previously described (Bruggen-
wirth et al. 1996). In brief, confluent cultures of genital skin fibroblasts were 
incubated with medium containing increasing concentrations of FH]R1881 
(O.02-3.0 nM) in either the presence or absence of a 2oo-fold molar excess of 
unlabeled ligand. All incubations were performed in duplicate. After 1 hour at 37 
°C, 50 ~ll culture medium was taken from each dish for determination of total 
counts. Cell monolayers were washed with 2 ml Tris-saline (20 mM Tris, 0.15 M 
Nael, pH 7.4) and scraped in 1 ml TEG buffer [20 mM Tris, 1.5 mM EDTA, 10% 
(vol/vol) glycerol, 600 pM PMSF, 500 11M bacitracin (pH 7.4)J. After centrifugation 
of the cell suspensions (10 minutes, 800xg), pellets were washed in TEG without 
protein inhibitors and dissolved in 1 ml 0.5 N NaOH (30 minutes, 56 'C). Five 
hundred microliters were taken for liquid scintillation counting, 100 ~ll were 
used in duplicate for protein determination. Scat chard calculations were perfor-
med using Microsoft Excel Personal Computer software (Microsoft Corp., Rich-
mond,WA). 
Immunoblot analysis 
Western immunoblot analysis was done as described previously (van Laar et al. 
1989) with only minor changes. Briefly, confluent cultures of genital skin fibro-
blasts (175 cm') or transfeded COS-l cells (75 cm') were lysed in a buffer contai-
ning 40 mM Tris-HCL (pH 7.4), 1 mM EDTA, 10% glycerol, 10 mM dithiothreitol, 1% 
Triton X-100, 0.08% SDS, 0.5% sodium deoxycholate, 600 ~lM PMSF, and 500 ~IM 
bacitracin. AR was immunoprecipitated from whole celllysates by the mono-
clonal antibody F39-4.1 (Zegers et al. 1991) coupled to goat antimouse agarose 
beads (Sigma Chemical Co., St. Louis, MO). Samples were separated by SDS-PAGE 
(4% stacking gel, 7% separating gel) for 1 h. at 200 V. Eledroblotting on cellulose 
nitrate membranes was performed for 1 h. at 100 V. After drying and rinsing 
several times with PBS, 0.1% Tween-20 (Bio-rad, Richmond, CAl. the membranes 
were blocked with PBS, 0.1% Tween-20, and 5% nonfat dry milk (blocking buffer) 
and subsequently incubated for 1 h. in a moist chamber with primary antibody 
Sp197 or Sp061 (each diluted 1:1000 in blocking buffer), directed against amino 
acids 1-20 or 301-320 of the AR, respectively (van Laar et al. 1989, Zegers et al. 
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1991). As second antibody, an antirabbit peroxidase conjugate (Sigma) was used 
in a 1:4000 dilution. Protein detection was performed by chemoluminescence 
using the Renaissance Western Blot Chemoluminescence Reagent (DuPont-New 
England Nuclear, Boston, MA). 
DNA studies 
Genomic DNA was extracted from peripheral blood leukocytes according to 
standard procedures and served as template for the PCR. Exons 1-8 of the AR gene 
were individually amplified, followed by mutation screening using nonisotopic 
SSCP analysis as reported previously (Hiort et al. '993, Hiort et al. '994a, Hiort et 
al. 1994b). After detection of an aberrant migration pattern on SSCP, a 414 bp PCR 
fragment representing segment 2 of exon 1 was purified employing the Qiaquick 
extraction kit (Qiagen, Hilden, Germany), and directly sequenced using [y-"Pl-
ATP end-labeled primers with the Sequenase sequencing kit (Amersham Buch-
ler, Braunschweig, Germany) (Hiort et al. 1993). AflII (New England Biolabs, 
Beverley, MA) restriction site analysis of the 4'4 bp exon 1 PCR fragment was 
done on genomic DNA derived from either blood leukocytes or genital skin fibro-
blasts according to instructions of the manufacturer. Several controls for wild 
type AR DNA contamination of the peR reactions were performed by repeating 
separate experiments in different laboratories and by using different genomic 
DNA preparations. Template-free conditions were always included. The samples 
were analyzed on a 5% glycerol polyacrylamide gel followed by silver staining. 
AR expression vectors and transjections 
The human AR expression vector pSVARo (Brinkmann et al. 1989) served as a 
starting point to create a mutant cDNA construct containing the stop codon TGA 
at codon position 171. After AjlIl digestion of pSVARo, the overhanging 5'- ends 
were blunted by a 15 min. incubation with 0.06 U/fll 51 nuclease (Pharmacia). 
This-was followed by BamHI digestion, thus removing a 2318 bp AjlII/S1-BamHI 
fragment from the vector. Two oligonucleotides (5'- TGAACTAGTCGATG-3' and 5'-
GATCCATCGACTAGTTCA-3') were hybridized to construct a linker containing the 
TGA stop codon, an additional SpeI-site, and a BamHI 5' overhanging end. Subse-
quently, the linker fragment was cloned into the prepared vector. In-frame liga-
tion was verified by plasmid sequencing. In a second cloning step, the above 
mentioned 2318 bp fragment was recloned into the first step product. The latter 
was pretreated before ligation by SpeI digestion followed by blunting of the 5' 
overhanging SpeI end (Sl nuclease) and an additional BamHI digestion. The final 
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Figure rrL2 DNA-sequencing of genomic DNA PeR-amplified fragments encompassing codons 169 to 173 
of the AR gene. The left panel represents a male control DNA; the right panel belongs to the Index 
patient. In codon 171, a point mutation leads to a substitution of a T by a G, thus creating a premature 
stop codon (marked by open arrows). The black arrow indicates the additional presence of the wild type 
T-band in the patient's DNA. 
construct pSVAR171-StOP was verified for the correct sequence by plasmid 
sequencing. The construction of the expression vector pSVAR121, representing an 
NH,-terminal-deleted AR cDNA encompassing codons 188 to 910, was published 
before by Jenster et al. (1995). COS-I and CHO cells were maintained as described 
above and transiently transfecled by the calcium-phosphate precipitation 
method (Chen and Okayama 1987). For transcription activation studies, CHO cells 
were cultured in 1O-cm2 six-well multidishes, using 12.5-2,500 ng AR expresion 
vector/dish (50-10,000 ng/ml precipitate), 0.5 r'g (2 rlg/ml) of the reporter plas-
mid Luc, regulated by the mouse mammary tumor virus promoter (MMTV) 
(Organon, ass, The Netherlands) (de Ruiter et 01. 1995) adjusting to a final 
amount of 5 r'g (20 rlg/ml) plasmid DNA with the pTZI9 carrier plasmid. Trans-
fections were performed in triplicate in three independent experiments (con-
centrations 100 ng-lO,ooo ng/ml precipitate: two experiments, each performed 
in triplicate). Twenty-four hours before cell lysis, cells were incubated with 
medium containing either no hormone or 1 nM R1881 (DUPont-New England 
Nuclear), Luciferase activity was determined as previously described (de Ruiter 
et al. 1995). For studying expression of the AR, 75 em' sub confluent cultures of 
COS-I cells were transfected with 1.5 rlg (Ir'g/ml) expression plasmid (pSVARo, 
pSVARI21 or pSVARI71-stop, respectively), adjusted to a final amount of 30 rlg (20 
r'g/ml) with the carrier plasmid pTZI9. Twenty-four hours after transfection, 
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cells were glycerol shocked by a 1.5 min.-incubation with 15% glycerol-MEM 
without FCS. Whole cell lysates were generated another 24 h. later preceding 
immunoprecipitation of the AR. 
Results 
Mutation detection analysis 
All eight exons of the AR gene of the patient's genomic DNA were successfully 
amplified by PCR and resulted in PCR fragments of the predicted length (Hiort et 
al. 1994b). Exons 2-8 were individually amplified in a single step, exon 1 was divi-
ded into seven overlapping segments. Because of an abnormal migration pat-
tern on SSCP analysis, the 414-bp segment of exon 1 of the gene was sequenced. 
At codon position 171 (numbering according to Brinkmann et al. 1989), a point 
mutation TTA to TGA, was detected that replaced the original leucine residue 
and created a premature stop codon (opal: Figure III.2), thus eliminating a res-
triction recognition site for the enzyme Af/Il. In addition to the mutant DNA 
sequence, also the wild type DNA sequence was observed (Figure IIl.2). To con-
firm these data, an AfIII restriction recognition site analysis of the respective 
4'4 -bp PCR fragment was performed. Restriction of PCR products from normal 
controls lead to formation of two fragments, 205 bp and 209 bp in length, respec-
tively. In separate DNA preparations from peripheral blood leukocytes and geni-
tal skin fibroblasts of the patient, however, the PCR products were partially 
digested (Figure 1Il.3, lanes 2 and 4, respectively). Hence, sequencing data and 
restriction site analysis both demonstrate the presence of mutant and wild type 
AR DNA sequences in the patient's blood leukocytes and genital skin fibroblasts. 
Because karyotype analyses excluded chromosomal mosaicism, and sequencing 
of the CAG-repeat in exon 1 supplemented the presence of only one X-chromo-
some, mosaicism due to a somatic mutation of the AR gene was considered. 
AR binding characteristics 
Androgen binding properties were studied in a whole cell assay of genital skin 
fibroblasts using the synthetic androgen methyltrienolone (R1881). In Figure 
III.4, a Scatchard plot is presented that demonstrates specific R1881 binding of 
genital skin fibroblasts of the patient. The calculation of the Bmax revealed a 
value of 22.56 fmol/mg protein, which is below the normal male range (39.0-
169.0 fmol/mg protein). A normal Kd of 0.063 nM was found (normal male 
range, 0.03-0.13 nM). This result indicates the expression of an AR containing a 
functionally intact androgen-binding domain. 
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Figure 111.3 Aflll restriction site analysis of 414-bp genomic DNA PCR fragments derived from the 
patient (blood leukocytes, genital skin fibroblasts) and a male control (blood leukocytes), respectively. 
lane 1, marker (base pair numbers are indicated on the left); lane 2, blood leukocyte DNA (patient), Afll!-
digest; lane 3. blood leukocyte DNA (patient) undigested: lane 4, genital skin fibroblast DNA (patient), 
Ajm-digest; lane 5, genital skin fibroblast DNA (patient), undigested; lane 6, blood leukocyte DNA (con-
trol), AfllI-digest; Jane 7, blood leukocyte DNA (control). undigested; lane 8, no tempiate. Partial dige-
stion of the patient's DNA is Indicated by open arrows and confirms the coexIstence ofwHd type and 
mutant AR gene sequences. 
Western immUl1oblot analysis on genital skin fibroblasts 
Investigation of AR expression in the patient's tissue was performed by immu-
noprecipitation of the AR from whole cell lysates of equally grown confluent 
cultures of genital skin fibroblasts preceding Western immunoblot analysis. 
Using monoclonal antibody F39.4.1 for immunoprecipitation and polyclonal 
antibody Sp061 for immunodetedion on cellulose nitrate membranes, a normal 
llO/112·kDa AR doublet was found in the genital skin fibroblasts of the patient 
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Figure lilA Scatchard plot representing R1881 binding on genital skin fibroblasts 
of the patient. Specific androgen binding, normal Kd and low Bmax. 
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(Figure Ill.S, lane 3), indicating the expression of the wild type AR. The signal 
intensity of the 110/112-kDa band in the patient was always severely reduced in 
comparison to the male control genital skin fibroblast strain (Figure Ill.S, lane 2 
vs. lane 3). This is in accordance with the low Bmax obs.erved in the Scatchard 
analysis and could be an indication of a reduced amount of wild type AR expres-
sed in a given population of genital skin fibroblasts of the patient. However, any 
quantitative interpretation should be restrained because the ratio of fibroblasts 
in tissue culture containing either the mutant or the wild type AR allele does not 
necessarily reflect in vivo conditions. 
Expression study of pSVAR171·stop, pSVAR121, and pSVARo 
AR expression using pSVAR171·StOP, pSVAR121 or pSVARo expression plasmids 
has been investigated in transiently transfected COS·, cells. Antibody F39-4.1 has 
been used for immunoprecipitation, whereas either Sp197 or Sp061 served for 
immunodetection on Western blots. Figure IlLS. lane 1, illustrates the formation 
of a normal l1olI12·kDa AR after transfection of the wild type AR construct 
pSVARo. Construct pSVAR121, encoding amino acids 188.910 (Jenster et al. 1995), 
demonstrated the expression of the predicted NH,·terminal·deleted 87·kDa AR 
8. 
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Figure IlLS Western immunoblot analysis. AR was immunoprecJpitated from whole ceJllysates from 
either genital skin ffbroblasts or transfeded COS-I cells using the monoclonal anttbody F39.4.1.1mmu-
nodetection on Western blot was performed by Spo61 (lanes 1-S), and Sp197 (lanes 6-8), respectively. 
Epitopes for antibodies and transfected constructs are Illustrated in the scheme (see also in the text). 
lane " C05-1 cells transfeded with pSVARo (1/20th lysate from one 75-cm' culture flask (d)]; lane 2, 
genital skin fibroblasts, control male (entire lysate from one 17S-cm' cf); lane 3, genital skin fibroblasts 
(patient) (entire lysate from one 175-cm' cf); lane 4. COS-I cells transfeded with pSVARl71-stop (l/20th 
lysate from one 75-cm' cf); lane 5. COS-I cells transfeded with pSVAR121 (1/20th lysate from one 75-cm' 
d); lane 6, COS-l cells transfeded with pSVAR171-stoP (1l2otl1 lysate from one 75-cm' d); lane 7. COS-l 
cells transfeded with pSVAR121 (1l2oth lysate from one 75-cm' cf); lane 8. COS-l cells transfeded with 
pSVARo (1/2Oth lysate from one 75-cm' cf).lane 3 demonstrates the expression of 11O/112-kDa wild type 
AR in the patient. The signal intensity is considerably reduced compared with that in the control male 
cell line in lane 2. lane 5 shows the expression of an 87-kDa AR fragment b-y pSVAR121 that cannot be 
recognized by Sp197 (lane 7). The same pattern Is seen in case of pSVARI71-stoP (lanes 4 and 6, respedl-
vely), and is consistent with downstream initiation of translation of an 87-kDa NH2-termlnally trunca-
ted AR using Methionine 188 as start codon. 
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fragment using Sp061 in immunodetection (Figure IlLS, lane 5). In accordance, no 
signal could be obtained using antibody Sp197 (Figure 111.5, lane 7). Remarkably, a 
weaker band following the same pattern in migration (87 kDa) and immunode-
tection (Sp061, signal; Sp197, no signal) as pSVAR121 was found for pSVAR171-stop 
(Figure 111.5, lanes 4 and 6, respectively), indicating the expression of an 87-kDa 
AR fragment, most likely caused by downstream initiation of translation at 
Methionine 188. The 87-kDa band that is visible in lane 3 representing the 
patient's genital skin fibroblasts, is also consistent with downstream initiation, 
because no 87-kDa signal could be obtained in a different blot using antibody 
Sp197 (data not shown). Whether the smaller bands in lane 2 representing the 
control fibroblast strain are also caused by the use of alternative start sites or by 
proteolysis has not been investigated. 
Transcription activation studies 
To exclude the possibility that partial virilization of the patient could have been 
significantly influenced by the NH,-terminal-truncated AR caused by the 
mutant AR allele, transcription activation properties of pSVAR171-stop compared 
with those of pSVAR121 and pSVARo were investigated. Induction of the MMTV-
Luc reporter plasmid using transiently transfected CHO cells was measured in 
either the presence or absence of 1 nM R1881. Maximum reporter gene induction 
by the wild type AR plasmid pSVARo was found using 12.5 ng expression plasmid 
in transfections of 10-cm2 cultures of CHO cell; a 46-fold induction (range, 45.2-
46.8) relative to basal activity in the absence of R1881 was observed (Figure 111.6). 
Under these conditions, no significant transcription activation of the reporter 
gene by pSVAR171-stOP was present (1.4-fold; range, 0.4-2.6; Figure III.6). Only at 
highly elevated concentrations of pSVAR17,-stOP, partial transcription activation 
of MMTV-Luc could be observed, with a maximum induction of 13-fold (range, 
10.3-15.7) using 1250 ng expression plasmid (5 flg/ml precipitate; Figure 111.6). 
With respect to the AR expression studies (Figure 111.5), this activity is most likely 
due to the NH2-terminal- truncated 87-kDaAR caused by downstream initiation. 
The pSVAR121 expression plasmid represents the same NH2-terminal-truncated 
AR as the downstream initiation product caused by pSVAR171-stOp. Partial trans-
cription activation of the reporter plasmid was observed using pSVAR121 (6.8-
fold; range, 5-8-4), corresponding to previously published data (Figure I1I.6) 
(Jenster et al. 1995). 
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Figure 111.6 Transcription adlvatlon study of wild type and mutant AR expression plasm Ids. The y-axis 
represents the fold induction of MMTV-Luc reporter gene In the presence of 1 oM RI8S1 In relation to 
basal activity In the absence of hormone. Results of transfections (each done In triplicate) are indicated 
by black points (- '" mean). On the x-axis, the amount of DNA per ml precipitate is indicated. 
Discussion 
In order to determine factors influencing the genotype-phenotype correlation in 
patients with AIS, we investigated a PAIS subject with discrepancies among phe-
notype, genotype, and the result of the SHBG response to stanozolol. The pheno-
typic appearance with obvious signs of virilization demonstrated significant 
androgen action in the patient. In contrast, the absent SHBG decrease in 
response to stanozolol would predict a CAIS phenotype with total abolishment 
of AR function (Sinnecker et al. 1997), a striking discrepancy with the clinical 
observations. Mutation detection analysis revealed a premature stop codon 
within the NH1-terminus of the AR gene. Again, this finding was not consistent 
with the PAIS phenotype of the patient, as in the current literature premature 
stop codons within the AR gene have always been associated with CAIS (Trifiro 
et al. 1991b, Batch et al. 1992, Zoppi et al. 1992, Hiort et al. 1994b, for review see 
also QUigley et al. 1995 and Gottlieb et al. 1996). 
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DNA sequencing and restriction site analysis demonstrated the presence of a 
somatic mosaic of mutant and wild type AR alleles in the patient. This was con-
firmed by the presence of normal androgen binding properties in cultured geni-
tal skin fibroblasts and the detection of a normalllo/1l2-kDa AR doublet in 
Western immunoblots, both indicating the expression of the wild type AR. A 
physiological significance of downstream initiation of translation at Methio-
nine 188 resulting in an 87-kDa AR, as demonstrated in Figure IlLS, seems unli-
kely, because only relatively high plasmid concentrations of the pSVAR'7'-StOp 
plasmid lead to relevant reporter gene induction in cotransfection assays. Diffe-
rent reports by others on premature stop codons of the AR gene in the human 
(Zoppi et al. 1992) as well as in the mouse (He et al. 1994) being associated with 
partially active NH2-terminal-truncated AR fragments caused by downstream 
initiation support our findings. The respective phenotypes have always been 
CAIS, despite the occurrence of downstream initiation (Zoppi et al. 1992, He et al. 
1994). Thus, we conclude that the partial virilization of our patient is most likely 
due to the expression of the wild type AR based on somatic mosaicism. The 
absent SHBG decrease in response to stanozolol may be due to variations in the 
tissue distribution of mutant and wild type AR alleles. One would expect, with 
respect to this consideration, that liver parenchymatous cells predominantly, if 
not exclusively, contain the mutant form of AR alleles. 
The occurrence of somatic mosaicism in genetic diseases is not a rare event. 
For example, the McCune-Albright syndrome is due to sOlnatic mutations of the 
gene coding for the r;-subunit of the G protein (G,a) (Weinstein et al. 1991, Shen-
ker et al. 1994). The variability in the severity of the clinical manifestations in 
this disease is consistent with the presence of different ratios of mutated and 
wild type alleles in tissues of individual patients (Weinstein et 01. 1991, Shenker 
et al. 1994). Concerning AlS, the possibility of somatic mosaicism hardly received 
attention in the current literature. Publications dealing with somatic mutations 
of the AR gene have mostly been restricted to malignant disease (Culig et 01. 
1993a, Suzuki et 01. '993, Schoenberg et al. 1994). To date, only one case of a soma-
tic mutation of the AR gene in AlS has been published (Hiort et al. 1993). Partial 
virilization of that patient has been suggested to be most likely due to the 
expression of the wild type AR based on the somatic mosaic. A comparable ani-
mal model has been studied with the XXTfm-Sxr mouse in detail (Cattanach et aI, 
1971, Drews 1975), Different ratios of androgen responsive and unresponsive cells 
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in the somatic mosaics of these mice are responsible for phenotypes ranging 
from predominantly male with hypospadias to severely ilnpaired masculiniza-
tion with predominantly female appearance (Drews 1975). 
Somatic mosaicism of the AR gene represents the first clearly defined mecha-
nism influencing significantly the genotype-phenotype correlation in patients 
with AIS. Expression of the wild type AR plays the crucial role in molecular gene-
tic constellation by shifting the AIS subtype to a higher degree of virilization 
than expected from the mutant allele alone. For clinical purposes, knowledge 
about somatic mosaicism of the AR gene in a particular patient with AIS provi-
des important information for further management. First, somatic mosaicism 
can elucidate possible discrepancies among phenotype, genotype, and the SHBG 
androgen sensitivity test and therefore be of help in the interpretation of the 
data obtained. Second, it provides the basis for genetic counseling of these fami-
lies as the risk for another child with AIS is low if somatic mosaicism is present 
in the index patient. Thirdly, early gonadectomy is prudent in all patients 
rendered female to prevent undesired virilization during puberty (diteromegaly 
deepening of the voice) because of presumed partial androgen action. 
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Summary 
Length of the polymorphic (CAG)nCAA-repeat in exon 1 of the human androgen 
receptor gene is inversely related to transcription activation capacity. Lower 
androgens, and androgen receptor levels are observed in elderly men. Under 
such conditions, the length of the (CAG)nCAA-repeat might become critical in its 
effect on physiological end points. In view of a possible role of androgens in 
bone metabolism, we hypothesized that the length of the (CAG)nCAA-repeat 
might be correlated with bone mass. This was investigated in 365 elderly men of 
55 yr. and older from the Rotterdam Study (Hofman et al. 1991). Individuals repre-
sented the upper and lower quintiles (20%) of the population with respect to 
bone mineral density at the femoral neck. Allele typing was performed, using a 
PCR-based assay and automated sequencing, and genotypes were correlated 
with bone density and anthropometric variables. Interestingly, alleles were 
unequally distributed among the low and high BMD groups. Individuals with 
low BMD were overrepresented among those with shorter (CAG)nCAA-repeats. 
We observed a positive association between length of the (CAG)nCAA-repeat and 
bone mineral density at the femoral neck and the Ward's triangle in individuals 
with low body mass index « 25.3 kg/m'). 
Introduction 
Osteoporosis, the most common bone disease, especially in old age, is characteri-
zed by low bone mass and microarchitectural deterioration of bone tissue 
leading to enhanced bone fragility and a consequent increase in fracture risk 
(Consensus Development Conference on Osteoporosis 1993). Bone mineral den-
sity (BMD), an important predictor for osteoporotic fractures, is influenced by 
many factors. Up to 75% of variation in BMD might be determined by genetic 
factors (Christian et al. 1989, Pocock et al. 1993). Allelic differences in genes 
playing a role in bone metabolism have been studied in order to identify protec-
tive or risk factors. So far several candidate genes have been analyzed in relation 
to BMD and/or osteoporotic fractures, including the col/agen raJ gene (Grant et 
al. 1996) and the interleukin-6 gene (Murray et al. 1997). Genes encoding the vita-
min D receptor (Morrison et al. '994, Morrison et al. '997, Uitterlinden et al. 1996) 
and the estrogen receptor (Kobayashi et al. 1996) were analyzed as well. Al-
though polymorphisms in these genes have been found associated with BMD, 
controversy remains, since others could not replicate these findings (Han et al. 
'997, Nelson et al. 1997). 
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Another steroid hormone receptor with effects on bone metabolism is the 
androgen receptor (AR). The AR is present in physiologic concentrations in 
human osteoblast-like cells (Colvard et al. 1989). Expression of the AR in normal 
developing human bone and in adult osteophytic bone was studied in situ by 
Abu et al. (1997). They showed that the AR was highly expressed by osteoblasts 
and chondrocytes in both males and females. In addition, hypogonadism in men 
is associated with reduced BMD (reviewed by Orwoll and Klein 1995). and testos-
terone administration resulted in increased BMO and lean body mass in men 
with acquired hypogonadism (Katz nelson et al. 1996). There are several lines of 
evidence for a direct role of androgens in bone formation, 5Cf.-Dihydrotestos-
terone which cannot be converted to 17P-estradiol, stimulated proliferation of 
bone cells in vitro. This effect was inhibited by antiandrogens, indicating that 
the AR was involved (Kasperk et al. 1989). In addition, 46,XY complete androgen 
insensitivity patients achieve a typically female bone mass (Orwoll and Klein 
1995, Soule et al. 1995). Moreover, in an adolescent complete androgen insensiti-
vity patient reduced BMD was observed before gonadectomy, although no lack 
of estrogens was found (Munoz-Torres et al. 1995). 
The AR consists of several distinct functional domains: an NH2-terminal 
domain involved in transcription activation, a DNA-binding domain, and a 
ligand-binding domain (Beato et al. 1995). In the NH,-terminal domain two poly-
morphic stretches are located: a GGC-repeat (encoding 16-24 glycine residues), 
and a highly polymorphic (CAG)nCAA-repeat with a length ranging from 9-33 
CAGs in normal individuals (Sleddens et af. 1992, Sleddens et af. 1993, Nance 
1997). Poly-glutamine stretches, encoded by CAG-repeats, are present in activa-
tion domains of many transcription factors, and stretches of variable length can 
modulate transcriptional activity of these factors (Courey et al. 1989, Gerber et al. 
1994). The function of the transcriptional glycine stretch is unknown. 
Influence of the length of the (CAG)nCAA-repeat on the transcription activa-
tion capacity of the AR was studied in vitro. Relatively long (CAG)nCAA-repeats 
(n 240) were inhibitory to transcription activation, although promoter depen-
dent differences were observed (Mhatre et af. 1993, Chamberlain et af. 1994, 
Jenster et af. 1994, Kazemi-Esfarjani et al. 1995). An extremely expanded 
(CAG)nCAA-repeat (n = 48-75) is associated with Spinal and Bulbar Muscular 
Atrophy (SBMA), characterized by progressive muscle weakness of upper and 
lower extremities (La Spada et al. 1991). In affected males, symptoms of mild 
androgen insenSitivity such as gynecomastia and reduced fertility are fre-
quently observed, indicating that repeat length influences receptor activity. 
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Recently Tut et a/. (1997) associated relatively long (CAG)nCAA-repeats with an 
increased risk of impaired spermatogenesis. Moreover, in two large case-control 
studies it was shown that shorter (CAG)nCAA-repeats were associated with a 
higher risk of prostate cancer (Stanford et a/. 1997) and with a more aggressive 
phenotype of prostate cancer (Giovannucci et a/. 1997). 
Although conflicting reports have appeared, many studies suggest that the 
bio-available testosterone level declines with age (Swerdloff and Wang 1993). 
Aging also changes target cell sensitivity for reproductive hormones (Supakar et 
a/. 1993). In pubic skin fibroblasts from elderly men a lower AR expression level 
was observed when compared to the AR expression level in pubic skin fibro-
blasts derived from younger men (Ono et a/. 1988). In rats, an age dependent 
decreased AR level was observed in the liver (Song et a/. 1991). In aging individu-
als the length of the (CAG)nCAA-repeat might become critical in its effect on 
physiological end points. We investigated whether the length of the (CAG)nCAA-
repeat in the AR gene was associated with BMD. Allele typing was performed in 
a sample of 365 men of 55 yr. and over from the Rotterdam Study (Hofman et a/. 
1991). 
Subjects and methods 
Population 
The Rotterdam Study is a prospective cohort study of determinants of disease 
and disability in elderly people, mainly of Caucasian extraction. At base line 
participants were 55 yr. and over, and living in Ommoord, a suburb of the city 
Rotterdam in The Netherlands. A total of 10,275 persons of whom 9161 (89%) 
were living independently were invited for the study. In the independently 
living population the overall response rate was 77% for the home interview and 
71% for the examination in the research center. Written informed consent was 
obtained from each participant. The Rotterdam Study has been approved by the 
Medical Ethics Committee of Rotterdam University Medical School. From all 5931 
independently living participants with bone density measurements, 1453 sub-
jects were excluded according to the following criteria: older than 80 yr., use of a 
walking aid, known diabetes, or use of cytostatics, thyroid hormone, or diuretics. 
From the 4478 remaining subjects 179 and 186 men were selected, representing a 
random sample of the upper and lower quintile (20%) of the BMD (althe femoral 
neck) (cut off values 0.987 g/cm' and 0.764 glcm', respectively). 
9' 
Bone mineral density measurements and anthropometry 
BMD at the femoral neck, the trochanter, and Ward's triangle (g/cm') was 
measured by dual-energy X-ray-absorptiometry (DXA, Lunar Corporation, 
Madison, WI, USA) as described previously (Burger el 01. 1994). The in vivo 
coefficient of variation was 3,2% in femoral neck, 2,5 % in the trochanter, and 
3.1 % in the Ward's triangle. Lumbar spine BMD measurements were not inclu-
ded in the analysis since lumbar spine values might be biased due to arthritis 
(Burger el al. 1994). Height and body weight (BW) was determined in a standing 
position without shoes, and body mass index (BMI) (kg/m') was calculated as a 
measure of obesity. 
Determination of (CAG)nCAA-repeal lenglh 
Genomic DNA was isolated from blood lymphocytes by standard procedures. 
Labeled PCR-products were generated and analyzed as described previously 
(Sleddens ef al. 1992). Six randomly chosen samples were directly sequenced by 
automated sequencing, to confirm allele typing. Template was made with pri-
mer -7oA and 320B, and sequenced with reverse primer 172B (Brliggenwirth et al. 
1996). 
Statistical analysis 
Data are presented as means ± standard deviations (SD). Mean BMD, BMI and 
BW were compared for different genotypes by analysis of covariance (ANA-
COVAl and by Student I-test. Frequencies of alleles among the low and high BMD 
group were compared by the X2 test. The relation between (CAG)nCAA-repeat 
length and BMD, BMI, and BW, respectively, was quantified with linear re-
gression analysis. All analyses were carried out after adjustment for age, which 
is a known determinant of bone density. Repeat length was used both as a conti-
nuous variable and as a categorical variable. Alleles were therefore divided in 2 
and 3 arbitrarily chosen groups of increasing repeat length (i.e. S 22 compared to 
> 22, and groups containing 14-19, 20-23, and 24-31 CAGs). Logistic regression ana-
lysis was used to calculate the Odds ratio as an estimate of the relative risk with 
95% confidence intervals (CI). 
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Results 
General characteristics of individuals in both study groups, i.e. upper and lower 
quintiles of BMD, are presented in Table IV.!. Body weight, height, and BMI were 
significantly lower in the low BMD group. 
The frequency distribution of AR (CAG)nCAA alleles in the groups with low 
and high BMD is presented in Figure IV.!. In both groups allele (CAG)21CAA was 
most frequently observed. Alleles that were observed in > 1% of the population 
showed a different distribution among both groups (X' test 36.93, dJ. ~ 12, 
P ~ 0.0002) (the expected values for the low BMD group are based on the allele 
frequencies that were established in the high BMD group). Repeat alleles 
containing::::; 22 repeat units were slightly overrepresented in the low BMD 
group (Figure IV.1 and Table IV.2). 
Table IV.l Characteristics of the population of elderly men studied 
Low BMD High BMD 
< 0.764 g I em' > 0.987 g I em' 
Number 186 179 
Age (yr.) 67·3 ± 7·1 67-4 ± 7-2 
BMD (g I em') 0.7 ± 0.06 1.06 ± 0.091 
BMI (kg 1m') 24.3 ± 2.6 26.7 ± 2.8 
BW (kg) 73.0 ±8·9 8}.1 ± 10.9 
Height (em) 173·4 ± 6·9 176-4 ± 6.1 
p-value 
0.96 
< 0.001 
< 0.001 
< 0.001 
< 0.001 
Values presented are the mean ± SO, p·values were calculated by the Student t-test. 
By stratifying high vs.low BMD according to BMD (cut off point ~ 0.90 g/cm') 
and number of CAGs (cut off point 22 repeats) the relative risk of having a low 
BMD was estimated for individuals carrying less than 22 CAGs, by applying 
logistic regression analysis (Table IV.3). Although there was a 1.3 increased risk 
when all individuals were analyzed this was not significant. However, the analy-
sis was also stratified according to the median BMI in this population (25.3 ± 2.7 
kg/m2) because BMI is a major determinant of BMD. A significantly increased 
risk of 1.9 was observed for individuals with a BMI lower than 25.3. Age- and 
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Figure IV.1 Distribution of AR (CAG)nCAA-repeat allele sizes. The open bars represent the population 
with the 20 % lowest BMO values, the black bars individuals with the 20% highest BMO values. Alleles 
with frequency> 1%: X' '" 36.93, d.f. eo 12, p '" 0.0002. 
weight -adjustment did not change these point estimates (Table IV.3). To further 
explore this association, mean BMD was compared between (CAG)nCAA-repeat 
groups (Table IV.4). This showed that individuals with a BMI < 25.3 and carrying 
longer (CAG)nCAA-repeats have a significantly higher bone mass at the femoral 
neck and the Ward's triangle. Similar differences were observed at the trochan-
ter although these did not reach significance (data not shown). For men with 
BMI ~ 25.3 no significant differences in BMD among genotype groups were 
observed. By applying linear regression analysis it was calculated that the in-
crease in BMD per increase in (CAG)nCAA-repeat group between genotype 
groups corresponds to 0.045 ± 0.019 (SE) (p = 0.02). When (CAG)nCAA-repeat 
alleles were analyzed individually this corresponded to o.oog ± 0.005 (SE) 
(p = 0.05) increase in bone mass per CAG copy. When adjustment for age was 
included in the regression analysis, point estimates did not change. 
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Table IV.2 Frequency distribution of (CAG)nCAA-repeat allele sizes 
(CAG)nCAA Low BMD High BMD 
14 0 (0) 2 (1.1) 
15 3 (1.6) 0 (0) 
16 (0.5) 4 (2.2) 
17 2 (1.1) 2 (1.1) 
18 12 (6-4) 6 (3-3) 
19 19 (10.1) 16 (8.8) 
20 21 (11.2) 17 (9-4) 
21 34 (18.1) 33 (18.2) 
22 22 (11.7) 19 (10.5) 
23 23 (12.2) 22 (12.2) 
24 19 (10.1) 22 (12.2) 
25 11 (5.9) 13 (702) 
26 11 (5·9) 15 (8.3) 
27 6 (3-2) (0.6) 
28 (0.5) 2 (1.1) 
29 3 (1.6) 4 (2.2) 
30 0 (0) 2 (1.1) 
31 0 (0) (0.6) 
Total 188 (100%) 181 (100%) 
Alleles with frequency> l%:·C '" 36.93, d./. '" 12, P '" 0.0002. 
Percentages are presented between brackets. 
Discussion 
Many genetic and environmental factors playa role in bone metabolism. Poly-
rnorphisms in genes involved in bone metabolism, have been analyzed in order 
to find risk factors for osteoporosis. The AR might be directly involved in bone 
metabolism (Kasperk et al. 1989, Orwoll and Klein 1995, Soule et al. 1995, Vander-
schueren et al. 1995). In the NH,-terminal part of the AR a polymorphic 
(CAG)nCAA-repeat is present, which influences receptor activity, as was shown 
in vitro (Mhatre et al. 1993, Chamberlain et al. 1994, Jens!er et al. 1994, Kazemi-
Esfarjani et al. 1995). Expansion of the (CAG)nCAA-repeat (>38-75 CAGs) in the AR 
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Table IV.3 Relative risk of low BMD by (CAG)nCAA-repeat length 
(CAG)nCAA Nr. of cases Controls OR' OR' 
low BMD High BMD Crude Age-adjusted 
All > 22 73 81 1 (reference value) 
~ 22 113 98 1.28 [0.84-1.94) 1.28 [0.84-1.94) 
Total 365 
BMI < 25.3 > 22 46 30 1 (reference value) 
~ 22 79 27 1.g1 [1.01-3.61J 1.g1 [1.01-3.62] 
Total 182 
BMI > 25.3 > 22 27 51 1 (reference va!ue) 
~ 22 34 71 0.91 [0-48-1.69) 0.90 [0.48-1.69) 
Total 183 
t OR, Odd's ratio; the 95% confidence interva! is presented between brackets. 
Table IV.4 Mean BMD by (CAG)nCAA-repeat group stratified by BMI 
(CAG)nCAA Cases Femoral neck p Ward's triangle p 
VS.14-19 vs.14-19 
n 
BMI < 25.3 14-19 33 0.76 ± 0.18 0.60 ± 0.20 
20-23 95 0.80 ± 0.18 0.26 0.65 ± 0.19 0.24 
24-31 54 0.85 ± 0.20 0.02 0.70 ± 0.20 0.03 
Total 182 
BMI ~ 25.3 14-19 34 0·97 ± 0.19 0.82 ± 0.21 
20-23 94 0.94 ± 0.18 0.50 0.80 ± 0.21 0·49 
24-3
' 
55 0.93 ± 0.21 0-40 0.78 ± 0.21 0.27 
Total 183 
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is associated with SBMA, a neuromuscular disease, which is often accompanied 
with mild symptoms of androgen insensitivity (La Spada et al. 1991). Therefore, 
length ofthe (CAG)nCAA-repeat in the AR was associated with possible androge-
nic end-points. Recently, two reports appeared in which shorter (CAG)nCAA-
repeats were associated with a higher risk for prostate cancer (Ingles et al. '997, 
Stanford et al. 1997). A significant association between (CAG)nCAA-repeat length 
and age at onset of prostate cancer was descibed by Hardy et al. (1996). Giovan-
nucci et al. (1997) found an inverse relation between (CAG)nCAA-repeat length 
and a more aggressive phenotype of prostate cancer. Moreover, Tut et al. (1997) 
showed that a relatively long (CAG)nCAA-repeat might be a risk factor for 
impaired spermatogenesis. 
In the present study, it was investigated whether length of the polymorphic 
(CAG)nCAA-repeat in the NH,-terminus of the AR gene was associated with 
BMD, in a population of healthy elderly men representing either low or high 
BMD. In the first instance an association between (CAG)nCAA-repeat length and 
BMD was not detected. Interestingly, alleles were unequally distributed among 
the low and high BMD group; i.e. individuals with low BMD were overrepresen-
ted among those with shorter (CAG)nCAA-repeats. Because weight and, conse-
quently, BMI (a measure of obesity), is a known determinant of BMD, the 
population was stratified according to median BMI (25.3 kg/m'). In the group 
with BMI < 25.3 a positive association was observed between repeat length and 
BMD. This observation might be explained by the fact that androgens inhibit the 
release of LH, an action that is mediated by the AR (Schwarz and McCormack 
1972). Sobue et al. (1994) measured plasma testosterone, LH, and FSH levels in 
SBMA patients and in controls after administration of fluoxymesterone 
(androgenic hormone). Their findings indicated a less strong negative feedback 
mechanism in SBMA patients compared to controls. In addition, Legro et ai. 
(1994) determined length of the (CAG)nCAA-repeat of female Hispanics, and 
found a positive association among waist -hip ratio and repeat length. This result 
might as well be explained by an effect of (CAG)nCAA-repeat length on the 
testosterone level. In a study by Elbers et al. (1997) it was shown that testoste-
rone administration in female to male transsexuals caused an increased amount 
of visceral fat, suggesting that under influence of testosterone the waist-hip 
ratio increases. However, because these women were gonadectomized, it might 
also be possible that a lower estrogen level is involved. 
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We postulate that an AR which harbors a relatively long repeat is less active, 
and thus exerts less strong negative feedback on the pituitary gland. A less 
strong negative feedback mechanism will result in a higher testosterone level, 
which might be beneficial with respect to BMD. An aspect that should be taken 
into account is that testosterone can be aromatized to estrogens (Purohit et al. 
1992), Estrogens are important for controlling bone turnover rate and for 
achieving peak bone mass, not only in women but also in nlen. This is illustrated 
by disturbed skeletal maturation, lower bone density, and higher bone turnover 
rate in male patients with aromatase deficiency, resulting from mutations in the 
CYP19 gene (Conte et al. '994, Morishima et al. 1995). In a man with estrogen 
resistance due to ER mutation, the same features were observed (Smith et al. 
1994). In a recent study by Slemenda et al. (1997) bone density in healthy elderly 
men was associated with serum sex steroids. A positive association between 
BMD and estrogen levels was established, whereas a weak negative association 
was observed between serum testosterone level and BMD. According to 
Slemenda et al. (1997) this negative association can be explained in part by the 
influence of BW on BMD. Weight is an important determinant of BMD, and 
testosterone level is inversely related with BW. No association was established 
between (CAG)nCAA-repeat length and BMD in the group with a BMI ;, 25.3. 
The effect of the (CAG)nCAA-repeat length on BMD might be overruled by BW. 
To find out whether length of the (CAG)nCAA-repeat in the normal population 
affects the negative gonadal-pituitary feedback mechanism, and whether this 
results in higher testosterone and/or 17P-estradiollevels, free testosterone and 
free 17P-estradiollevels, and/or a change in the SHBG level, will be determined in 
sera of the men under study. Moreover, the study population will be expanded 
with elderly men, in whom intermediate BMD was established, to study in more 
detail a possible relation between length of the (CAG)nCAA-repeat in the AR 
gene and BMD and/or anthropometric variables. 
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100 V Amino Acid Substitutions in the First Zinc Cluster of the AR 
Summary 
In the androgen receptor of a patient with androgen insensitivity the alanine 
residue at position 564 in the first zinc cluster of the DNA-binding domain was 
substituted by aspartic acid. In other members of the steroid-receptor family, 
either valine or alanine is present at the corresponding position, suggesting the 
importance of a neutral amino acid residue at this site. The mutant receptor was 
transcriptionally inactive, which corresponded to the absence of specific DNA 
binding in gel-retardation assays and its inactivity in a promoter-interference 
assay. Two other receptor mutants with a mutation at this same position were 
created to study the role of position 564 in the human androgen receptor on 
DNA binding in more detail. Introduction of asparagine at position 564 resulted 
in transcription activation of a mouse mammary tumor virus promoter, 
although at a lower level compared to the wild type receptor. Transcription acti-
vation of an (ARE),-TATA promoter was low, and binding to different hormone 
response elements could not be visualized. The receptor with a leucine residue 
at position 564 was as active as the wild type receptor on a mouse mammary 
tumor virus promoter and an (ARE),-TATA promoter, but interacted differentially 
with several hormone response elements in a gel-retardation assay. The results 
of the transcription activation and DNA-binding studies could partially be pre-
dicted from three-dimensional modeling data. The phenotype of the patient was 
explained by the negative charge, introduced at position 564. 
Introduction 
The AR gene is composed of eight exons and encodes a protein of 910 amino 
acids with an apparent molecular mass of no kDa (Brinkmann et al. 1989). The 
AR belongs to a superfamily of nuclear receptors for steroid hormones, thyroid 
hormones, vitamin D, and retinoids. These receptors are characterized by dis-
tinct functional domains: an NHAerminal part, involved in transcription activa-
tion, a DBD, a hinge region, and a C-terminal part involved in ligand binding, 
dimerization and transcription activation (Beato et al. 1995, Mangelsdorf et al. 
1995). The DBD of steroid receptors is encoded by two exons and consists of two 
functionally different DNA-binding zinc clusters (Freedman et al. 1988). Steroid 
receptors bind to HREs as homodimers, in contrast to several other nuclear 
receptors that can heterodimerize with the retinoid X receptor (Freedman et al. 
1988). Although the structure of the DBD is well conserved between nuclear 
receptors, several groups of receptors bind to specific DNA sequences (Forman 
and Samuels 1990). The GR and ER DBDs interact with distinct, although related 
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HREs (Green et al. 1986, Freedman et al. 1988). Three amino acid residues located 
in the so-called P-hox (proximal box) are essential for specific interaction with 
base pairs from the HRE, located in the major groove of DNA (Danielsen et al. 
1989). The GR, the AR, the MR, and the PR recognize the same HRE (AGAACAnn-
nTGTTCT) (Forman and Samuels 1990). Specificity with respect to transcription 
activation is probably introduced by auxiliary factors, which can change the 
affinity and specificity of binding sites (Freedman et al. 1988). However, recently 
Claessens et al. (1996) reported an ARE in the probasin promoter that is AR speci-
fic. The consensus HRE for steroid receptors is an imperfect palindromic 
sequence, consisting of two half-sites, spaced by three nucleotides (Dahlman-
Wright et al. 1991). Binding of the first receptor molecule enhances binding of the 
second molecule. Important determinants for this so-called cooperativity of 
binding are the spacing between the two half-sites of the HRE and protein-
protein contacts (Dahlman-Wright et al. 1991). 
Male sex differentiation and development proceed under direct control of 
the male sex hormones testosterone and SCI.-dihydrotestosterone, and actions of 
both androgens are mediated by the AR. Mutations in the AR gene of 46,XY indi-
viduals are associated with AIS, a disorder of sex differentiation. Many abnorma-
lities have been described, causing a wide spectrum of phenotypes, ranging 
from subjects with an external female phenotype and the absence of milllerian 
and wolffian duct derivatives, designated as CAIS, to a phenotype with 
ambiguous genitalia, called PAIS (Quigley et al. 1995). The most frequently 
reported defects are point mutations in the ligand- and DNA-binding domains of 
the AR (Quigley et al. '995, Gottlieb et al. 1997). 
In the present study a mutation in exon 2 of a subject with CAIS is reported. 
The alanine residue at position 564 in the DBD was substituted into aspartic acid 
(mutant AS64D). The effect of the AS64D mutation on AR function was investi-
gated, as was the effect of an asparagine substitution (mutant A564N) and a leu-
cine substitution (mutant A564L) at this same position. These studies were 
completed with molecular modeling. 
Subjects and methods 
Materials 
Primers were obtained from Pharmacia Biotech Benelux (Roosendaal, The 
Netherlands). [y-"PjATP (specific activity: 3000 Ci/mmol) was obtained from 
Amersham (Little Chalfont, UK). 17P-HydroxY-17C1.-[3Hjmethyl-4,9,1l-estratrien-3-
one (['HjRI881; specific activity 85 Cilmmol) and unlabeled R1881 were purcha-
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sed from New England Nuclear-DuPont de Nemours ('s Hertogenbosch, the 
Netherlands). The double stranded probe, containing an ARE, derived from the 
tyrosine aminotransferase (TAT) promoter (half-sites in italics) was obtained 
from Promega (Woerden, the Netherlands). The 27 bp oligonucleotides, used to 
produce two other double stranded probes, (half-sites in italics), containing, 
respectively, the strongest ARE from the MMTV promoter (Ham et al. 1988) and a 
consensus ARE, (Roche et al. 1992), were obtained from Pharmacia Biotech 
Benelux. 
ARE TAT: 
AREMMTV: 
5' TCGACTGTACAGGATGTTCTAGCTACT 3' 
5' TCGACGTTACAAACTGTTCTAGCTACT 3' 
ARE consensus: 5' TCGACGGTACAGTTTGTTCTAGCTACT 3' 
Clinical data 
The patient exhibiting female external genitalia, atrophic epididymides and 
vasa deferentia, was diagnosed as having AIS at the age of 1 yr. in the absence of 
a positive family history. A blind ending vagina was present, the uterus was 
absent and testes with a normal histology for a boy of this age were present in 
the inguinal canal. Testosterone synthesis disorders were excluded as a cause of 
the 46,XY sex reversaL Genital skin fibroblasts were obtained from the index 
patient for Scatchard analysis and structural analysis of the AR gene. AR 
sequence analysis of relatives was performed on white blood cell genomic DNA. 
Mutation detection 
PCR-SSCP analysis and direct sequencing were performed as described pre-
viously (Briiggenwirth et al. 1996). 
Ligand-binding study 
For determination of ligand-binding characteristics of the AR of the AlS subject, 
Genital skin fibroblasts were incubated with serial dilutions ['HJR1881 (0.02, 
0.05,0.3.1.0,3.0 nM, respectively) in serum free medium. The binding assay was 
performed as described previously (Briiggenwirth et al. 1996). 
Western blot analysis 
AR protein, derived from genital skin fibroblasts or transiently transfected CHO 
cells was immunoprecipitated and analyzed by Western immunoblotting 
according to the method of Ris-Stalpers et al. (1991). 
Construction of AR expression vectors 
pAR(o), a human wild type AR complementary DNA expression plasmid was 
described previously (Brinkmann et al. 1989). Expression plasmids encoding the 
various mutants, pAR(AS64D), pAR(AS64N) and pAR(AS64L) respectively, were 
constructed by site directed mutagenesis. The Kpnl-Aspl digested fragment of 
pAR(o) was exchanged with mutated Kpnl-Aspl fragments generated in two 
separate PCR amplifications (Higuchi et al. 1988). Sense primer 470A (Briiggen-
wirth et al. 1996), located upstream of the Kpnl site in exon " was combined with 
an antisense primer, containing the mutation (antisense primers: construct 
AS64D, S'CATGTGAGAtCTCCATAGTGACAC 3'; construct AS64N, S'CATGTGAGAtt-
TCCATAGTGACACCC 3'; construct AS64L, S' CATGTGAGAagTCCATAGTGACACCC 
3'). A sense primer, introducing the mutation (sense primers: construct AS64D, 
S' GTGTCACTATGGAGaTCTCACATG 3'; construct AS64N, S' GGTGTCACTATG-
GAaaTCTCACATGTGG 3'; construct AS64L, S' GGTGTCACTATGGActTCTCACAT-
GTGG 3'), was used in combination with an antisense primer 14NB 
(Briiggenwirth et al. 1996), located downstream of a unique Aspl site in exon 4. 
One microliter of both PCR products was used as template in a second peR reac-
tion using primers 470A and 14NB. The resulting PCR fragment was digested 
with Kpnl and Aspl, and exchanged for the corresponding wild type fragment in 
pARo. 
pSGSAR(o), a human wild type AR cDNA expression vector (provided by 
Dr. A.c.B. Cato, Karlsruhe, Germany) was used for transient transfection of C05-1 
cells. pSGSAR(AS64D), pSGSAR(AS64N) and pSGSAR(AS64L) were constructed by 
exchanging the 472 bp Kpnl-Aspl insert from pSGSAR(o) and the Kpnl-Aspl frag-
ment from the pSVAR plasmids, encoding the variant ARs. MMTV-Luc reporter 
plasmid, cytomegalovirus (CMV)-Luc and the CMV-(ARE)'-Luc reporter plasmids 
and plH4-(ARE),-TATA-Luc, containing the TATA-box and an Spl-site derived from 
the Oct 6-gene promoter have been described previously (Blok et al. 1992, de Rui-
ter et al. '99S, Kuil and Mulder 1996). 
Cell culture conditions and transfections 
Genital skin fibroblasts and C05-1 cells were cultured as previously described 
(Ris-Stalpers et al. 1990). CHO cells were cultured according to the COS-l cell cul-
ture protocol. The CHO cells, used for transcription activation studies and pro-
moter-interference assays were plated in 7 or 11 em" (promoter-interference 
assay) wells and grown for 24 hours. Cells were cotransfected, using the calcium-
phosphate method (Chen and Okayama 1987), with AR expression plasmid (10 
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nglml precipitate) and reporter plasmid (2 flg/ml precipitate). Carrier DNA 
(pTZ19) was added to a total of 20 fIg DNA/ml precipitate, and 90 fll precipitate 
were added per well. In the promoter-interference assay, 300 ng AR expression 
plasmid and 30 ng reporter plasmid (CMV-Luc or CMV-(ARE),-Luc), respeclively, 
were added per ml precipitate. pTZ19 was added to a total of 20 fIg DNA/ml pre-
cipitate, and 250 ~ll precipitate were added to 11 cm2 wells. The transfedion and 
luciferase assay were performed as described before (Kuil et al. 1995). Both trans-
cription activation studies and the promoter-interference assay were performed 
at least three independent times in triplicate, using three independent isolates 
of expression plasmid. In case of transcription activation studies, luciferase acti-
vity was expressed, relative to basal activity measured after culturing in the 
absence of hormone. For promoter interference studies, luciferase activity in 
cells, transfecled with CMV-(ARE),-Luc and AR expression plasmid and cultured 
in the absence of hormone was set at 100%. Inhibition of promoter activity in the 
presence of hormone was expressed relative to this 100% activity. CHO cells used 
for expression studies by Western blotting were also transiently transfecled by 
the calcium-phosphate method. To this end, cells were plated in 17S cm' culture 
flasks and transiently transfecled with 20 fig expression plasmid. COS-1 cells 
were plated in 80 cm2 culture flasks and transfected with 9.4 I-lg expression 
plasmid, using the diethylaminoethyl-dextran method (Gerster et al. 1987). 
Twenty-four hours before harvesting, CHO and COS-1 cells were washed and 
incubated with medium containing 1 nM R1881. 
Gel-retardation assays 
Transfecled COS-1 cells were collected in S ml PBS and the pellet was resuspen-
ded in extraclion buffer [10 mM NaH,PO, (pH 7-4), 0.4 M KCI, 1 mM EDTA, 10% 
(vol/vol) glycerol, o.S mM bacitracin, o.S mM leupeptin and 0.6 mM PMSF, 10 mM 
DTTJ and subjecled to four freeze- thaw cycles, followed by 10 minutes centrifu-
gation at 400,000xg at 4 °C in a TLA120.2 rotor (Beckman, Fullerton, CAl in a 
Beckman Optima TLX ultracentrifuge. The TAT ARE containing probe (S'-
TCGACTGTACAGGATGTTCTAGCTACT-3') (half-sites in italics) was obtained from 
Promega. Two other probes were produced by annealing a 27-bp oligonucleotide 
with an oligonucleotide of complementary sequence. One of them (S'-TCGACGT-
TACAAACTGTTCTAGCTACT-3') (half-sites in italics) contains the strongest ARE 
from the MMTV promoter (Ham et al. 1988), and the other probe (S'-TCGACG-
GTACAGTTTGTTCTAGCTACT-3') (half-sites in italics) contains a consensus ARE 
(Roche et al. 1992). The ARE containing probes were end-labeled using T4 polynu-
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Figure V.l Sequence of the AR DOD with the A-JD mutation, located In the first zinc cluster. The muta-
tion found in the index patient's AR Is present at position 564 of the AR DBD, located near the pobox of 
which the circled amino acid residues are involved in ARE recognition. The boxes indicate amino acid 
residues that interact with the phosphate backbone of DNA, either at specific (black boxes) or at non-
specific sites (open boxes) (Luisi et al. 1991, lobaccaro et 01.1996). The second zinc cluster contains the 
D-box, which is involved in dimerizatlon with an other AR molecule. The first part of the nuclear 
localization signal (NlS) Is also shown (underlined). The numbering of the various codons is based on a 
total of 910 amino acid residues in the human AR (Brinkmann et al. 1989). 
cleotide kinase and double stranded probe was purified from a 4% acrylamide 
gel, in 0.5 x TBE (1 x TBE= 50 mM Tris base, 50 mM boric acid, 1 mM EDTA, pH 8.6). 
Cellular extracts were incubated in binding buffer [10 mM HEPES (pH 7.9), 60 
mM KCI, 1 mM DTT, 1 mM EDTA, 4% ficolll, 1 flg polydeoxyinosinic-deoxycitidylic 
acid (poly[dl-dCl-poly[dl-dC]) in the absence or presence of the polyclonal AR 
antibody Sp197 (lO-fold diluted) (Kuiper et al. 1993a). After an incubation period 
of 10 minutes on ice, 2 fll purified DNA probe (50,000 cpm/fll) were added and 
incubation was continued for 20 minutes at room temperature. The 20-~ll sample 
was separated on a 4% polyacrylamide gel in 0.5 x TBE. Gels were fixed for 10 
minutes in 10% acetic acid-lO % methanol, and subsequently dried and exposed. 
Molecular modeling 
The crystal structure of the rat GR DBD, bound to a GRE was used as a basis upon 
which the 3-D AR models were built. The 3-D model of AR bound to a GRE has 
previously been described (Lobaccaro et al. 1996). The AS64D, AS64N and AS64L 
mutants were built according to the same strategy as that used to build the wild 
type model. Briefly, the side-chains of the AR mutants that were substituted in 
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the GR model were placed in energetically favorable conformations, using the 
SMD program (Tufferey et al. 1991). The whole system was then energy mini-
mized with the AMBER program (Pearlman et al. 1991, University of California, 
San Francisco, CAl. During the optimization process, the oligonucleotide was 
kept frozen to prevent unrealistic deviation from the initial crystal structure. 
Moreover, positional restraints on the backbone and on side-chains of conserved 
residues were applied and gradually released during the optimization. 
Figure V.5A was generated with the Insight II viewer (Biosym Technologies, 
San Diego, CAl and Figure V.5B was generated using the program MOLSCRIPT 
(Kraulis 1991). 
Results 
Mutation detection 
Genomic DNA of the index patient was used to amplify the coding part and 
intronic sequences flanking the exons of the AR gene, followed by SSCP analysis 
performed under two different conditions. An aberrant banding pattern was 
found for exon 2, which encodes the first zinc cluster of the DBD. Direct sequen-
cing showed a single nucleotide substitution at codon 564 (C to A) that resulted 
in substitution of alanine to aspartic acid (Figure V.l). The numbering of amino 
acid residues throughout the text is based on a total number of 910 amino acid 
residues in the human AR (Brinkmann et al. 1989). The mutation created a Bg/II 
site, which was used to investigate the segregation of this mutation in the 
family of the index patient. The mother and grandmother of the index patient 
were heterozygous carriers of this AR mutation (results not shown). 
Functional properties of tlte mutant receptor 
The AR protein was isolated from genital skin fibroblasts, obtained from the 
index subject. Molecular mass was checked by immunoblotting after immuno-
precipitation. The AR protein migrated as a normal 110-112 kDa doublet on SDS-
PAGE (data not shown). For Scatchard analysis, cultured genital skin fibroblasts 
were incubated for 1 hour with increasing concentrations of PH]R188l either in 
the presence or absence of a 2oo-fold molar excess of non-radioactive R188l. 
Both the Kd (0.07 nM) and Bmax (58 fmol/mg protein) values were within the 
normal range (Kd: 0.03-0.13 nM, Bmax: 39-169 fmol/mg protein), indicating that 
ligand binding was not affeeled by the mutation. 
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Figures V.2A and B Transcriptional activity of AR AS64D at different promoters. CHO cells were (otrans-
feeled with a reporter plasmid [(AREkTATA-Luc or MMTV-lucJ and the wild type or mutant expression 
plasmid. After 24 hours celis were cultured with medium containing Increasing concentrations of RIBS1 
for another 24 hours before a luciferase assay was performed. Each data point was tested In triplicate. 
A Induction of luciferase activity was calculated from five different experiments, In which (ARE)2-TATA-
Lu( was used as a reporter gene. Symbols represent the mean ± SEM (. : wild type, 0: AS64D). 
Transcription activation by AR AS64D was significantly different from that by the wild type AR (by Stu-
dent's t test, p "" 0.05). B Induction of luciferase activity was calculated from three different experi-
ments, In which MMTV-Luc was used as a reporter gene. Symbols represent the mean ± SEM (0 :wild 
type; a :AS64D). Transcription actIvation by AR AS64D was sIgnificantly different from that by wild type 
AR (by Student's t test, p "" 0.05). 
Transcriptional activity of AR AS64D 
AR AS64D was inactive in CHO cells colransfected with (ARE),-TATA-Luc, in con-
Irast to the wild type AR (Figure V.2A). The promoter of this reporter construct 
contains a TATA-box and an Spl site derived from the Oct-6 gene promoter, and 
two AREs (Blok et al. 1992). In general, comparable levels of wild type and mutant 
receptor protein were expressed in tranSiently transfeded CHO cells, as verified 
by SDS-PAGE and immunoblotting (for example, see Figure V.3c). AR AS64D was 
also unable to activate transcription from the complex MMTV promoter in CHO 
cells (Figure V.2B). 
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FIgure V.2e Promoter Interference of wild type AR and AR AS64Dz.CHO cells were transiently transfec-
ted with expression plasmid and CMV-(ARE),-luc reporter plasmid. Twenty-four hours after transfec-
tlon, cells were cultured in the absence or presence of 1 nM RIBS, and incubated for another 24 hours 
before performing a ludferase assay. Each data point was tested In triplicate. (MV-Luc reporter con-
struct cotransfeded with wild type AR was taken as a control (noo2). The luciferase signal, measured In 
the absence of R1881 was arbitrarily set at 100%, and activities, measured in the presence of 1 nM RI8S1 
were related to these values. The mean promoter activity ± SEM in the presence of hormone Is repre-
sented. 
In vivo DNA binding of AR AS64D 
In vivo DNA binding was studied with a promoter-interference assay. CHO cells 
were cotransfected with CMV-(ARE),-Luc. Three consensus AREs are inserted 
between the TATA-box of the constitutively active CMV promoter and the trans-
cription start site of the Zuciferase gene (Roche et aZ. 1992). Binding of the AR hin-
ders the assembly of a transcription initiation complex and, therefore, also 
interferes with the expression of the Zuciferase gene (Kuil and Mulder 1996). The 
level of inhibition is taken as a measure of specific DNA binding. In the presence 
of I nM R1881, the wild type AR showed a 48% reduction of luciferase activity 
whereas no reduction was seen in cells cotransfeded with AR AS64D (Figure 
V.2C). The AR could sequester factors that are essential for transcriptional acti-
vity of the CMV promoter (squelching). However, no reduction of luciferase 
expression was seen in cells cotransfected with CMV-Lue (Figure V.2C). 
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Figures V.3A and B Transcription activation by the wild type receptor and AS64N and AS64l using diffe-
rent reporter genes. (HO cells were cotransfected with a reporter plasmid [(ARE),-TATA-Luc or MMTV-
lue) and either the wild type or one of the mutant expression plasmids. Twenty-four hours after 
transfectlon, cells were cultured in medium containing increasing concentrations of RIB81 for another 
24 hours. Each data point was tested in triplicate. A Induction of luciferase adivity was calculated (rom 
five different experiments in which (ARE),-TATA-Luc was used as a reporter gene. Symbols represent the 
mean ± SEM (. : wild type, 0: AS64N, 8: AS64l). Transcription activation by AR AS64N was significantly 
different from that drsplayed by the wild type AR (by Student's t test,p = 0.05). B Induct ron of luclferase 
activity was calculated from five different experiments In which MMTV-luc was used as a reporter 
gene. Symbols represent the mean ± SEM (. : wild type, 0: AS64N, 6: AS64l). Transcription activation 
by AR AS64N was significantly different from activation, displayed by the wild type receptor (Student's 
t-test, p '" o.OS). 
Transcriptional activities of AR AS64N and AR AS64L 
To investigate whether the inactivity of AR AS64D was caused by sterie hin-
drance or by a conformational change due to the introduction of a negative char-
ged amino acid residue, the alanine residue was replaced by either a leucine 
residue (AS64L) or an asparagine residue (AS64N)_ Leucine has a larger side 
chain, like the aspartic acid residue. However, leucine is a neutral amino acid as 
is the alanine residue present in the wild type receptor. Asparagine has also a 
larger side chain, but is a polar amino acid residue. CHO cells were transiently 
cotransfected with AR expression plasmids and (ARE),-TATA-Luc_ Wild type AR 
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Figure V.3C Western blot analysis of wild type and mutated ARs after transient transfectlon in CHO 
cells. culture flasks with (HO cells were transfected with expression plasmid and after 48 hours cell 
lysates were prepared. From these Iysates, the receptor was lmmunoprecfpitated with monoclonal 
antibody f39.4.1 and separated on a SD$·PAGE gel. After blotting, receptor protein was detected with 
polydonal antibody Sp061 and an alkaline phosphatase-coupled goat anti-rabbit antibody. lane " wild 
type AR; lane 2, AR As64D; lane 3, AR AS64N; lane 4. AR AS64L. 
Figure V.3D Promoter·lnterference assay of AR A564N and AR AS64L. The DNA-binding properties of the 
mutated receptors were also tested in Intact cells. CHO cells were transiently transfected with expres-
sion plasmid and CMV-{ARE)2-luc reporter plasmid. Twenty-four hours after transfection, cells were 
cultured in the absence or presence of 1 nM R1881 and incubated for another 24 hours before perfor-
ming a luciferase assay. Each data point was tested in triplicate. The CMV-luc reporter construct, 
cotransfected with wild type AR was taken as a control (n=2). The luciferase Signal, measured in the 
absence of R1881 was arbitrarily set at 100%, and activities, measured in the presence of 1 nM R1881 
were calculated relative to these values. The mean promoter activity ± SEM in the presence of hormone 
is represented (n=4). *, Significantly different from inhibition shown by the wild type receptor (by Stu-
dent's t test, p < 0.05). 
and AR AS64L showed comparable activation of the minimal promoter at 
increasing amounts of RI88I, whereas AR AS64N showed strongly reduced 
transcription activation compaTed to the wild type AR (Ffgure v'3A). On the more 
complex MMTV promoter AR AS64L showed activity comparable to that of the 
wild type receptor and AR AS64N displayed a low level of hormone induced 
transcription activation (Figure V.3B). All proteins were expressed, and in 
general, expression levels were comparable (Figure V.3C). 
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In vivo DNA binding of AR AS64N and AR AS64L 
DNA binding was studied in CHO cells, cotransfected with CMV-(ARE),-Luc 
(Figure V.3D). In contrast to the wild type AR, luciferase expression was not 
lowered after cotransfection of cells with AR AS64N and culture in the presence 
of hormone. AR AS64L showed 38% inhibition, which was significantly different 
(p<o.OS) from the 48% inhibition observed for the wild type receptor. Protein 
expression levels were identical for all mutant receptors (see also Figure V.3C). 
In vitro DNA binding, comparing different ARBs 
The DNA-binding capacities of the wild type and the different AR mutants were 
tested in vitro in gel-retardation assays, using probes containing various AREs. 
AR was produced in transfeded COS-1 cells. The amount of receptor protein was 
checked by Western blotting, followed by immunostaining. Comparable 
amounts of AR in COS-1 cellular extracts were incubated with a np-Iabeled probe 
in either the absence or presence of polyelonal antibody Sp197, which stabilizes 
AR-dimers bound to the DNA (Kuiper et al. 1993a). Wild type AR and AR AS64L 
did bind to the ARE, derived from the TAT promoter (Figure V.4A: lanes 3 and 9, 
respectively) whereas binding of AR AS64D and AR AS64N could not be detected 
(Figure V.4A: lanes 5 and 7). Gel-retardation assays were also performed with two 
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Figure V.4A, Band C Gel-shift assay with three different ARE-probes. Each labeled ARE-probe (So,ooo 
(pm) was Incubated with nuclear extracts, prepared from transiently transfected COS-1 cells. Incuba-
tions were performed in the absence (-) or presence (+) of the polydonal antibody Sp197. The complexes 
were analyzed by polyacrylamide gel electrophoresis as described in the methods section. The position 
of the shifted complex is indicated by an arrow, FP indkates the position of the free "P-probe. 
A The probe contained an ARE, derived from the TAT promoter. lane 1, No receptor protein; lanes 2 and 
3, wild type AR; lanes 4 and S,AR AS64Di Janes 6 and 7, AR AS64N; lanes 8 and 9, AR AS64L; lane 10, free 
probe. After incubatIon of the probe wIth the antIbody, no specific shIfted band could be seen. 
B The probe contained the strongest ARE, derived from the MMTV promoter (Ham et 01. 1988). Lane 1, 
No receptor protein; lanes 2 and 3, wild type AR; lanes 4 and S, AR AS64D; lanes 6 and 7, AR AS64N; lanes 
8 and 9, AR AS64l. C The probe contained an consensus ARE (Roche et 01. 1992). lane 1: No receptor 
protein; lanes 2 and 3, wild type AR; lanes 4 and S, AR AS64D; Janes 6 and 7, AR AS64N; lanes 8 and 9, AR 
AS64l. 
other probes. One of the probes contained the strongest ARE from the MMTV 
promoter (Ham et al. 1988), which was also present in {ARE}2-TATA-Luc. The 
other probe contained a consensus ARE (Roche et al. 1992), which was also cloned 
behind the constitutively active CMV promoter that was used for promoter 
interference studies. Wild type AR was able to shift the probes in the presence of 
antibody, indicative of specific DNA binding (Figure V.4B: lane 3, and Figure V.4C: 
lane 3). Neither probe could be shifted with AR AS64D (Figure V.4B, lane 5, and 
Figure V.4C,lane 5) or AR AS64N (Figure V.4B, lane 7, and Figure V.4C, lane 7), al-
though AS64N showed transcription activation on a complex MMTV promoter 
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and even on a minimal ARE promoter. AR AS64L interacted with both probes, alt-
hough less efficiently than the wild type AR, which is in agreement with the 
results of the promoter-interference assay (Figure V.4B, lane 9, and Figure V.4C, 
lane 9). 
Molecular modeling 
The alanine residue at position 564 is buried, as it is involved in a hydrophobic 
cluster that is mainly formed by leucine 551, isoleucine 552, cysteine 610, alanine 
613, and methionine 615 (Figures V.l and V.S, A and B). The Ca-Cp bond of the ala-
nine residue at position 564 is directed towards the cysteine residue at position 
610 in the protein core. The backbone of residue 564 is hydrogen-bonded with 
the backbone of histidine residue 561, as both residues belong to a p-hairpin 
(Figure V.SB). They are located at the same side of the hairpin at facing positions. 
The histidine residue at position 561 is involved in direct contacts with DNA and 
participates in ARE recognition (Figure V.SB). Molecular modeling showed that 
in the AS64D mutant the aspartic acid residue is still buried. However, burying of 
charged residues is unfavorable, unless a compensatory charge forms a salt 
M615 
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Figure V.SA View of the hydrogen bonding between the alanine residue at position 564 and the histid-
ine residue at position 561. The hydrogen bonding Is shown by the dashed lines. Also shown are resi· 
dues constituting the hydrophobic pocket in which the alanine residue at position 564 Is buried 
(I.e. leucine 551, isoleucine 552, threonine 566, alanine 613, and methionine 615). The backbone is shown 
by thin lines, and the side chains are shown as thick lines. 
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Helix III 
Figure V.S8 Schematic view of part of the ARE and the wild type AR. Helix I, helix III, and the side chains 
of the histidine residue at position 561 and the alanine residue at position 564 (ball and stick) are 
shown. The histidine residue and the alanine residue belong to a small p-hairpin (strands shown as 
thick arrows) and the histidine residue makes direct contacts with DNA. Part of the ARE is displayed as 
long thin antiparallel arrows. 
bridge and is also buried at the same site. The only way AR A564D can take a 
more favorable conformation, is by breaking of the ~-hairpin and the hydrogen 
bonding with the histidine residue at position 561. This most likely affects the 
conformation of the histidine residue 561, resulting in disturbed ARE recogni-
tion. The asparagine residue in AS64N should lead to smaller perturbations 
because it will remain buried, although asparagine is a polar residue. The model-
ing showed that hydrogen bonding of asparagine with threonine 566 may 
roughly compensate for the unfavorable burying of polar atoms. Modeling of the 
A564L mutant showed that the larger leucine Side-chain could be accommo-
dated without difficulties in the hydrophobic pocket. Burying of the larger 
hydrophobic surface may even provide additional stability to the AR. Therefore, 
the leucine mutant was not expected to significantly perturb DNA recognition. 
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Discussion 
The DBD is the most conserved region within the nUclear-receptor family. 
Characteristic are the eight cysteines in this domain, forming the two zinc 
clusters. Zinc ion-coordinated binding is essential for proper folding and DNA 
binding. The structure of the DBDs of the GR and ER respectively, in complex 
with their response element on the DNA, was solved by X-ray crystallography. 
Almost similar conformations were displayed (Luisi et at. 1991, Schwabe et al. 
1993). The AR DBD is more closely related to the GR DBD sequence than to the 
ER DBD sequence. Fifteen amino acid residues in the AR DBD, which is defined as 
a 65 amino acid domain starting at lysine 548, are different from the GR DBD 
(Hollenberg et al. 1985, Trapman et al. 1988). Only 5 of them are located in the 
first zinc cluster, and 1 of these should be considered as a conservative change 
according to the chemical properties of its side-chain (Trapman et al. 1988). 
Therefore, it seems reasonable to deduce the structural consequences of muta-
tions in the AR DBD from the 3-D structure of the GR DBD. 
In the present paper the characterization of a mutation at position 564 in the 
first zinc cluster of the DBD of the human AR is reported. Mutations in the first 
zinc cluster of the AR have been described previously (Gottlieb et al. 1997). 
Some of them disrupt the zinc cluster structure because one of the cysteines is 
substituted, resulting in a CAIS phenotype (Gottlieb et al. 1997). Alanine 564 is 
partially conserved in other members of the receptor family. At the correspon-
ding position in the vitamin D receptor (VDR) an alanine residue is present as 
well (Baker et al. 1988). In the human ER, human GR, human PR, and human 
MR a valine residue is located at the corresponding position, implying that 
thepresence of a neutral amino acid residue at this position is critical for proper 
interaction of the receptor with DNA (Hollenberg et al. 1985, Green et al. 1986, 
Arriza et al. 1987, Misrahi et al. 1987). In the AR of the patient, described in this 
report, alanine was substituted by the negatively charged aspartic acid residue. 
The aspartic acid residue is located upstream of an a-helical region that is 
expsed to the major groove of DNA. and downstream of cysteine 560, histidine 
561 and tyrosine 562, which are involved in specific as well as non-specific con-
tacts with the phosphate backbone of the DNA (Luisi et al. 1991). Substitution of 
the latter residues by non-conservative amino acids in the GR resulted in loss of 
function (in vivo) and in vitro reduced DNA-binding affinity was seen (Schena et 
al. 1989). Warriar et al. (1994) substituted the cysteine residue at position 560 in 
the human AR by a serine residue. Although this is a relatively conservative 
change, decreased DNA binding and transcription activation were observed, 
which was attributed to the instability of the AR mutant-DNA complex. 
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We showed that AR A564D displayed defective transcription activation. 
Specific binding to DNA, which was studied in vilro by gel-shift assays with 
oligonucleotide probes containing different AREs, and in vivo with a promoter-
interference assay, could not be detected. From 3-D modeling studies it became 
clear that the alanine residue at position 564 is buried in a hydrophobic cluster 
(Figures V.1 and V.5A). A hydrogen bond is formed between the backbone of 
alanine 564 and the backbone of histidine 561. This latter residue is involved in 
direct interaction with the phosphate backbone of the DNA and is conserved in 
other nuclear receptors. Vagi el al. (1993) reported a patient with hereditary 1,25-
dihydroxyvitamin D-resistant rickets caused by substitution of the conserved 
histidine at position 35 of the VDR, comparable to histidine 561 in the AR. The 
phenotype of the patient was caused by perturbation of the conserved site that 
contacts the phosphate backbone of DNA. For AR A564D, the computer model 
displayed almost the exact conformation as that seen for the wild type, showing 
that there is no sterk hindrance due to the mutation. However, buried charged 
residues are only observed in proteins when they can form salt bridges with 
residues of opposite charge. Therefore, the modeled conformation appears un-
likely. Probably, aspartic acid 564 adopts a more favorable conformation, and as a 
result, the main chain hydrogen bond between aspartic acid 564 and histidine 
561 will be broken, which has consequences with respect to DNA binding. 
To investigate the role of the alanine residue at position 564 in more detail, 
the residue was also replaced by an asparagine or a leucine residue. 3-D model-
ing predicted that introduction of an asparagine residue should have inter-
mediate effects with respect to transcription activation. Hydrogen bonding 
between asparagine 564 and threonine 566 might compensate for unfavorable 
burying of the polar amino acid residue. Substitution by an asparagine residue 
resulted in a less stable AR-DNA complex which had clear consequences for 
transcription activation on a minimal (ARE)2-TATA promoter and to a lesser 
extent on a complex MMTV promoter. DNA binding was not observed in vitro 
by gel-shift analysis. DNA-binding capacity remained undetectable, even when 
studied in whole cells. However, the functionality of AREs is determined by 
additional transcription factor binding sites in the vicinity of AREs. Interaction 
with other proteins might stabilize the AR-DNA complex. This might explain as 
well the stronger activation of AR A564N on the MMTV promoter, compared to 
its activity on the minimal (ARE),-TATA promoter (Schule el al. '988, Rundletl 
and Miesfeld '995, Claessens el al. 1996). 
Modeling showed that no particular constraint resulted from the larger size 
of the leucine residue. It was predicted that the leucine residue, because of its 
larger hydrophobic surface, provides even more favorable stability to the AR. 
However, reduced DNA-binding affinity, in vitro as well as in vivo, was observed 
for AR A564L. Transcription activation was comparable with activation displayed 
by the wild type AR. Apparently, molecular modeling has some limitations, with 
respect to the prediction of complex interactions which might be explained by 
the fact that the model was based upon the crystal structure, which was solved 
for the GR DBD. In addition, functional studies were performed with the intact 
receptor and not only the DBD. 
In conclusion, the negative charge, introduced by the aspartic acid residue, 
destabilizes the normal conformation of the AR DBD, resulting in disturbed ARE 
recognition, in agreement with the phenotype of the patient expressing this 
mutant receptor. Results from the functional assays were partially supported by 
predictions, made by 3-D modeling. Although not predicted by molecular model-
ing, steric hindrance might have an impact on the DNA-binding capacities of AR 
AS64N and AR AS64L. 
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Summary 
In the coding part and the intron-exon boundaries of the androgen receptor 
gene of a patient with partial androgen insensitivity, no mutation was found. 
The androgen receptor of this patient displayed normal ligand-binding parame-
ters, and migrated as a 110-112 kDa doublet on SDS-PAGE in the absence of 
hormone. However, after culturing of the patient's genital skin fibroblasts in the 
presence of hormone, the slower migrating 114-kDa protein, which reflects 
hormone-dependent phosphorylation, was hardly detectable. Furthermore, 
receptor protein was undetectable in the nuclear fraction of the fibroblasts, after 
treatment with hormone, which is indicative of defective DNA binding. By 
sequencing part ofintron 2, a T-.A mutation was found 11 base pairs upstream of 
exon 3. In our screening of 102 chromosomes from unrelated individuals this 
base pair substitution was not found, indicating that it was not a polymorphism. 
mRNA analysis revealed that splicing involved a cryptic splice site located 71/70 
base pairs upstream of exon 3, resulting in generation of mRNA with an insert of 
69 nucleotides, In addition, a small amount of a transcript with a deleted exon 3 
and a very low level of wild type transcript were detected. Translation of the 
extended transcript resulted in an androgen receptor protein with 23 amino acid 
residues inserted in between the two zinc clusters, displaying defective DNA 
binding and defective transcription activation. 
Introduction 
Expression of a number of genes involved in male sex differentiation and 
development is regulated by the AR. The AR belongs to the family of steroid 
hormone-activated transcription modulators (Evans 1988). Like the other steroid 
hormone receptors, the AR consists of distinct functional domains. The NH~­
terminal part is involved in transcription activation and is encoded by exon 1 
(Faber et al. 1989). Two highly conserved DNA-binding zinc clusters are encoded 
by exons 2 and 3. The NH2-terminal zinc cluster recognizes specific consensus 
DNA sequences, whereas the (-terminal zinc cluster is involved in dimerization 
(Dahlman-Wright et al. 1991, Luisi et al. 1991). Parts of exons 3 and 4 encode the 
hinge region, which contains a NLS that is involved in nuclear import, and exons 
4-8 encode the LBD. 
On ligand binding. the AR undergoes conformational changes and binds to 
AREs in the promoter regions of androgen-regulated target genes (Beato and 
sanchez-Pacheco 1996). Recently, coactivators, interacting with the LBD of 
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steroid hormone receptors have been cloned (reviewed by Horwitz et al. 1996). 
One of these, ARA70, appears to be involved in transcription activation by the AR 
(Yeh and Chang 1996). 
Defects in the hAR cause disturbed virilization in 46,XY individuals, which is 
called AIS (reviewed by Quigley et al. 1995). Many qualitative and quantitative 
AR abnormalities, causing a broad range of AIS phenotypes, have been described 
(Gottlieb et al. 1997). The spectrum of phenotypes ranges from individuals with 
completely female external genitalia and absence of mullerian and wolffian 
duct derivatives (complete AIS) to patients with ambiguous genitalia (partial 
AIS) or with mild hypospadias (Quigley et al. 1995). The mutations that are most 
frequently observed, are nonsense or missense point mutations. Mutations 
resulting in aberrant splicing are much less common, only six of them have been 
reported (Gottlieb et al. 1997). In five of these, a consensus splice donor site was 
mutated, resulting in complete AIS. 
PCR~SSCP analysis is a screening method, often used for mutation detection 
in the hAR. Using this method, we and others have reported that in some indivi-
duals, clinically diagnosed as having AIS, no mutation was found in the coding 
region and exon flanking intronic sequences of the AR gene (Morel et al. 1994, 
Briiggenwirth et al. 1996, Weidemann et al. 1996). In the present study, we inves-
tigated and characterized the AR gene of a patient with partial AIS. Initially no 
mutation was detected in the coding region of the AR gene in this patient, 
although several biochemical and cell biological assays revealed that the enco-
ded AR of this patient was unable to bind to DNA. 
Subjects and methods 
Clinical subjects 
A family with three individuals clinically suspect for AIS (Il-4, III-I and III-2; for 
pedigree, see Figure VI.1), was referred for further diagnosis, treatment and 
genetic counseling. All affected individuals were 46,XY and had a female habitus 
with normal female external genitalia, and normal but underdeveloped testes 
with epididymides and vasa deferentia were present. No miillerian remnants 
were found. One postpubertal patient (Il-4) was Tanner P3, MS and had axillary 
hair. Testosterone synthesis disorders, which could be another cause for such a 
46,XY phenotype, were excluded by analysis of the circulating levels of steroid 
hormones and their precursors in this patient. At the age of 15.5 yrs., she had a 
normal male level of testosterone (21 nmol/liter) (normal range in adults: 10-30 
nmol/liter) combined with high levels of LH (13 IV/liter) (normal range in adult 
122 VI Aberrant Splicing of the Human AR 
'-1 ,-, 
• 
11-1 11-2 11-3 11-4 
111-1 111-2 
11-1 11-2 111-1 111-2 11-3 11-4 
26 _ 
25 _ 
2 4 6 
Figure Vl.l Pedigree and sizing of the poly-glutamine streich of the present family with AIS. peR 
products, obtaIned by amplificatIon of genomic DNA by primers flanking the (CAG)nCAA-repeat, were 
resolved on a 7% denaturating polyacrylamide gel. lane 1, normal male; lane 2, mother of the index sub-
ject; lane 3. 46,XY sIster of the index subject; Jane 4. 46,XY index subject; lane 5. normal male; lane 6, 
46,XY affected aunt. The index subject (IH-2) is indicated with an arrow. Numbers in the left margin of 
the lower part of the figure represent the numbers of glutamine residues encoded by the (CAG)nCAA-
repeat. 
males, l.s-8lU/liter). For final proof of the diagnosis and for the purpose of gene-
tic counseling of this family, DNA analysis of the AR gene was started. Blood cells 
were obtained from the three 46,XY patients, and genital skin fibroblasts from 
Ill-I and 1ll-2. Genital skin fibroblasts containing wild type AR protein and AR 
protein with an exon 3 deletion, derived from a patient with Reifenstein syn-
drome, previously described by Ris-Stalpers et al. (1994b), were used for compa-
rison. Genomic DNA from 74 unrelated individuals was used for intron 2 
screen-ing. Informed consent was obtained from all individuals. 
'" 
Mutation detection 
Genomic DNA was isolated from blood cells or genital skin fibroblasts, according 
to standard procedures (Sambrook et 01.1989). Single strand conformation poly-
morphism analysis and direct sequencing were performed as described pre-
viously (Briiggenwirth et al. 1996). A total of 102 normal chromosomes from 
unrelated individuals were analyzed by automated sequencing. Template was 
made using intron 2 sense primer C1 and intron 3 antisense primer C2 (Lubahn et 
01. 1989), and purified by use of the Boehringer High Pure PCR Product Purifica-
tion Kit (Boehringer Mannheim). Sequencing was performed with antisense 
primer 3BB (Table VI.1). Determination of the length of the polymorphic CAG-
repeat in exon 1, used as an intragenic polymorphic marker, was performed 
according to Sleddens et 01. (1992). 
Reverse-transcriptase-PCR (RT-PCR) reaction 
Total RNA was extracted from genital skin fibroblasts using TRlzol reagent 
(Gibco BRL) and quantified by absorption at 260 nm. Amplification of genomic 
DNA was prevented because the primers used in the RT-PCR reaction resulted in 
a PCR product spanning several introns of the AR gene. In the cDNA synthesis 
reaction, the exon 5 antisense primer SBB (Table VI.1) was used for first strand 
cDNA synthesis. cDNA amplification was performed by PCR with antisense 
primer 5BB combined with sense primer J3A (Table VI.1), spanning the 3' end of 
exon 1 and the 5' end of exon 2. To obtain sufficient quantities of template DNA 
spanning exon 2 and 3 sequences, for direct sequencing, a nested-PCR reaction 
was performed, by use of sense primer 13A and exon 4 antisense primer 14NB 
(Table VI.1). 
Ligand-binding study 
For determination ofligand-binding characteristics of the AR of the AIS patients, 
a whole cell assay was performed on genital skin fibroblasts as described else-
where (Briiggenwirth et al. 1996). 
Western blot analysis 
AR protein, obtained from cultured genital skin fibroblasts or transiently trans-
fected CHO and COS-1 cells, was immunoprecipitated and analyzed by Western 
immunoblotting according to Ris-Stalpers et al. (1991). 
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Table Vl.l Oligonucleotides used for cDNA synthesis and allele specific hybridization 
Oligonucleotide Location 
3BB intron 3 
5BB exon 5 
J3 A exon , ~ exon 2 
14NB exon 4 
470 A exon 1 
wild type exon 2 - exon 3 
69 bp insertion exon 2 - intron 2 
exon 3 deletion exon 2 - exon 4 
zAA exon 2 
lower case lettering indicates mismatches 
Construction of expression vectors 
Sequence 
5' AGAGAAAGAAAAGTATCTTAC 3' 
5' CGAAGTAGAGgATCCTGGAGTT 3' 
5' gAtGGatcCATGCGTTTGGAGACTGC 3' 
5' TGCAAAGGAGTtGGGCTGGTTG 3' 
5' GTAGCCCCCTACGGCTACA 3' 
5' GCTGAAGGGAAACAG 3' 
5' CTGAAGAAATACCCG 3' 
5' CTGAAGCCCGGAAGC 3' 
5' CAGAAGACCTGCCTGATCTGT 3' 
Human wild type AR cDNA expression plasmid pSVARo (Brinkmann et al. 1989) 
was used to construct pSVAR129, encoding an AR with 23 additional amino acid 
residues between the two zinc clusters. To this end, the 472-bp Kpnl-AspI frag-
ment from pSVARo was exchanged with the 541 bp Kpnl-Aspl fragment, genera-
ted by RT-PCR from the AR mRNA of patient III-2. cDNA was synthesized as 
described in Mr~tation detection above. In the peR reaction, following first strand 
cDNA synthesis, exon 1 sense primer 470A (Table Vl.J) was used, allowing diges-
tion with Kpnl. A nested PCR was performed by use of sense primer 470A and 
exon 4 antisense primer 14NB (Table Vl.J). All PCR products were checked by 
sequencing. Expression plasmid BHEX-AR33, an expression plasmid with an in~ 
frame deletion of exon 3, was constructed as described elsewhere (Ris-Stalpers et 
al. 1994b). To generate pSG5AR129 and pSG5AR33, the 541 bp Kpnl-Aspl fragment 
containing the 69 additional bp, and the 355 bp fragment from which exon 3 had 
been deleted were exchanged with the 472 bp Kpnl-AspI fragment of wild type 
AR expression vector pSG5ARo (provided by Dr. A.C.B. Cato, Karlsruhe, Germany). 
pSG5 plasm ids were used to obtain AR protein for gel-shift assays. 
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Cell culture and transjections 
Genital skin fibroblasts and COS-1 cells were cultured as described by Ris-Stal-
pers et al. (1990). CHO cells were treated like COS-1 cells. CHO cells were plated at 
7 cm, wells and grown for 24 hours before they were transiently transfeeled, by 
the use of the calcium phosphate method (Chen and Okayama 1987), with AR 
expression plasmid (10 ng DNA/ml precipitate suspension) and the MMTV-Luc 
reporter plasmid (2 ~lg DNA/ml precipitate suspension) (de Ruiter et al. 1995). 
Carrier DNA (pTZ19) was added to 20 ~lg DNA/ml precipitate suspension, and 90 
~tl precipitate suspension was added per well. Twenty-four hours after transfec-
tion, cells were incubated with increasing concentrations of R1881. Luciferase 
assays were performed as described before, after 24 hours incubation (Kuil et al. 
1995). Each receptor mutant was assayed three times in triplicate, by use of three 
independently isolated expression-plasmid preparations. Luciferase activity was 
related to basal activity, measured in the absence of hormone. CHO cells, used for 
expression studies, were plated in 175 cm2 culture flasks and transfected with 
200 ~ll DNA precipitate, as described above, by use of the calcium phosphate 
method. (OS-1 cells were transiently transfected in 80 cm1 culture flasks with 9-4 
~lg expression plasmid, by use of the diethylaminoethyldextran method (Gerster 
et al. 1987). Cells were shocked with 80 ~IM chloroquine for 2 hours. Transfeeled 
CHO and COS-1 cells were washed after 24 hours and cultured for another 24 
hours in either the presence or absence of 10 nM R1881. 
Preparation of cytosolic fractions and nuclear extracts 
Genital skin fibroblasts were grown until confluence in 175 cm2 culture flasks, 
incubated for 24 h in culture medium (Ris-Stalpers et aI. 1990) containing 10% 
hormone-depleted fetal calf serum, and were cultured for another 24 hours with 
medium either with or without 10 nM R1881. Next, cells were washed twice in 
PBS, were colleeled in 1 mllysis buffer A [40 mM Tris, 1 mM EDTA, 10% (vol/vol) 
glycerol, 10 mM DTT, 10 mM Na2Mo04 , 0.5 mM bacitracin, O.5Ieupeptin, 0.6 mM 
PMSF], and subjeeled to four freeze-thaw cycles, followed by lO-min centrifuga-
tion at 800xg in a Biofuge (Heraeus) at 4 "c. The supernatant was centrifuged for 
10 min. at 400,000xg at 4 "C (TLA120.2 rotor; Beckman, Fullerton, CAl. The cytosol 
fraction (supernatant) was stored at -80 "e until use. The pellet, remaining after 
the first 800xg centrifugation step was resuspended in buffer B (buffer A with 
0.2 % Triton X-IOO) and incubated for 5 min at 4 "e, followed by 10 min centrifu-
gation at 800xg in a Biofuge 13. The resulting pellet (nuclear fraction) was wash-
ed with buffer C (buffer A without leupeptin), and was resuspended in equal 
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volumes of 1 M NaCl and 0.5 M NaCl and incubated for 1 hour at 0 0c. Nuclear 
extract (supernatant) was obtained by centrifugation for 10 min at 400,000xg at 
4 °C (TLAI20.2 rotor). The total nuclear extract and 250 pI cytosol fraction were 
taken separately for immunoprecipitation. 
Gel-shift assay 
After transfection with pSGSARo, pSGSAR33 or pSGSARI29, COS-I cells were col-
lected in 5 ml PBS. The pellet was resuspended in extraction buffer [10 mM 
NaH,PO, (pH 7-4), 0.4 M KCI, 1 mM EDTA, 10% (vol/vol) glycerol, 0.5 mM bacitracin, 
0.5 mM leupeptin and 0.6 mM PMSF, 10 mM DTTJ and was frozen and thawed 
four times, followed by 10 min centrifugation at 400,000xg (TLAI20.2 rotor) at 
4 0c. The double-stranded DNA probe, containing the ARE from the TAT promoter 
(S'-TCGACTGTACAGGATGTTCTAGCTACT 3') (half-sites in italics), was obtained 
from Promega (Woerden, the Netherlands). Labeling and purification of the DNA 
probe and the gel-shift assay were performed as previously described by Briig-
genwirth et ai, (1998) (see also Chapter V), 
Allele-specific oligonucleotide hybridization 
RT-PCR and nested-peR reactions were performed as described above (see the 
Construction of expression vectors subsection above). The resulting peR product 
was amplified once more in a peR reaction of 30 cycles, by use of exon 1 sense 
primer 470A and exon 4 antisense primer 14NB. Plasmid (pSVARO, BHEX-AR33, 
and pSVAR129) fragments were amplified once under identical conditions, by 
use of the same primers. Dot blots were prepared in a Schleicher & Schuell appa-
ratus according to the manufacturer's protocol. In the case of peR product obtai-
ned by plasmid amplification, an equivalent amount of DNA was spotted. 
Membranes were preincubated for 10 min with hybridization mix {50 mM 
NaH2P04, 0.75 M NaCI, 5 mM EDTA (= sxSSPE); 1% SDS; 0.05 mg/ml herring sperm 
DNA], For each of the splice variants, specific oligonucleotides were designed: a 
wild type probe, an exon 3 deletion probe, and a 69-bp insertion probe (Table 
VI.J) (Pharmacia Biotech Benelux). The filters were subsequently hybridized and 
rinsed as described by Boehmer et al. (1997), but at a temperature of 35 °C instead 
of 37 0c. The membranes probed with wild type probe or exon 3 deletion probe 
were washed for an additional 10 and 15 min, respectively, in 0.1 x SSC/0.1 % SDS 
at 38 °C, before exposure. After autoradiography, the membranes were stripped 
and the procedure was repeated with probe 2AA (Table VI.1) as a control. 
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Results 
Screening for mutations 
PCR~SSCP analysis was performed under two conditions to screen for mutations 
in the AR gene of an index subject with partial AIS. In the coding part and the 
exon-flanking intronic sequences, no mutation was found. To study segregation 
of a presumed AR defect, the length of the AR gene CAG-repeat was determined 
in DNA from several family members. Results are presented in Figure VLl. The 
mother (H-2) of the two 46,XY sisters (III-1 and III-2) had two different alleles, one 
with a (CAG)24CAA unit coding for 25 glutamine residues and one with a 
(CAG)25CAA unit coding for 26 glutamine residues. The three affected 46,XY 
individuals (H-4, III-1 and III-2) had the (CAG)24CAA allele. Therefore, X-linked 
inheritance could not be excluded (Figure VI.l). The marker was informative, 
since two brothers of the 46,XX carrier (H-1 and H-3) had the (CAG)25CAA allele. 
Receptor characteristics 
AR protein isolated from genital skin fibroblasts from the index patient (III-2) 
appeared as a normalno-l12 kDa doublet after SDS-PAGE and immunoblotting. 
Hormone-binding parameters were determined in a whole cell-binding assay of 
genital skin fibroblasts. The receptor displayed a Kd of 0.08 nM and a Bmax of 64 
fmollmg protein, both within the normal range (Kd: 0.03-0.13 nM; Bmax: 39-169 
fmol/mg protein). The AR of patient III-1 displayed a Kd of 0.07 nM and a Bmax of 
63 fmollmg protein. Therefore, the 46,XY individuals (III-1 and III-2) in this AIS 
family were classified as having receptor-positive AIS. 
Hormone-dependent receptor phosphorylation 
The AR is phosphorylated and many potential phospho-sites are located in the 
part encoded by exon 1. In preparations from cells cultured in the absence of hor-
mone, usually two receptor isotypes are present, which are visible as a 110-112 
kDa doublet on a SDS-PAGE immunoblot (Kuiper et al. 1991). AR protein was iso-
lated from control genital skin fibroblasts and from genital skin fibroblasts of 
the index patient (1II-2). In both genital skin fibroblast preparations, cultured in 
the absence of androgens, the 110 and the 112 kDa AR isotypes were present 
(Figure VI.2A, lanes 1 and 2). The AR from patient III-2 contains a relatively long 
glutamine stretch (25 glutamines compared with 19 in the control AR), resulting 
in a slower migration pattern. On hormone binding, the AR undergoes addi-
tional phosphorylation, reflected by a 114-kDa isoform. The appearance of this 
isoform is dependent on DNA binding and/or transcription activation (Jenster et 
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Figure VI.2A and B Western blot analysis of wild type and mutant androgen receptor proteins. 
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A Western blot, showing receptor isotypes of the wild type AR and the mutant AR. AR protein was pre-
pared from genital skin fibroblasts, that had been cultured in the absence (-) or presence (+) of 10 nM 
R1881. After immunoprecipitation with monoclonal antl-AR antibody F39.4.1, receptor protein was 
separated on a 7% SDS-f'AGf gel. After immunobfotting the blot was incubated with Sp061, a poly-
clonal antl-AR antibody. The blot was washed and then Incubated with an alkaline phosphatase-coup-
led goat-anti-rabbit antibody to visualize the AR.lanes 1 and z, wild type AR; lanes 3 and 4, mutant AR. 
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B Subcellular localization of the wild type AR and the mutant receptor in genital skin fibroblasts of 
patient llI-z, after culturing of genital skin fibroblasts in the absence or presence of R1881. Genital skin 
fibroblasts were cultured for 24 hours either in the absence H or presence (+) of 10 11M R18S1. Nuclear 
and cytosol fractions were prepared, and the AR was immunoprecipitated with monoclonal antibody 
F39.4.1 from both the total nuclear extract and one-fourth of the cytosol fraction, Western blotting and 
immunostaining were performed as described in the legend to Figure VI.2A. AR was visualized with a 
peroxidase-coupled goat-anti-rabbit antibody. lanes 1 and 2, cytosol fraction from wild type genItal 
skin fibroblasts; lanes 3 and 4, nuclear extract from wild type genital skin fibroblasts; lanes 5 and 6, 
cytosol fraction from patient 1[[-2 genital skin fibroblasts; lanes 7 and 8, nuclear extract from patient 
III-z genital skin fibroblasts. 
al. 1994). This hormone-induced phosphorylation was used as a marker for 
proper receptor functioning. Control cells cultured in the presence of hormone 
displayed the expected, slower migrating, third isoform (114 kDa) (Figure VI.2A, 
lane 2). However, the 114-kDa isoform was hardly detectable in preparations 
derived from patient 1ll-2 (Figure VI.2A, lane 4). 
Subcellular localization studies in genital skin fibroblasts of the index 
subject 
Because the appearance of the 114-kDa isoform depends on DNA binding (Jenster 
et al. 1994), we investigated whether AR was detectable in the tightly nuclear 
bound AR fraction in genital skin fibroblasts from the patient. Control genital 
skin fibroblasts and genital skin fibroblasts from the index patient were cultu-
red in either the absence or presence of 10 nM R18S1, and cytosol and nuclear 
fractions were prepared. When cells were cultured in the absence of hormone, 
AR was found in the cytosol fraction (Figure VI.2B, lanes 1 and 5), but not in the 
nuclear fraction (lanes 3 and 7). After culture in the presence of hormone, al-
though AR was still detectable in the cytosol fractions (lanes 2 and 6), wild type 
AR was clearly present in the nuclear extract (lane 4), whereas AR protein was 
not observed in the nuclear extract of the patient's genital skin fibro-blasts (lane 
8). This suggests a defect in DNA binding of the AR in the index patient (1ll-2). 
Mutation detection and the effect of the mutation on the splicing process 
Although PCR-SSCP analysis was not informative about an AR gene mutation in 
patient 1ll-2, the AR gene was studied in more detail. Sequencing of the flanking 
intronic regions of exons 2 and 3 of the AR gene of patient III-2 demonstrated a 
mutation (T-'A) 11 bp upstream of exon 3 (Figure VI.3A). The same mutation was 
found in the AR gene of patients 11-4 and Ill-I. Because the mutation is located in 
the region where forward primer (primer 3A) anneals, the mutation remained 
undetected in PCR-SSCP analysis. In RT-PCR experiments, two different receptor 
variants were found. Predominantly, a transcript containing 69 additional 
nucleotides between the sequences of exons 2 and 3 (mutant transcript I), and 
a smaller amount of a transcript from which exon 3 was deleted (mutant trans-
cript II) (Figure VI.3B) were detected. Translation of transcript I will result in an 
AR with a 23 amino acid insertion between the two zinc clusters, and transcript 
II encodes a protein that lacks the second zinc cluster. Wild type transcript was 
not detected by RT-PCR. SDS-PAGE and immunoblot analysis revealed only a pro-
tein with an increased molecular mass in genital skin fibroblasts from patient 
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Figures VI.3A and B Characterization of the point mutation 
splice donor 
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splice acceptor 
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acceptor site 
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-----1 
t 
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EXON 3 1-- 3' 
EXON 3 1-- 3' 
A Position of the point mutation, found in intron 2. Represented are exons 2 and 3 and significant 
flanking intron 2 sequences of both wild type and the mutant AR pre-mRNAs. The positions of the 
splice donor site, the branch site, and the splice acceptor site are indicated. The mutation Is located at 
position -11 in lntron 2 in the conserved pyrimidine·rich region 5' upstream of the splice acceptor site of 
lntron 2. 
---lL_-=-'X",O"N .. '"--,f- INTRON' ---1 'XON l f- INTRON l ---1L._-=-''''XO'''N'--4'----_.Jf-
Wild type transcript 
Mutant transcript I 
Mutant transcript II 
B illustration of the wild type and the aberrant splicing process, resulting from the intron 2 mutation. 
Black bars represent exons 2, 3, and 4; gray bar represents 69 additional nucleotides. Mutant transcript 
I and mutant transcript II were found by RT·PCR studies on genital skin fibroblast mRNA from the Index 
subject. 
'l' 
III-2 (Figure VI.2A, lanes 3 and 4). The 23 additional amino acid residues, as well 
as the relatively long glutamine stretch, contributed to the slower migration pat-
tern seen with SDS-PAGE analysis, as compared with the control AR. To prove 
that the mutation at position -11 is not a common polymorphism, 102 normal 
chromosomes from unrelated individuals were screened for the presence of this 
mutation in intron 2 of the AR gene. The mutation was not detected in these 
control individuals. In addition, a larger part of intron 2 of the AR gene of the 
index patient was sequenced to exclude the presence of an additional mutation 
that could have induced the preferential use of the cryptic splice site. No other 
alterations were found in intron 2 up to position -137. 
Immunoblot analysis oj the AR protein 
The expression plasmids pSGSARo, pSGSAR129, and pSGSAR33, encoding the wild 
type AR, AR II, and AR TIl, respectively, were transiently expressed in COS-1 cells. 
In the cells transfeeled with pSGSARo, the 114-kDa isoform was deteeled after 
culturing in the presence of hormone. However cells, transiently lransfeeted 
with either one of the receptor mutants almost lacked this third isoform (Figure 
V1.4A. lanes 4 and 6). 
Gel-retardation assay 
In order to establish whether DNA binding by the mutant AR was affeeled, 
in vitro binding to a consensus ARE was studied. In the presence of polycIonal 
antibody Sp197, which stabilizes the protein-DNA complex (Kuiper et al. 1993a), 
the wild type receptor was able to bind to a consensus ARE, resulting in a shifted 
probe (Figure VI.4B, lane S). No shifted probe was deteeled for the mutant AR II 
and TIl (Figure VIAB, lanes 7 and 9) or in the control lane (Figure Vl.4B, lane 3). 
The amount of receptor protein was checked by Western blotting and immuno-
staining. Comparable amounts of AR protein were incubated. 
Transcription-activation assay 
The wild type AR showed transcription activation on the MMTV promoter 
in CHO cells (Figure VI.4C). However, AR TI and TIl were unable to aelivate 
transcription on an MMTV-Luc promoter (Figure VI.4C). SDS-PAGE, followed by 
immunoblotting, showed that AR protein expression was identical for the three 
different receptor molecules (results not shown). 
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Figure Vl.4A Functional analysis of wild type and mutant androgen receptors Hormone-induced ups-
hift of the AR proteins. AR protein variants were expressed in C05-1 cells after trans(ection with 
pSGSARo (WT), pSGSAR33 (TIl), or pSGSAR129 (TI). The cells were cultured for 24 hours in the absence (-) 
or presence (+) of 10 oM R1B8l. After immunoprecipitation using monoclonal antibody f39.4.1, SDS-
PAGE was performed followed by immunoblottlng. The AR was detected by immunostaining using 
polydonaf antibody Sp061 and an alkaline phosphatase-coupled anti-rabbit-antibody. lanes 1 and 2, 
wild type AR (WT); lanes 3 and 4, AR deletion mutant (Tll); lanes 5 and 6, AR Insertion mutant (Tl). 
COS -1 WT TI Til 
FP 
, 4 6 7 8 9 
Sp197 + + + + + 
Figure Vl.4B Functional analysis of wild type and mutant androgen receptors Gel-shift assay. Cell 
extracts, prepared from COS-1 cells were incubated for 10 min. on ice In binding buffer with poly[dl-dC]-
poly(dl-dC}, either in the presence {+J or absence (-) of polydonal anti-AR antibody Sp197. Labeled ARE 
probe (so,ooo cpm) was added and the samples were incubated for 20 min. at room temperature. Com-
plexes were analyzed by polyacrylamide gel electrophoresis, as described in Subjects and Methods. The 
position of the shifted complexes Is indicated by an arrow, and FP indicates the position of the free 
probe. Lane 1, free probe; lanes 2 and 3, COS-1 extract; lanes 4 and 5, wild type AR {WT}; lanes 6 and 7, 
mutant AR, encoded by transcript I (Tl); lanes 8 and 9, mutant AR, encoded by transcript II {TIl}. 
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Figure VI.4C Functional analysis of wild type and mutant androgen receptors Transcriptional activity. 
(HO cells were (otransfected with MMTV-luc reporter plasmid and with either wild type or mutant AR 
expression plasmids. Twenty-four hours before a luciferase assay was performed, cells were incubated 
with increasing concentrations of R1881. Each datapoint was tested in triplicate. 0 : mean-fold induc-
tion ± SEM of wild type AR, for three different experiments; 0: mean-fold induction ± SEM calculated 
for AR mutant with the insertion of 23 amino acids; 6.: mean-fold induction ± SEM of the AR mutant 
with the exon 3 deletion. 
Allele-specific oligonucleotide hybridization 
To investigate whether a wild type transcript was present in genital skin fibro-
blasts of the two affected siblings in the partial-AIS family, an allele specific oli-
gonucleotide-hybridization assay was developed. First-strand cDNA was 
synthesized from total mRNA, derived from genital skin fibroblasts, and was 
amplified in three consecutive peR reactions. mRNA was isolated from wild type 
genital skin fibroblasts, from genital skin fibroblasts from patients lIl-l and 1I1-2, 
and as a control from genital skin fibroblasts derived from a patient with partial 
AIS who has been described previously by Ris-Stalpers et al. (l994b). The muta~ 
tion, found in this latter patient causes differential splicing, resulting in 10 % 
wild type mRNA and 90% mRNA of a splice variant with a deletion of exon 3. The 
peR products were spotted on membranes and subsequently hybridized with oli-
gonucleotides specific for the splice variants and the wild type AR (Table Vl.l). 
Hybridization with the wild type probe revealed wild type mRNA in genital skin 
fibroblasts from a normal control male, in genital skin fibroblasts from the par-
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tial~ AIS patient (positive control), and in genital skin fibroblasts from one of the 
46,XY patients (lIH) (Figure Vl.S, WT~lb, lC, and Id, respectively). In genital skin 
fibroblasts from patient JJ1~2, wild type transcript was either not present or 
below the detection limit of the assay (Figure Vl.S, WT~le). TI was only present in 
genital skin fibroblasts from patients III~l and III~2 and not in wild type genital 
skin fibroblasts (Figure Vl.S, TI~3d and 3e, respectively). TIl was detected in geni~ 
tal skin fibroblasts of the positive control and patient III~l (Figure Vl.S, T"~sc and 
Sd, respectively). The signal at position se in Figure Vl.S (patient III~2), which was 
comparable to the a~specific signal at position Sb in Figure Vl.S, resulted from 
WT TI Til 
a 
b 
d 
• 
3 4 6 
Figure VLS Allele specific oligonucleotide hybridization. DNAs were amplified using exon 1 sense 
primer 470A and exon 4 antisense primer '4 NB In two consecutive peR reactions. The expression 
ptasmids (pSVARo, BHEX-AR33, and pSVAR12g), used as controls, were amplified in one peR reaction. The 
resulting peR products were spotted on three separate membranes, which were subsequently hybridi-
zed with allele spedflc oligonucleotides as descrIbed in Subjects and Methods. Membrane WT: wild 
type probe; membrane Ti: 69 bp insertion mutant; membrane Til: exon 3 deletion mutant. For lanes 1 
(WT},3 (TI), and 5 (TIl), a '" blank; b '" amplified eDNA of normal control; c '" amplified eDNA of a patient 
wIth Relfenstein syndrome; d ;; amplified eDNA of patient 111-1; e '" amplified eDNA of patient 111-2. For 
lanes 2 (WT), 4 (Tl), and 6 (Til), a'" denaturation buffer; b '" amplified wild type expression plasmid; e;; 
amplified expression plasmid (BHEX-AR33); d == amplified expressIon plasmid {pSVAR129}; e '" mixture 
of amplified expressIon plasmids pSVARo, BHEX-AR3J, and pSVAR129 (1:1:8). 
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cross-hybridization of the probe with wild type DNA and was considered as 
background. DNA, amplified from expression plasmids, which was used as a 
positive control, is visible in rows 2,4 and 6 of Figure VLS. Comparable amounts 
of DNA were spotted, as was assessed by hybridization with an exon 2 probe 
(results not shown). 
Discussion 
It is well established that AIS is caused by mutations in the AR gene. However, 
reports have appeared about patients with an AIS phenotype in which no muta-
tion was detected by use of PCR-SSCP analysis (Briiggenwirth et al. 1996; Weide-
mann et al. 1996) and DNA sequencing (Morel et al. 1994), in spite of clear 
phenotypic, endocrinological, and biochemical evidence for AIS. Mutations 
might be missed because PCR-SSCP is not 100% sensitive. Often, only the exonic 
sequences and their flanking intronic regions are screened, leaving mutations in 
intronic and promoter regions undetected. For the AR, if cells from patients are 
available, RT-PCR studies and Western immunoblotting can be very informative, 
in particular when mutations are present in intronic regions (Ris-Stalpers et al. 
1990,1994b). 
In the present report, a family presenting with partial AIS is described. 
No mutation was detected in the AR gene of the index patient after PCR-SSCP 
analysis or sequencing of the exons. However, biochemical studies revealed that 
the AR of the affected family members was unable to bind to DNA. In the 
absence of hormone, wild type receptor derived from transiently transfected 
COS-I cells migrates as a 110-112 kDa doublet (Kuiper etal. 1993a). AR preparations 
derived from cells cultured in the presence of hormone contain, in addition to 
the 110-112 kDa doublet, a slower-migrating, 114-kDa isoform, representing 
hormone-dependent phosphorylation (Jenster et al. 1994). It has been shown 
that the appearance of the 114-kDa isofonn is correlated with DNA binding 
and/or transcription activation (Jenster et al. 1994). In the present report, 
hormone-dependent phosphorylation of the AR protein was used as an indicator 
of receptor dysfunctioning. Since the 114-kDa isoform was hardly detectable in 
genital skin fibroblasts derived from the index subject (III-2) and her sister (III-I), 
cellular distribution of the AR from the index subject was studied. AR was un-
detectable in the tight nuclear-bound fraction of hormone-exposed genital skin 
fibroblasts from the index subject, which points to disturbed AR-DNA binding 
and, consequently, to a defed in transcription activation. Sequencing analysis 
revealed a mutation at position -11 in intron 2, in the AR gene of both siblings, 
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their 46,XY aunt, and the index patient's mother (carrier of the mutation). Since 
this mutation was not found in 102 chromosomes derived from unrelated 
controls, we have concluded that it is not a common polymorphism. 
The effect of the mutation on the splicing process was studied. Splicing of 
pre-mRNA begins with the cleavage at the 5' splice donor site, which is attacked 
by the 2-0H group of the branch-site adenosine. The 3' splice site is attacked by 
the newly formed 3'-OH of the upstream exon, the intron is released in the form 
of a lariat, and the exons are joined (Sharp 1985). Around the splice acceptor site 
a consensus sequence, (TIC, TIC, T, T, TIC, TIC, TIC, TIC, TIC, TIC, N, C, A, G, G) 
important for proper splicing, is present (Shapiro and Senapathy 1987). The 
present AR mutation was located in this pyrimidine-rich consensus sequence 
preceding the splice acceptor site. Aberrant splicing took place, resulting in 
different transcripts encoding defective ARs, which might explain the observed 
phenotype. The cryptic splice site, that was used is located at position -711 -70 in 
intron 2, thus resulting in a mRNA variant containing an insertion of 69 nucleo-
tides. We determined that sequences in and around this cryptic splice site did 
not contain any mutation, thereby not enhancing preferable usage of this site. 
According to Nakai and Sakamoto (1994), almost all major cryptic splice sites, 
which are activated by mutations, are located within 100 nucleotides from the 
original splice site. On the basis of comparison with a consensus sequence, the 
cryptic splice site located at position -71/-70 in the AR shows more homology 
with the consensus sequence than does the wild type splice acceptor site (the 
cryptic splice site is T, C, T, T, T, T, C, T, G, T, T, C, T, A, G, A; the wild type intron 2 
splice site: T, A, T, T, T, G, T, T, C, T, C, C, C, A, G, C). However, RT-PCR studies perfor-
med on wild type mRNA demonstrated that this cryptic splice site is normally 
not used. Watakabe et al. (1992) proposed that suboptimal 3' splice site sequen-
ces require stimulation by downstream sequences. Thus, exon 3 sequences of the 
AR may playa role in splice acceptor site selection. The newly created splice 
acceptor site at position -11/-10 was not used, probably because, compared with 
the novel cryptic site at position -71/-70, the sequence was less favorable for spli-
cing. A small amount of a transcript, from which exon 3 was deleted, was detec-
ted. wild type transcript was not observed, although this could be expected on 
the basis of the partial-AIS phenotype of the affected individuals. We concluded 
that the wild type splice acceptor site has become weaker because of the base 
pair substitution at position -11. Alternatively, closely spaced splice sites can 
inactivate each other because of sterical hindrance of bound splicing factors 
(Black 1991). Nelson and Green (1988) showed with in vitro splicing experiments 
that, in a p-globin intron, insertion of a new splice donor site close to the wild 
type splice donor site prevented splicing at both sites, Therefore, aberrant spli-
cing in our patients could also be the result of interference by two closely spaced 
splice acceptor sequences. 
Quigley et ai, (1992b) have previously described the so-called null phenotype 
of AIS, A deletion of the X chromosome spanning the complete AR gene caused 
complete AIS, The patient showed ingUinal or abdominal testes, no wolffian-
duct development, and absence of masculinization of the external genitalia. 
Sparse pubic and axillary hair was detected. Also, a complete external female 
phenotype and absence of secondary hair were seen in a 46,XY individual with a 
complete deletion of the AR gene, as reported by Hiort et al. (1996), All AIS sub-
jects in the family reported in this paper showed remnants of vasa deferentia 
and epididymides, The aunt (1l-4), clinically investigated postpubertally, has 
pubic and axillary hair. These phenotypic characteristics suggest that some resi-
dual AR activity is present. Therefore, DNA binding and transcription-activation 
capacities of the splice variants were investigated, The AR, expressed in genital 
skin fibroblasts from the index subject has 23 additional amino acids between 
the first zinc cluster and the second zinc cluster. Ducouret et ai, (1995) cloned a 
teleost-fish glucocorticoid receptor (GR) with 9 additional amino acid residues 
between the two zinc clusters. This fish GR, however, was still capable of activa-
ting a reporter gene, from which it was concluded that the folding of the GR 
could compensate for separation of the two zinc clusters by an extra 9-amino-
acid stretch. The AR mutant with the insertion of 23 amino acid residues did not 
bind to a consensus ARE (on the basis of a gel-retardation assay), Consequently, 
there was absence of transcription activation. The splice variant with a deletion 
of the second zinc cluster was also unable to bind specifically to DNA, correspon-
ding to the results reported by Quigley et ai, (19920) and Ris-Stalpers et ai, 
(1994b), On the basis of these results and in view of the phenotype of the affec-
ted family members, we concluded that splicing was not completely aberrant, 
Indeed, a very small amount of wild type transcript was detected in genital skin 
fibroblasts of patient 111-1, by use of the allele-specific oligonucleotide-hybridiza-
tion method, The transcript with the deletion of exon 3 (i.e" AR TIl) was detected 
in genital skin fibroblasts of patient 111-1 and not in genital skin fibroblasts of 
patient III-2. However, this was not reproduced in all experiments, since AR TIl 
had previously been detected by RT-PCR studies using RNA from patient 111-2, 
The intronic mutation, discussed in this paper was missed by PCR-SSCP 
analysis. There are several other explanations for the apparent absence of AR 
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mutations in several cases of AIS. Neutral mutations, for example, have to be 
interpreted with caution. Richard and Beckmann (199S) found a synonymous-
codon mutation (GGC->GGT) in the cDNA of the cafpain (CANP3) gene, which 
turned out to be pathogenic, because a splice donor site was created. Kallio et al. 
(1996) suggested that in 46,XY subjects without a mutation in the AR gene and a 
typical AIS phenotype, post-receptor defects might be the cause of the disease. 
This may involve receptor-specific cofactors or corepressors. Recently, a family 
with dominant inheritance of thyroid hormone resistance was reported, which 
could not be linked to defects in the thyroid hormone-receptor a or ~ genes 
(Weiss et of. 1996). It was postulated that an abnormal cofactor, playing a role in 
regulation of thyroid-hormone action, might be involved. Most cofactors, repor-
ted to date are not AR specific, so mutations in these factors will probably be 
lethal or give rise to complex phenotypes. One coactivator, ARA70, which binds 
to the ligand-bound AR, has been reported by Yeh and Chang (1996). 
In conclusion: the mutation presented in this paper relnained undetected with 
PCR-SSCP analysis. AR genes from AIS subjects for whom the clinical diagnosis is 
well established, and in whom no mutation can be detected after PCR-SSCP 
screening and additional sequencing of the coding parts of the gene should be 
analyzed for intronic mutations. RT-PCR studies and Western immunoblotting. 
using cultured genital skin fibroblasts, can provide important information. 
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Table J.l Mutations observed in unrelated Individuals with AIS. Based on the AR gene mutation 
database (Gottlieb et al. 1997) 
CAIS 
Structural gene defects 
partial deletions 10 
complete gene deletion 3 
1~4 bp deletion / insertion 11 
intronic deletion 
Single base mutation 
premature termination codon 21 
splice junction abnormality 6 
amino acid substitution 59 (92) 
multiple amino acid substitution 3 
Total number 113 (146) 
CAIS/PAIS PAIS 
9 (37) 
9 (37) 
57 (73) 
3 
MAIS 
7 (8) 
Total 
11 
3 
12 
21 
7 
131 (2°9) 
6 
192 (270) 
The total numbers of different mutations, identified In unrelated patIents with A'S are summarized. 
The total number of unrelated individuals, in whom a particular type of mutation was detected, are 
indicated between brackets. 
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VII,1 Mutations in the androgen receptor gene 
During the first years after the cloning of the AR gene in 1988, mainly mutations 
in the LBD were studied. However, later on many mutations were identified also 
in the DBD. An overview of the type of mutations, reported worldwide until Sep-
tember '997, is given in Table VI!.1 (Gottlieb et al. 1997). Missense mutations 
were most frequently reported; in total, 131 different missense mutation have 
been identified. In 92 unrelated individuals with CAIS due to a missense muta-
tion, 59 different mutations were found. Nine different missense mutations cau-
sed either CAIS or PAIS (genotype-phenotype variation) in 37 individuals. 
Fifty-seven different missense mutations caused PAIS in 73 individuals, and 6 
different missense mutations caused MAIS in 7 individuals. 
Mutations in the NH2-terminal domain and the hinge region 
So far, only three missense mutations have been reported in exon 1 of the AR 
gene. A transition of guanine to adenine in codon 2, which changed the glutamic 
acid residue at position 2 into a lysine residue, was associated with 
PAIS (Choong et al. 1996b). The bp change disturbed the translation initiation 
consensus sequence, causing reduced translational efficiency, finally resulting 
in a lower AR expression level (Choong et al. 1996b). In addition, a slightly in-
creased hormone dissociation rate was established, indicating an effect of the 
AR NH,-terminus on androgen bind-ing kinetics (Choong et al. 1996b). In an 
individual with CAIS, apart from substitution of the proline residue at position 
389 by an arginine residue, the glycine residue at position 442 was changed into 
an arginine residue (Gottlieb et al. 1997). Other types of mutations that were 
identified in exon 1 result in premature stop codons, frameshifts, or extreme 
expansion of the polymorphic glutamine stretch. The latter mutation is the 
cause of spinal and bulbar muscular atrophy (SBMA) (La Spada et al. 1991). 
The premature stop codons in exon 1, either resulting from nonsense mutations 
or introduced by a frameshift mutation, were all associated with CAIS (Gottlieb 
et al. 1997). Most of the individuals having such a mutation were receptor nega-
tive, i.e. specific androgen binding was not detected (Gottlieb et al. 1997), with 
the exception of a patient described by Zoppi et al. (1993). Fibroblasts of this 
patient displayed a low amount of androgen binding, which was ascribed to 
reinitiation of translation. Reinitiation of translation offers also an explanation 
for the specific androgen binding that was measured in the rfm mouse. In the 
AR gene of this mouse a single nucleotide insertion was detected that caused a 
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frameshift, introducing a stop codon at position 4'2 (Charest et al. 1991, Gaspar et 
al. 1991, He et al. 1991). Despite the presence of a ligand binding AR, both the Tfm 
mouse and the AIS subject had a complete phenotype. This should be ascribed to 
impaired transcription activation capacity of the truncated receptors, and to 
their low expression levels (Zoppi et al. 1993). The low AR expression levels might 
result from mRNA instability (Charest et a1.1991) andlor inefficient reinitiation 
of translation, and lor instability of the NH,-terminally truncated protein (Zoppi 
et al. 1993). 
In the hinge region, which harbors part of the NLS and is encoded by the 
s'-half of exon 4, only 2 (missense) mutations have been found that were located 
out-side the NLS. Both substitutions (Ala-636-Asp, Ile-64S-AsP) were underlying 
PAIS (Pinsky et al. 1992, Hiort et al. 1996b). However, functional studies have not 
been performed with these mutant receptors. 
The NH2-terminal domain and the hinge region are the least conserved 
regions of the AR, and are therefore believed to be important with respect 
to receptor specificity. It is remarkable that only a low number of amino acid 
substitutions have been found in the NHz-terminal domain and in the first part 
of the hinge region. This seems to suggest that the presence of substitutions in 
these particular regions do not cause a pathogenic phenotype. Indeed, it was 
shown that parts of the NH,-terminus could be deleted without dramatic effect 
on transcription activation (Simental et al. 1991, Jenster et al. 1991, Jenster et al. 
1995). Schena et al. (1989) studied mutations in the GR that were obtained by 
random mutagenesis. Point mutations were not recovered in the part of the gene 
encoding the NH2-terminal half of the hinge region. This indicates that also in 
the GR single amino acid changes in this particular region do not result in a 
defective receptor with respect to transcription activation. 
Mutations in the DBD 
Many different mutations have been detected in the DBD, and the majority of 
these mutations probably affects DNA binding. Some amino acid residues were 
substituted more than once in unrelated individuals (GlY-SS9, CYS-S79, Phe-S73, 
Arg-606, Leu-607, and Arg-608) (Gottlieb et al. 1997). Although it is theoretically 
possible that mutations in the pobox change DNA-binding specificity, the pheno-
type of the patient in whom the valine residue at position 572 was substituted 
by a phenylalanine residue indicates complete androgen insensitivity (Lum-
broso et al. 1993). As was discussed in Chapter I, mutations that were identified 
in exon 3 of the AR in cases of male breast cancer did not result in altered DNA-
binding specificity (Poujol et al. 1997). A mutation, found in the D-box (Ala-s87-
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Thr) interfered with dimerization, causing PAIS (Gast ef al. 1995). A mutation 
identified in the NLS (Leu-607-Pro) resulted in an inactive receptor due to defec-
tive DNA binding. Molecular modeling predicted that the amino acid substitu-
tion might interfere with protein structure or dimerization (Lobaccaro et al. 
1996). 
The amino acid composition of the GR-DBD is closely related to that of the 
AR. Therefore it seems reasonable to build a 3-D model of the AR-DBD, based on 
the crystal structure of the rat GR-DBD. Molecular modeling was applied to 
predict consequences of mutations in the AR (Lobaccaro et al. 1996, Poujol et al. 
1997, Briiggenwirth ef al. 1998). As was shown by Briiggenwirth ef al. (1998) (see 
also Chapter V), molecular modeling might have its limitations. Because only the 
DBD of the GR was crystallized (Luisi ef al. 1991), the influence that the liganded 
LBD might have on the conformation of the DBD (Glass 1994) was not taken into 
account. Moreover, the crystal structure is obtained under static conditions, 
while DNA binding is a very dynamic process. In addition, modeling based on 
the crystal structure of the AR-DBD, which is at present unknown, would be 
more precise, as not all amino acid residues are conserved between the AR- and 
GR-DBD (see also Chapter V). 
Mutations in the LBD 
Mutations that are the cause of either PAIS or CAIS show a comparable distribu-
tion over the length of the AR-LBD, with the exception of p-sheet 1 (see Table 
VI!.2). The majority of mutations in the LBD were found to alter binding affinity. 
One mutation was reported (Gln-789-Glu) that impaired receptor activity while 
ligand binding was not affected (Bevan et al. 1996). A large part of the mutations 
that were associated with prostate cancer influence ligand binding specificity, 
suggesting that these mutations affect the ligand binding pocket in a subtle 
way. Only one mutation (Gln-789-Glu), found in prostate cancer, was also identi-
fied in a patient with AIS (Bevan et al. 1996, Evans et al. 1996). The mutation was 
not only present in the tumor, but also in blood cells of the man with prostate 
cancer, indicating its genomic origin (Evans et al. 1996). The prostate cancer 
patient was married but had no children, whereas the patient described by 
Bevan et al. (1996) had PAIS. 
Recently, the crystal structure of the unliganded hRXR-o: LBD, and the 
liganded hRAR-y, rat TR-o:, and hER-a LBDs were solved (Bourguet et al. 1995, 
Renaud et al. 1995, Wagner et al. 1995, Brzozowski et al. 1997). The overall 
structure of the different LBDs appeared to be quite Similar, and therefore the 
structure of the AR-LBD could be predicted (see Figure 104) (Wurtz et al. 1996). 
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Table VI!.2 Mutations in the AR-lBD 
A Rnenotyue 
(AIS PAIS MAIS Prostate 
carcinoma 
< 658 Ala 636 Asp Ser 638 Asn 
lie 655 Asn 
658-675 leu 668 Pro Pro 662 His Gin 661 Arg 
Helix 1 Glu 672lys lie 663 Thr 
Val 675 lie Gly 674 Ala 
676-688 Gly679 Glu Cys 677 Arg 
Asn 683 del Ala 678 Val 
Asp 686 Asn Asp 681 del 
Asp 686 His Asp 686 Asn 
689-711 Ser 693 Ala Ser 694 Gly leu 692 His 
Helix 3 Asn 6g6 Ser (3) Gly6ggAIa Val 706 Met (2) 
leu 698 Arg leu 703 Phe lys 711 Glu 
Gly 699 Val 
712-720 leu 713 Phe Phe 716 leu Asn 718lys Ala 712 Thr 
leu 719 Ser Arg 717 leu 
721-730 Asp 723 Asn Gin 724 His Val 721 Met (2) 
Helix4 Asp 723 Tyr (3) IIq28Thr 
Tyr 730 Arg 
731-742 Trp 732 Arg Met 733 Val 
Helix 5 GIY734 Val Met 733 lie 
Met 740 Val (2) GIY734 Val 
Gly 74' Asp (2) leu 735 Phe 
Trp 742 Arg Me1736 Thr 
Val 737 Met (2) 
Ala 739 Asp 
743-751 Arg 743 Gin (2) Phe 745 leu (2) Val 748 Ala 
Phe 745 Val (2) Asn 747 Ser 
Se, 750 Phe (2) 
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B Phenotype ' 
(AIS PAIS MAIS Prostate 
carcinoma 
752-757 Leu 753 Phe (2) Tyr 754 Cys (2) 
p-sheet 1 Tyr 754 His 
Phe 755 Leu (3) 
Ala 756 Tyr (4) 
Ala 756 Val 
Pro 757 Ser 
758-762 Asp 758 Glu Asn 762 His 
p-sheet 2 
763-768 Arg 765 Cys (6) Glu 763 Ala 
Helix 6 Arg 765 His (4) Glu 763 Gly 
Arg 765 His 
769-774 Arg 770 Trp (3) Met 771 lie (4) 5er 773 Asn 
Met 771 lie (2) 
775-787 Met 778 Val leu 781 Phe 
HeliX7 Phe 785 5er (2) Glu 784 Asp 
788-791 Gin 789 Glu (3) Gin 789 Glu 
792-803 Val 798 Met Cys 797Thr 
Helix8 Met 798 Arg 
804-814 Gly 811 Ala 5er 80S Asn (2) 
leu 812 Val 
815-836 Arg 822 Gin (2) Arg 831 Cys (3) 
Helix 9 Arg 822 Leu (2) Arg 831 His (11) 
Tyr 825 Cys lie 832 Ser 
lie 833 Thr lie 833 Thr 
837-845 Asn 839lys Arg 845 Lys 
'47 
c PHenotype ' , 
CAIS PAIS MAIS Prostate 
carcinoma 
846-863 Arg 846 Cys (9) Arg 846 His (6) Arg 862 Gly 
Helix 10 Arg 846 His (3) Val 857 leu (4) 
leu 854 Arg Val 857 Met (2) 
Asp 855 Asn lie 860 Met 
Asp 855 Gly Ala 861Vai 
Val 857 Met (3) 
Val 857GIU 
Ala 861 Gly 
864-874 leu 872 Val His 865 Tyr (2) 
Helix 11 Thr 868 Ala (5) 
Thr 868 Ser 
875-883 Val 880 Met Val 880 Met Met 875 Val (2) 
884-891 
Helix 12 lie 889 Thr 
892-910 Pro 895 Ser Val 894 Met Gin 893 Arg 
Pro 895 His GlY900 leu Gin 910 Arg 
leu 898 Phe Pro 904 Ser 
Structural domains are indicated In the first (olumn. The phenotype, associated with the mutations, 
is specified in columns 2-5. The frequency of mutations, which are identified more than once, is indica-
ted between brackets. Structural domains were derived from homologous locations between AR and 
hRXR-(.( (Wurtz et al. 1996). Numbering of amino add residues is based on an AR with a poiy-glutamine 
stretch of 20 glutamines, and a polymorphic glycine stretch of 16 residues (Brinkmann et al. 1989). 
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In Table VII.2 the a-helical regions, the 2 p-strands, and the linker regions, 
as predicted for the AR by Wurtz et al. (1996), are indicated. Mutations that are 
associated with several forms of AIS and/or prostate cancer are categorized 
according to these structural elements. Except for one amino acid residue, 
all residues forming the first p-strand were mutated in individuals with AIS. 
The hydrophobic ligand-binding pocket of the ER-a-LBD is formed by parts of 
helices 3, 6, 8, the preceding loop of helix 11, helix 12, and the two p-strands 
(Brzozowski et al. 1997), which might be similar in the other NHRs as well 
(Brzozowski et al. 1997). Amino acid residues Glu-353, Arg-394, and His-52410ca-
ted in helices 3 and 11, respectively, were identified as the ones that are directly 
contacting 17P-estradiol (Brzozowski et al. 1997). Wurtz et al. (1996) proposed a 
model for dexamethasone binding by the hGR, in which the D-ring was bound 
between helices 3 and 6. Based on the results obtained by Brzozowski et al. (1997) 
this model should be rejected, as the A-ring of 17P-estradiol was bound between 
helices 3 and 6, by Glu-353 and Arg-394. This result corresponded to the 
predictions made by Anstead et al. 1997. The arginine residue (Arg 394 in hER-a) 
is conserved in the AR, PR, GR, and MR, whereas the histidine residue is 
conserved at the corresponding position in the AR and the PRo Instead of the 
glutamic acid residue at pOSition 353. a glutamine residue is present at the 
corresponding position in the AR, PR, GR, and MR, which might be involved in 
hydrogen bonding with the 3-keto group in the A-ring of steroids (Brzozowski et 
al.1997)· 
Interestingly, mutations that were identified in prostate tumor specimens, 
and associated with a broadened ligand-binding specificity, map to regions 
predicted to form helix 3 (Val-706~Met), helix 4 with its preceding loop 
(Arg-717-Leu, Val-721~ Met), and helix 11 (His-865-Tyr, Thr-868-Ala, Thr-868-Ser) 
(Table VI!.2). The conserved histidine residue (position 865 in the AR) was substi-
tuted by a tyrosine residue, in a case of prostate cancer (Taplin et al. 1995). 
Threonine-868 (LNCaP~AR mutation) was substituted by an alanine residue in 
several prostate tumor specimens, and by a serine residue in another prostate 
tumor sample (Veldscholte et al. 1990, Gaddipati et al. 1994, Taplin et al. 1995, 
Suzuki et al. 1996, Gottlieb et al. 1997). In the ER-a, a serine residue is present at 
the corresponding position, and, indeed, mutant Thr-868-Ser displayed in-
creased activity after incubation with 17P-estradiol, although this effect was 
observed also after incubation with R5020 (synthetic progestagen) (Ris-Stalpers 
et al. 1993). Threonine-868 is very likely to be involved in ligand binding. 
The observation that the equivalent cysteine residue, present in the mouse and 
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rat GR, could be crosslinked to triamcinolone acetonide (Carlstedt-Duke et al. 
'988, Byravan et al. 1991), is further proof that this residue is positioned very 
close to the ligand. 
Mutations causing aberrant splicing of the AR mRNA 
About 15% of the point mutations in different genes, associated with diseases in 
humans, alter mRNA splicing. Splice donor sites are most frequently affected 
(Cooper and Krawczak 1993). Mutations causing splicing alterations are a rare 
cause of AlS (7 out of 270 mutations: 2.6 %) (see also Table VI!.l). Seven of such 
mutations were reported, and 5 of them were affecting splice donor sites (Figure 
VII.1B). The guanine at position +1 of the splice donor site, which is completely 
conserved (Figure VII.1A) (Shapiro and Senapathy 1987), was found to be mutated 
in three unrelated AIS patients. Skipping of exon 3 was observed in an individual 
with a transition of the conserved guanine at position +1 of intron 3 to adenine 
(Gottlieb et al. 1997). Transition of guanine to adenine at position +1 in intron 7 
caused skipping of exon 7. Exons 6 and 8 were joined, which caused a frame shift 
(Lim et al. 1997). In another patient, transition of guanine to thymine at position 
+1 in intron 4 caused activation of a cryptic splice donor site in the preceding 
exon, resulting in an in frame deletion (Ris-Stalpers et al. 1990). Splice donor site 
analysis revealed that an adenine at position +3 is most common (60%), followed 
by guanine (35%) (Shapiro and Senapathy 1987). Due to the insertion of thymine 
at position +3 (intron 1), only a very small amount of wild type mRNA was 
detected in an individual with CAIS (Trifiro et al. 1997). Transversion of adenine 
to thymine at position + 3 of the splice donor site in intron 6 caused joining of 
exons 5 and 7, in turn generating a premature stop (Trifiro et al. 1997). A large 
deletion in intron 2 (> 6 kbl. starting from the nucleotide at position -18 and 
containing the branch point site (BPS), resulted mainly in an exon 3 deleted 
transcript (Ris-Stalpers et al. 1994b). The BPS is involved in assembly of the 
spliceosome; base paring between the BPS and U2snRNP is observed. Due to 
usage of a cryptic BPS, a small amount of wild type transcript was found, which 
explains the Reifenstein phenotype of this case (Ris-Stalpers et al. 1994b). 
Recently, a mutation was detected in the pyrimidine-rich sequence preceding 
the splice acceptor site in intron 2 of the AR (Briiggenwirth et al. 1997; see also 
Chapter VI). Transversion of thymine to adenine created an AG-sequence at posi-
tion -11/-lD. A cryptic splice site 5' of the wild type splice site was used predomi-
nantly, resulting in an in frame insertion of 69 base pairs in between exons 2 
and 3. 
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splice donor site BPS splice acceptor site 
5'--{L-__ -'Ac:G=-1lGUAAGU - _. _. ............. A············ (PY'l"NCAGj f'G'-----__ -----'r- l 
Intron 
Figure VIl.1A location of splice donor and splice acceptor sites. The consensus sequences are Indicated 
(Shapiro and Senapathy Ig87). 
PAIS 
del >6kb'18 t-11a 
5'---1C=::I::' ~II--~h----I -~" 
inS t+3 g+la g+1t a+3t g+la 
(AIS 
Figure VILIB Structural organization of the AR gene. The positions of mutations that are causing 
aberrant splicing are indicated. Upwards: mutations resulting In PAIS; downwards: mutations resulting 
in (AIS. 
Mutatiolls affectillg phosphosites 
The function of basal and hormone· dependent phosphorylation of the AR is 
largely unknown. Kuiper et al. (1993b) observed that the majority of potential 
phosphosites are located in the NH2-terminal domain, in the region where AF-l 
was mapped (Jenster et al. 1995), but residues that undergo basal or androgen· 
dependent phosphorylation have not been identified yet. Phosphosites in both 
PR-A and PR-B have been mapped, and the effeel of phosphorylation on their 
function was studied by mutagenesis. Only subtle effects were observed in vitro 
(Takimoto et al. 1996). One consensus phospho site (casein kinase II site) was 
found to be mutated in an individual with PAIS (Ser-694-Gly). The mutation cau-
sed reduced ligand-binding affinity (Kaspar et al. 1993), probably due to interfe-
rence with ligand binding because it is located in the region predicted to form 
helix 3. Defective hormone-dependent phosphorylation was associated with an 
intronic mutation in the AR gene. Due to the mutation, 23 additional amino acid 
residues were inserted between the two zinc clusters of the DBD, which comple-
tely destroyed DNA-binding capacity (Briiggenwirth et al. 1997). 
'5' 
Tyrosine-537, located NH,-terminally of AF-2 in the hER-IX was identified as a 
tyrosine phosphorylation site (Arnold el al. 1995). Substitution of this tyrosine 
residue (Tyr-541) in the mouse ER-IX either by an asparagine or a glutamic acid 
residue (both negatively charged), or by an alanine residue, caused ligand-
independent activation (White el al. 1997). Because these ER-IX mutants inter-
acted with coactivators RIP140 and SRC-1, it is likely that the above-mentioned 
amino acid residue changes and probably tyrosine phosphorylation as well, 
induce a different conformation. Phosphorylation of the tyrosine residue was 
not required for ligand-dependent activity, suggesting that it renders AF-2 inac-
tive in the absence of an agonist (White et al. 1997). Mutations, causing a consti-
tutively active receptor might be involved in steroid hormone-related cancer. 
VII.2 Polymorphic glutamine stretch as a nlOdifier of androgenic end 
points 
Kashi et 01. (1997) proposed that simple sequence repeats might be modulators of 
gene expression and function, causing quantitative genetic variation. Thus, 
aparl from causing SBMA when expanded, the polymorphic glutamine stretch 
in the AR might as well be a modifier of several androgenic end points, even 
when the length of the stretch is within the normal range. Glutamine stretch 
expansion is associated with a loss of receptor function in individuals with 
SBMA. Testis atrophy, gynecomastia, infertility, and elevated LH, FSH, and eslra-
diollevels are frequently observed (Danek et al. 1994). Overall sex differentiation 
appears to be normal. The appearance of endocrine abnormalities later in life 
might be related to a lower AR expression level and a lower testosterone level, as 
is generally observed in elderly men (Ono el al. 1988, Swerdloff and Wang 1993). 
Evidence supporting the idea that the length of the glutamine stretch in the 
AR is a modulator of androgenic end points, also without evident signs of AR 
malfunction, came from epidemiological studies. Results reported by Tut et al. 
(1997) imply that individuals with a relatively long poly-glutamine stretch are at 
a higher risk of defective spermatogenesis. (CAG)nCAA-repeat length might be a 
determinant of prostate cancer, as was discussed in Chapter I (Irvine et al. 1995, 
Hardy el 01.1996, Giovannucci el al. '997, Stanford el al. 1997). In a population of 
healthy elderly men the possible relation between length of the (CAG)nCAA-
repeat and BMD was studied (Chapter IV). However, the data obtained were not 
conclusive. One intriguing question now remains. It is known that androgens 
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exert negative feedback through the AR, resulting in a lower LH level, which 
in turn gives a lower androgen level (Schwartz and McCormack 1972). ARs con-
taining a relatively short glutamine stretch were associated with higher AR acti-
vity, and thus it is possible that such receptors exert stronger negative feedback 
on LH production by the pituitary gland. Sobue et al. (1994) indeed observed a 
less strong negative feedback mechanism in SBMA patients after administration 
of fluoxymesterone (androgenic synthetic hormone). It would be interesting to 
study whether (CAG)nCAA-repeat length is associated with free testosterone, 
free 17P-estradiol, and SHBG levels, in a large population of healthy individuals. 
VII.3 An androgen insensitivity~lil{e phenotype without a mutation in the 
androgen receptor gene 
Several reports describe patients with an AIS-like phenotype without a muta-
tion in the AR gene (Brliggenwirth et al. '996, Weidemann et al. '997, Morel et al. 
1994). It can be hypothesized that in these cases honnone resistance might be 
caused by mutations in genes encoding specific coactivators or corepressors. 
Weiss et al. recently described a family without mutations in the genes encoding 
TR-a and TR-P, although thyroid hormone resistance has never been associated 
with TR-a alterations. Far-Western blotting and gel-retardation assays, in which 
nuclear extracts prepared from cultured skin fibroblasts obtained from family 
members, revealed a protein that specifically interacted with the TR-P of affec-
ted individuals. The molecular mass of the protein did not correspond to that of 
the RXR or TripI, a thyroid hormone receptor interacting protein. The interacting 
protein might be a defective factor, specifically involved in thyroid hormone 
receptor -mediated gene regulation. Mutations in AR-specific coactivators, which 
aberrantly interact with the AR-LBD, and therefore result in AIS, can as yet not be 
excluded. 
It is also possible that mutations in the AR gene have not been detected, 
using standard screening procedures. In these cases it might be helpful to screen 
cDNA, prepared from mRNA, derived from genital skin fibroblasts from the 
patients. Protein studies could provide important additional information, as was 
shown in Chapter VI. Special attention should be paid to silent rnutations, which 
might create new splice donor or acceptor sites (Richard and Beckman 1995). As 
was recently shown by Liu et al. (1997) silent mutations which do not directly 
affect these splice sites may still affect the splicing mechanism, for example by 
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changing sequences involved in binding of splicing factors. In another study, 
silent mutations were identified being responsible for enhanced translation 
(Milland et a1. 1995). 
VII.4 Future directions 
Bevan et a1. (1997) reported that some mutant receptors, identified in individuals 
with PAIS, were functionally more impaired than mutant receptors associated 
with CAIS, implying that additional factors which are variant between individu-
als influence AR activity. In addition, it is to be expected that individual genetic 
background is underlying genotype-phenotype variation in the expression of AR 
function. Therefore, better insight in functioning of the AR might be obtained by 
transfection of cultured fibroblasts, derived from the patients, with a reporter 
plasmid (McPhaul et a1. '993a, and McPhaul et a1. 1997). Furthermore, important 
information may be obtained by studying expression levels of endogenous 
androgen-regulated genes. Genital skin fibroblasts, however, are not androgen 
target cells, and there are practical and maybe also ethical objections against 
obtaining real target cells from AIS patients. The SHBG-test (Sinnecker et a1. 
'997, and described in the Introduction and in Chapter Ill) is therefore a welcome 
supplementary test. 
Development of several (human) androgen target cell lines is necessary to 
investigate AR structure-function relationship on a particular cellular back-
ground. These studies provide insight in tissue-specific androgen action. 
The development of mouse models would be important to study possible effects 
of subtle mutations, including those affecting phosphosites. As was suggested 
by Takimoto et a1. 1996, cellular transfection systems probably lack sensitivity. 
In addition, it would be very interesting to create a female AR knockout mouse 
to study the role of the AR in females. This can be performed by crossing a 
female mouse, carrying an inactivating AR mutation, with a male mouse, 
expressing an androgen receptor gene of which the expression can be repressed. 
Mice that are either overexpressing a SHR-coactivator or corepressor, or in which 
such a gene is inactivated, would also provide interesting data. 
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Summary 
The androgens testosterone and dihydrotestosterone are important for male sex 
differentiation, and in addition the androgens are involved in development of 
male secondary sex characteristics during puberty and functioning of the male 
sex organs throughout adult life. In females androgens playa much less promi-
nent role. Androgens bind to the androgen receptor (AR), a transcription factor 
that is expressed in androgen target cells. Upon hormone binding the AR 
becomes activated, and the hormone-receptor complex translocates to the 
nucleus where it recognizes and binds to androgen-response elements on the 
DNA. Androgen-response elements are located in the promoter regions of 
androgen-regulated genes, and AR binding regulates expression of these genes. 
Mutations in the AR gene are the cause of androgen insensitivity syndrome 
(AIS). Target organs of 46,XY individuals with AIS show either reduced sensiti· 
vity or are completely insensitive to androgens, which results in the develop~ 
ment of ambiguous genitalia or female genitalia, respectively. Research 
described in this thesis was performed to obtain information about the struc-
ture-function relationship of the AR. In addition, information that is relevant for 
other steroid hormone receptors might be obtained, because of the large homo-
logy observed between those receptors. Furthermore, identification and subse-
quent characterization of mutations might be important for patients with AIS. 
Based on results obtained from functional studies, better treatment can some-
times be given. Moreover, genetic counseling can be offered to families, to iden-
tify possible carriers of the mutation. Mutations were detected in individuals 
with different forms of AIS. The present study was focussed on patients with the 
receptor positive form of AIS. AR protein is normally expressed in androgen tar-
get cells of these individuals, and normal hormone binding characteristics can 
be observed. This implied that mutations were mainly found in exons 1-3, which 
respectively encode the NH,-terminal part of the receptor (exon 1) and the DNA-
binding domain (DBD) (exons 2 and 3). These domains were not always inten-
sively screened in the past. In previous studies, predominantly AR genes from 
patients with androgen-binding abnormalities were screened. In addition, exon 
1 is relatively large and GC -rich, which has hampered screening. Mutations in 
the NH2-terminal domain and DBO can provide information about amino acid 
residues, or protein regions, involved in DNA binding and/or transcription acti-
vation. In addition, many potential phosphosites are located in exon 1. 
In the General Introduction (Chapter I) the mechanism of action and func-
tional characteristics of steroid hormone receptors are discussed, with particular 
emphasis on the AR. Male sex differentiation and the role of the AR therein is 
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described. Apart from being the cause of AIS, mutations in the AR are also asso-
ciated with other diseases, such as prostate cancer, and also Kennedy's disease, 
which is a progressive neuromuscular disease. Kennedy's disease is caused by 
expansion of a polymorphic poly-glutamine stretch, located in the NH,-terminal 
part of the AR. Interestingly, several other neuromuscular diseases, for example 
Huntington's disease, are associated with expansion of poly-glutamine 
stretches. Mechanisms that might underlie the role of these poly-glutamine 
stretches in these diseases are discussed. 
In Chapter II, several mutations found in exon 1 of the AR gene are described. 
Amino acid substitutions were not detected. However, we found point muta-
tions that either directly or indirectly caused introduction of a premature stop 
codon. All these mutations were associated with complete AIS. Although in 
theory reinitiation of translation could occur from a codon for an internal 
methionine residue, resulting in expression of an NH1-terminally truncated AR 
protein, evidence supporting such a mechanism was not 0 btained. 
In Chapter !l[ a 46,XY individual is described, who was completely insensitive 
to androgens, according to the sex hormone-binding globulin (SHBG) test, but 
the phenotype of this patient was typical for partial AIS. The SHBG-test is being 
used to study the activity of the endogenous AR in the patient's target cells (in 
vivo). SHBG-expression is studied before and after administration of stanozolol, 
which is a synthetic androgenic anabolic steroid. In normal individuals, treat-
ment with stanozolol results in lower SHBG levels. Normal hormone binding 
and a low number of binding sites were established in genital skin fibroblasts, 
derived from this patient. Molecular analYSis finally showed that the patient had 
a somatic mosaicism for a mutation in exon 1 of the AR gene. The mutation intro-
duces a premature stop codon, which either results in a truncated, non-func-
tional AR protein, or in absence of the protein, due to mRNA instability. Liver 
cells, which produce SHBG, probably express only the mutated AR, which gives 
an explanation for the fact that lower SHBG-levels could not be observed after 
administration of stanozolol. 
AR protein containing an expanded poly-glutamine stretch is less active with 
respect to transcription activation, a finding which explains the mild symptoms 
of AIS in patients with Kennedy's disease. Variable length of the poly-glutamine 
stretch is observed also in the general population without clear signs of AIS, but 
yet might be related to a minor change in receptor activity. AR protein is expres-
sed in osteoblasts, cells that are involved in bone formation. There is also 
evidence for a direct role of the AR in bone metabolism. In view of this, length of 
,., 
the poly-glutamine stretch was analyzed in relation to bone mineral density in a 
cohort of elderly men from the Rotterdam Elderly Study (Chapter IV). Although a 
clear association could not be established, individuals with low bone mineral 
density were over-represented among those with relatively short poly-gluta-
mine stretches. 
In Chapter V, a mutation, found in exon 2 of the AR gene of a 46,XY individual 
with complete form of AIS is discussed. This particular exon encodes the first 
zinc cluster, which is involved in specific DNA binding. The neutral asparagine 
residue at position 564 is substituted by an aspartic acid residue, introducing a 
negative charge. To study whether inactivity of the aspartic acid mutant was 
caused by steric hindrance, or by the introduction of negative charge, the mutant 
AR and two other receptor mutants were expressed and functionally investiga-
ted. In addition, a 3-dimensional (3-D) model was created for the DBDs of the AR 
and the three AR mutants. The wild type AR model was based upon the 3-D 
model that was made for the DBD of the glucocorticoid receptor, of which the 
crystal structure was clarified. Results obtained with both approaches were 
compared. It was concluded that the phenotype of the patient can be explained 
by the introduction of an extra negative charge, which destabilized the normal 
conformation of the AR-DBD. 
In Chapter VI a family with partial AIS is described. After molecular analysiS 
of the coding parts and the exon flanking intronic regions of the AR gene, no 
mutation was identified. Testosterone biosynthesis defects, another cause of 
male pseudohermaphroditism, were excluded. The polymorphic CAG-repeat 
located in exon 1 of the AR gene was used as an X-chromosomal marker. 
The three affected individuals had the same X chromosome, and X-linked in 
heritance could not be excluded. Protein studies showed an abnormal electro-
phoretic mobility pattern of the AR protein during SDS-PAGE, reflecting defective 
hormone-dependent phosphorylation, which is associated with disturbed DNA 
binding. Indeed, receptor protein was not detectable in a nuclear fraction of 
genital skin fibroblasts that were cultured in the presence of hormone, which is 
indicative of defective DNA binding. By reexamining the gene, finally a muta-
tion was found in intron 2 at position -11 of the AR gene. Due to this mutation, a 
new splice acceptor site was created at pOSition (-lO)-(-l1) in intron 2, which was 
not used. However, a cryptic splice site at position (-70)-(-71) in intron 2 and at 
position (-l)-(-Z) in intron 3 were activated. Both splice variants, an AR protein 
with 23 additional amino acid residues in between the two zinc clusters, and an 
AR protein from which the second zinc cluster was deleted, were inactive. 
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Finally, a very small amount of wild type transcript was detected in genital skin 
fibroblasts, derived from the index patient, by use of an allele-specific oligo-
nucleotide-hybridization assay. This explains the phenotype of the affected 
individuals. The mutation was not detected in 102 chromosomes of unrelated 
individuals, indicating that it is not a common polymorphism, but a pathogenic 
mutation. 
In the General Discussion (Chapter VII) an overview is presented of muta-
tions detected in AIS. Recently the 3-D structures of the ligand-binding domains 
(LBDs) of several nuclear hormone receptor family members were clarified. 
Because the overall structure turned out to be quite similar, a 3-D model for the 
AR-LBD could be predicted. In Chapter VII, a distribution of mutations identified 
in the LBDs of the AR of patients with AIS and prostate cancer over the different 
structural regions is presented and discussed. Furthermore, the possible 
influence of the length of the poly-glutamine stretch on several androgenic end 
points is discussed. The possible existence of post -AR defects, causing an AIS-like 
phenotype in the presence of an intact AR is discussed. However, because cofac-
tors specific for the AR have not been identified yet, post-AR defects are not very 
likely to occur. Finally, some future directions, concerning AR research are given. 
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Samenvatting 
De androgenen testosteron en dihydrotestosteron zijn belangrijk voor de 
geslachtsdifferentiatie bij de man, en postnataal voor de ontwikkeling van de 
mannelijke secundaire geslachtskenmerken en het functioneren van de manne-
lijke geslachtsorganen. Bij de vrouw spelen ancirogenen een beperkte Tal. 
Ancirogenen binden aan de androgeenreceptor (AR), een transcriptiefactor 
welke aanwezig is in androgeen doelwitcellen. Na binding van het hormoon 
wordt de AR geactiveerd. Het hormoon-receptor complex verhuist van het cyto-
plasma naar de celkern, waar het complex androgeen-responsieve elementen 
van het DNA herkent, waaraan het vervolgens bindt. Deze hormoon-responsieve 
elementen zijn gelegen in de promotor regia van androgeen-gereguleerde 
genen. Het binden van de AR reguleert de expressie van deze genen, hetgeen 
uiteindelijk leidt tot een respons. Mutaties in het gen dat codeert voor de AR zijn 
de oorzaak van het androgeenongevoeligheidssyndroom (ArS). De doelwitorga-
nen van genetisch mannelijke (46,XY) individuen met AIS zijn verminderd 
gevoelig of totaal ongevoelig voor androgenen, waardoor deze individuen am-
bigue genitalien, dan weI vrouwelijke genitalien ontwikkelen (mannelijk pseu-
dohermaphroditisme). Het onderzoek, beschreven in dit proefschrift werd 
verricht om inzicht te verkrijgen in structuur-functie relatie van de AR. 
Dit onderzoek verschaft tevens informatie omtrent het functioneren van andere 
steroidhormoonreceptoren, die veel homologie vertonen nlet de AR. Het vast-
stellen en vervolgens karakteriseren van mutaties is ook van belang voor patien-
ten met AIS. Fundionele studies kunnen informatie opleveren die in sommige 
gevallen gebruikt kan worden voor behandeling van patienten. Indien gewenst 
kan familieonderzoek worden uitgevoerd, zodat eventuele draagsters van muta-
ties kunnen worden opgespoorrl. In patient en met verschillende vormen van 
androgeenongevoeligheid werd naar mutaties in het AR gen gezocht. In het 
bijzonder werden patienten bestudeerd met de receptor positieve vorm van 
androgeenongevoeligheid. In de androgeen-doelwitcellen van deze individuen 
komt het AR eiwit normaal tot expressie. Bovendien vertonen deze receptoren 
normale hormoonbindings-karakteristieken. Over het algemeen betreft het dan 
mutaties in de exonen 1, 2 en 3, welke respectievelijk coderen voor het NH,,-ter-
minale gedeelte van de AR (exon 1), en het DNA-bindend domein (DBD) (exonen 
2 en 3). In het verleden zijn deze gebieden niet uitgebreid onderzocht, enerzijds 
omdat de nadruk lag op het screenen van patienten met afwijkende hormoon-
binding, en anderzijds omdat exon 1 relatief groot en CG-rijk is, hetgeen een 
belemmering vormde voor screening op grote schaal. Mutaties in het NH2-termi-
nale gedeelte en het DBD kunnen meer informatie opleveren omtrent amino-
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zuurresiduen of eiwit regio's, betrokken bij receptor DNA binding en/of trans-
criptieactivatie, processen die van belang zijn met betrekking tot het normaal 
functioneren van de AR. Bovendien zijn er in de NH2-terminus van de AR veel 
aminozuur residuen gelegen, die mogelijk gefosforyleerd kunnen worden. 
In de General Intraduc!ion (Chapter I) wordt het functioneren van de AR en 
andere steroidhormoonreceptoren beschreven. Vervolgens wordt de mannelijke 
geslachtsdifferentiatie en de specifieke ral die de AR daarin vervult, toegelicht. 
Mutaties in de AR zijn ook geassocieerd met andere ziekten, zoals prostaatkan-
ker, maar ook de ziekte van Kennedy, een progressieve neuromusculaire aandoe-
ning. Deze laatste aandoening wordt veroorzaakt door een extreme expansie 
van een polymorfe poly-glutamine-keten, gelegen in het NH,-terminale gedeelte 
van de AR. Diverse andere neuromusculaire aandoeningen, zoals de ziekte van 
Huntington, zijn geassocieerd met verlengde poly-giutamine-ketens in andere 
eiwitten. Mechanismen die mogelijk ten grondslag liggen aan deze neuromus-
culaire aandoeningen worden besproken. 
In Chapter II worden diverse mutaties beschreven die gevonden zijn in het 
eerste exon van het AR gen. Er werden geen aminozuur substituties gevonden, 
maar weI verschillende puntmutaties die direct of indirect leiden tot de intro-
ductie van een prematuur stopcodon. Al deze mutaties veroorzaken complete 
AIS. Hoewel in theorie een translatie herstart vanaf een codon voor een intern 
methionine residu zou kunnen leiden tot expressie van een eiwit dat aan NH2-
terminale zijde verkort is, zijn hiervoor geen aanwijzingen gevonden. 
De sex hormone-binding globulin (SHBG) test word! ge bruikt om de ac!iviteit 
van de endogene AR in doelwitcellen van patienten (in vivo) te bestuderen. Voor 
en na behandeling met stanozolol, een anabool steroid, wordt de expressie van 
SHBG, een androgeen-gereguleerd gen, bestudeerd. Stimulatie met stanozolol 
leidt normaliter tot verlaging van de SHBG spiegel. In Chapter III wordt een 
46,XY individu beschreven waarbij een volledige ongevoeligheid voor androge-
nen was voorspeld aan de hand van de SHBG-test, terwijl he! fenotype van de 
patient duidelijk partieel was. In genitale huidfibrablas!en van de patient werd 
een normale hormoonbinding aangetoond, alhoewel het aantal receptoren laag 
was. Moleculaire analyse van het gen wees uit dat bij deze patient sprake is van 
een somatisch mozaYcisme voor een mutatie in exon 1. Ais gevolg van deze muta-
tie wordt een prematuur stopcodon gelntroduceerd, hetgeen leidt tot de aanwe-
zigheid van een verkort niet-functioneel AR eiwit, of de afwezigheid van AR 
eiwit als gevolg van instabiel boodschapper RNA. In levercellen, die SHBG pradu-
ceren, wordt vermoedelijk aileen het gemuteerde AR eiwit tot expressie 
gebracht, hetgeen een verklaring is voor het feit dat er geen daling van het SHBG 
werd waargenomen bij de patient. 
Een AR eiwit ciat een geexpandeerde poly-glutamine-keten bevat, vertoont 
verminderde activiteit, hetgeen bij patienten met de ziekte van Kennedy veelal 
resulteert in milde verschijnselen van AIS. Oak binnen de norma Ie populatie 
varieert de lengte van de poly-glutamine-keten, en daarmee mogelijk de recep-
toractiviteit. De AR is aangetoond in osteoblasten, de botvormende cellen. EI zijn 
aanwijzingen dat de AR een directe ral speelt met betrekking tot botmetabo-
lisme. Gezien de mogelijke modulerende activiteit van de poly-glutamine-keten 
met betrekking tot receptor activiteit is bestudeerd of er rnogelijk een associatie 
bestaat tussen botmineraaldichtheid en de lengte van de poly-glutamine-keten 
binnen een cohort mannen van de Rotterdam Ouderen Studie (Chapter IV). 
Hoewel een duidelijke associatie niet kon worden aangetoond, waren indivi-
duen met een lage botmineraaldichtheid oververtegenwoordigd in de groep met 
een relatief korte poly-glutamine-keten. 
In Chapter V wordt een mutatie bespraken welke gevonden werd in exon 2 
van het AR gen van een 46,XY individu met compleet AIS. Exon 2 codeert voor 
het eerste zink-cluster, betrakken bij specifieke DNA binding. Als gevolg van de 
mutatie is het neutrale alanine residu op positie 564 veranderd in een asparagi-
nezuur, waardoor een extra negatieve lading wordt ge'introduceerd. Deze AR 
mutant en een tweetal andere mutanten werden tot expressie gebracht en func-
tioneel onderzocht. Op deze wijze kon worden nagegaan of de defecte DNA 
binding, waargenomen in geval van de asparaginezuur mutant, veroorzaakt 
werd door de introductie van negatieve lading dan weI door sterische hindering. 
Tevens werd een 3-dimensionaal (3-D) model gecreeerd voor het DBD van de 
wild type AR en de drie gemuteerde receptoren. Het wild type AR model is geba-
seerd op het 3-D model voor het DBD van de glucocorticoid receptor, waarvan de 
kristal structuur is opgehelderd. De resultaten, verkregen middels beide benade-
ringen, werden met elkaar vergeleken, en wezen uit dat met narne de negatieve 
lading, ge'introduceerd door het asparaginezuur residu, verantwoordelijk is voor 
het fenotype van de patient. 
Een familie met partiele androgeenongevoeligheid wordt beschreven in 
Chapter VI. Na moleculaire analyse van de coderende gedeelten van het AR gen 
en de flankerende introngedeelten werd geen mutatie gevonden. Testosteron-
biosynthesestoornissen, ook een oorzaak voor mannelijk pseudohermaphrodi-
tisme, konden worden uitgesloten. Met behulp van de polymorfe CAG-repeat, 
gelegen in exon 1 van het AR gen, werd aangetoond dat de 3 aangedane indivi-
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duen hetzelfde X chromosoom hadden, en daardoor kon X-gebonden overerving 
niet worden uitgesloten. Studies van het receptoreiwit lieten een afwijkend 
fosforylerings-patroon zien, hetgeen nog niet eerder bij AIS patienten was aan-
getoond. Dit afwijkende patroon is geassocieerd met verstoorde DNA binding. 
Na opnieuw analyseren van het AR gen werd uiteindelijk toch een mutatie 
gevonden in intron 2 op positie -11. Als gevolg van de mutatie wordt een nieuwe 
acceptor splitsingsplaats gecreeerd op positie (-10)-(-11) in intron 2, welke echler 
niet gebruikt wordt. Daarentegen worden een cryptische acceptor splitsings-
plaats op positie (-70)-(-71) in intron 2 en de acceptor splitsingsplaats op positie 
(-1)-(-2) in intron 3 geactiveerd. Beide splitsingsvarianten, een AR eiwit met 23 
additionele aminozuren tussen de twee zink-clusters en een AR eiwit met een in 
frame deletie van het tweede zink-cluster zijn functioneel onderzocht. Geen van 
beide vertoonde enige activiteit. Middels een zeer gevoelige dot-blot techniek is 
een geringe hoeveelheid wild type mRNA aangetoond in genitale huidfibroblas-
ten, hetgeen het partiele AIS fenotype van de patienten kan verklaren. Het gege-
ven dat deze mutatie niet werd gevonden na analyse van 102 chromosomen van 
niet gerelateerde contrale personen, vormt additioneel bewijs voor de pathoge-
niciteit van de intron mutatie. 
In de General Discussion (Chapter vII) wordt een overzicht gegeven van aile 
mutaties, gevonden in AIS. Recentelijk zijn de 3-D structuren van de ligand-
bindende domeinen (LBDs) van een aantalleden van de kernreceptorfamilie, 
waartoe ook de AR behoort, opgehelderd. In Chapter Vll zijn alle mutaties, 
gevonden in het AR-LBD van patienten met AIS en prostaatkanker, onderver-
deeld naar de diverse strudurele eenheden binnen het LBO. Verder wordt de 
mogelijke invloed van de lengte van de poly-glutamine-keten op diverse andro-
geen gereguleerde process en besproken. Vervolgens wordt er gespeculeerd over 
mogelijke defeden in de door androgenen en AR gereguleerde processen (post-
AR defeden), welke zouden kunnen resulteren in een fenotype dat gelijkenis 
vertoont met AIS. Aangezien er tot op heden geen AR-specifieke co-factoren zijn 
beschreven is dit niet aannemelijk. De discussie wordt afgesloten met een korte 
toekomstvisie, betreffende onderzoek aan de AR. 
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